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3ABSTRACT
Research into the association between migraine and menstruation has been 
hampered by lack of an agreed definition for 'menstrual' migraine. This thesis 
presents evidence for increased risk of migraine w ithout aura on or between the 
two days before menstruation and the first three days of bleeding. W ith in  
individual women menstrual attacks differ from attacks at other times of the cycle, 
being longer and more severe. These findings led to the development of 
defin itions for 'pure menstrual migraine' and 'menstrually-related migraine', 
w h ich  have subsequently been adopted by the International Headache Society.
Further research identified an inverse relationship between oestrogen and 
m igraine incidence. The fo llicu lar phase oestrogen rise was associated w ith 
reduced risk of migraine; late luteal oestrogen 'w ithdraw a l' at menstruation was 
associated w ith  increased risk of migraine.
In order to counteract the luteal phase oestrogen drop and prevent menstrual 
attacks, oestrogen supplements were used from the luteal phase oestrogen peak 
(day -6) through to the early fo llicu lar rise of endogenous oestrogen (day +2). 
Identification of ovulation using a fertility  monitor enabled prediction of 
menstruation and accurate tim ing of oestrogen supplements, despite a w ide inter- 
and intra-individual range in cycle length. The results showed that use of 
oestrogen supplements was associated w ith  a significant reduction in migraine 
days compared to placebo. However, the benefits were offset by delayed 
oestrogen 'w ithdraw al' migraine.
In wom en w ith  migraine in the pill-free interval o f combined hormonal 
contraceptives, there was a trend for oestrogen supplements to prevent 
'menstrual' attacks, although the dose used was suboptimal.
These findings support the hypotheses that menstrual migraine is a discrete 
c lin ical entity and is associated w ith oestrogen 'w ithdraw a l'. Further, oestrogen 
'w ithdraw al' migraine can be independent of menstruation and independent of 
ovulation. Oestrogen 'w ithdraw al' migraine can be prevented w ith  oestrogen 
supplements, although the optimal regime has yet to be established.
4"IN ANY INVESTIGATION INVOLVING HUMAN SUBJECTS THE 
MOST DIFFICULT PART IS GETTING HOLD OF THEM"
Hamilton M. BMJ 1965;2:1048-1051
This thesis is dedicated to all the women who took part in these research projects. 
Their interest and willingness to find the answers to the hypotheses has been as 
great as my own. The success of the research presented here is the result of their 
com m itm ent to the demands made of them and adherence to the protocols,
sometimes at great personal cost.
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ABBREVIATIONS
COCs Combined oral contraceptives
CHCs Combined hormonal contraceptives
DM PA Depot medroxyprogesterone acetate
EE Ethinyloestradiol
EiG Oestrone-3-glucuronide
EMU Early morning urine
FSH Follicle stimulating hormone
GCP Good c lin ica l practice
HRT Hormone replacement therapy
IHS International Headache Society
LH Luteinizing hormone
PdG Pregnanediol 3-glucuronide
PF! PiII-free interval
RR Relative risk
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AIMS OF THE THESIS
HYPOTHESES
1. Menstrual m igraine is a discrete c lin ica l entity
2. Menstrual migraine is associated w ith  oestrogen 'w ithdraw al'
3. Menstrual m igraine can be prevented w ith oestradiol supplements
RESEARCH UNDERTAKEN TO TEST THE HYPOTHESES
1. Menstrual migraine is a discrete c lin ica l entity
1.1. Define menstrual migraine (PAPERS I, II, II, IV)
1.2. Assess the clin ica l differences between menstrual migraine and 
non-menstrual attacks (PAPERS III, IV, V)
2. Menstrual m igraine is associated w ith  oestrogen 'w ithdraw al'
2.1. Evidence for the association between oestrogen 'w ithdraw al' and 
m igraine during the natural menstrual cycle (PAPER V)
2.2. Evidence for the association between oestrogen 'w ithdraw al' and 
m igraine during the hormone-free interval in women using 
combined hormonal contraceptives
3. Menstrual m igraine can be prevented w ith oestradiol supplements
3.1. Identify the optimal dose and tim ing of oestradiol supplements for
prevention of menstrual migraine during the natural menstrual cycle
(PAPER V)
3.2. Identify a method to time the start of perimenstrual oestradiol 
supplements accurately (PAPER VI)
3.3. Study the effect perimenstrual oestradiol supplements on the
prevention of menstrual migraine during the natural menstrual cycle
(PAPER VII)
3.4. Study the effect oestradiol supplements on the prevention of 
m igraine during the pill-free interval in women using combined oral 
contraceptives (PAPER VIII)
17
INTRODUCTION 
PREVALENCE OF MIGRAINE
Headache is the most common neurological condition, w ith more than 90% of 
the population reporting headaches at some time in their lives.(Rasmussen, 1995) 
M igraine affects more than 14% (7.6% of men and 1 8.3% of women) of the UK 
population - over 6 m illion  people - and is more prevalent than diabetes, epilepsy 
and asthma combined.(Steiner et al., 2003) Prevalence of migraine varies w ith 
age, rising through early adult life and peaking during the most productive 
w orking years (Figure 1).
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THE BURDEN OF MIGRAINE
Migraine has been ranked by the W orld  Health Organization as 19th among all 
diseases w orldw ide  causing disability and 12th in wom en.(W orld Health 
Organization, 2001) Research shows that in the United Kingdom alone, an 
estimated 5.7 w orking days are lost per year for every working or student 
migraineur and each working day up to 90,000 people are absent from work or 
school as a result o f migraine.(Steiner et al., 2003)
Despite the high prevalence and disability, migraine is not seen as a public health 
problem; it is w ide ly  under diagnosed and under treated, both in children and 
adults.(Lipton et al., 2003; Bigal et al., 2006; Stovner et al., 2007) It has been 
estimated that in the UK and the USA around two-thirds of people w ith  migraine 
never consult their doctor, are not given a correct diagnosis, and treat attacks only 
w ith  over-the-counter medication.(Lipton et al., 2003) Many migraineurs w ould 
benefit from correct diagnosis and treatment w ith more specific drugs. Under­
treatment -  as w ell as causing unnecessary disability and suffering -  is not 
econom ically cost-effective in terms of time lost from w ork and burden placed on 
the families of sufferers. More effective health care w ould  alleviate much of the 
suffering and therefore reduce both the personal and financial costs of migraine.
MIGRAINE IN WOMEN
The burden of migraine particularly falls on women. Epidemiological studies 
confirm  the c lin ica l impression that migraine is a predom inantly female disorder, 
affected by the changing hormonal environment during the reproductive years.
A study of 9059 children undertaken by Bille in 1955 showed that before puberty 
there was no sex difference in the prevalence of migraine; between the ages of 7 
to 9 years migraine prevalence was approximately 2.5% in both boys and 
girls.(Bille, 1 962) After the age of 11 there was an increasing female 
predominance, which became more marked in 13 to 15 year-olds. Notably, the 
median age at menarche is 12.8 years (range 9.1-1 7.7) in developed 
countries.(Speroff & Fritz, 2004)
By m id-life, migraine is three times more prevalent in women than in men.(Lipton 
et al., 2001) Overall, studies suggest that by age 40 prevalence of migraine in
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women is around 25%, compared w ith only 8% in men (Figure 2).(Rasmussen et 
al., 1991; Scher et al., 1999) In later life, migraine prevalence declines in both 
sexes although a female predominance remains.
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FIGURE 2: M IGRAINE PREVALENCE AT AGE 4 0  YEARS. BASED ON 1 8  POPULATIONS STUDIES THAT USED IHS
CRITERIA.(SCHER ET AL., 1 9 9 8 )
W ith regard to hormonal changes, ovarian function wanes around age 40 and the 
frequency of ovulation decreases, heralding the menopause. This stage of life, 
known as the climacteric, typ ically lasts around 10 years, centring on the mean 
age at menopause of 50.8 years.
The sex difference during the reproductive years is generally considered to result 
from the additional trigger of the menstrual cycle, an association that has long 
been recognised. Hippocrates noted that: "Shivering, lassitude and heaviness of
the head denotes the onset of menstruation".(Bronfen, 1 998) The term 'hysteria' 
was used, w hich had physical rather than psychological connotations in historic 
times, simply meaning 'arising from the wom b'. The recommended cure was 
marriage.
In 1 666 johannis van der Linden described a particularly severe case of one-sided 
headache w ith  nausea and vom iting associated w ith menstruation in the 
Marchioness of Brandenburg.(Van der Linden, 1666)
Fordyce noted an association between migraine and the premenstruum, w riting in 
1 758 in his 'Dissert de FHemicrania': "In women who are subject to attacks of this 
malady at the catamenial period, the pain does not abate until the uterine 
discharge appears".
The English Quaker physician Fothergill (1 712-1 780), the Swiss physician Tissot 
(1 728-1 797), the French chemist and pharmacist Labarraque (1 777-1 850), and 
the French psychiatrist Calmeil (1798-1895), all commented on the association 
between migraine and menstruation.
THE ROLE OF MENSTRUAL CYCLE HORMONES
Despite evidence for the clin ical relationship, the underlying mechanisms 
remained elusive to researchers over the centuries. In 1 873, Liveing noted that 
this variety o f migraine was relieved by pregnancy w ith  attacks "renewed again 
some time after delivery, occasionally w ith unusual severity; and this lends 
additional support to the general impression that there is some real connection 
between the attacks and the catamenial function."(Liveing, 1 873)
The influence of menstrual cyc lic ity  was suggested in epilepsy, 'paroxysmal 
insanity', asthma and various forms of neuralgia. Liveing asked: "FHow are we to 
interpret the facts; what is the character of the influence exerted and to what 
extent is it the cause of the malady?" In response, he quoted Dr Symonds 1858 
'Gulstonion Lectures': "The menstrual function only acts as an exciting cause on 
an antecedent constitutional or neurotic susceptibility". Liveing also remarked 
that migraine could occur at monthly intervals in men and considered that the 
relationship of migraine to the catamenial period in women could be 
coincidental.
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During the 20th Century, several hormonal treatments for migraine were 
attempted, w ith  varying success. These included pituitary extracts containing 
gonadotrophins, human chorionic gonadotrophins extracted from the urine of 
pregnant women, ovarian oestrogens, progesterone, progestogens and 
testosterone.(Pardee, 1919; Blackie & Hossock, 1932; Thompson, 1932; Moffat,
1937; Singh & Singh, 1 947; Moehlig, 1955; Hudgson et al., 1 967; Bradley et al., 
1968; Lundberg, 1969; Dalton, 1973; Greenblatt & Bruneteau, 1974)
The 1960s heralded the development of the contraceptive 'P ill', containing 
synthetic hormones ethinyloestradiol and progestogen. Reports of its negative 
effects on migraine abounded.(W hitty et al., 1966; Sluglett & Lawson, 1967; 
Phillips, 1968; Larsson-Cohn & Lundberg, 1970; Pluvinage, 1970; Bickerstaff, 
1975; Kudrow, 1975; Dalton, 1976; Ryan, 1978) In contrast, oestrogen 
replacement for migraine associated w ith ovarian failure showed benefit.(Chinn, 
1968; Eichner, 1968; Chaudhuri & Chaudhuri, 1975)
W ith  greater understanding of the hormones involved, more recent research has 
focused on the association between migraine and the declin ing levels of 
oestrogen and progesterone during the luteal phase of the menstrual cycle as well 
as w ithdrawal of ethinyloestradiol and progestogens in the hormone-free interval 
of combined hormonal contraceptives. However, research has been hampered by 
the lack of an accepted definition for menstrual migraine.
MENSTRUAL MIGRAINE
In 1988, the International Headache Society published the first classification and 
diagnostic criteria for headache disorders.(Headache Classification Committee of 
the International Headache Society, 1988) This classified most headaches but 
noted that there were no generally accepted criteria for so-called 'menstrual 
migraine'.
When I started working at the City of London M igraine C lin ic  in 1988, it was 
notable that many women reported that they had more migraine attacks around 
the time of menstruation. Menstrual attacks were c lin ica lly  different from non- 
menstrual attacks, being more severe, lasting longer and less responsive to 
treatment.
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A review of the literature at this time was unhelpful -  the studies used numerous 
different definitions for 'menstrual' migraine and so were non-comparable.
In order to define the condition, I considered that the first step should be to study 
the incidence of migraine at different stages of the menstrual cycle. A definition 
could be based on the time of peak incidence. Once defined, research could 
focus on specific mechanisms that relate to the precise tim ing of increased 
incidence. Sim ilarly, treatment trials could ensure that tim ing of treatment was 
targeted to the 'prone' time in a defined population of 'menstrual1 migraine 
patients.
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PART ONE:
MENSTRUAL MIGRAINE IS A DISCRETE CLINICAL ENTITY
24
1.1. DEFINING MENSTRUAL MIGRAINE
'Menstrual' migraine is a term commonly (mis)used by both patients and doctors 
w ithout certainty of its existence.
In 1988, The International Headache Society published the first classification and 
diagnostic criteria that classified most headaches but not menstrual migraine. It 
stated:
'M igraine w ithout aura may occur almost exclusively at a particular time o f the 
menstrual cycle -  so-called menstrual migraine. Generally accepted criteria for 
this entity are not available. It seems reasonable to demand that 90%  o f attacks 
should occur between two days before menses and the last day o f menses, but 
further epidem iological knowledge is needed'.{Headache Classification 
Committee of the International Headache Society, 1988)
If menstrual migraine does exist as an entity, an accepted definition is essential to 
enable more specific research into its pathophysiology, and to develop more 
effective and specific treatment for this disabling condition. The definition should 
continue to be revised on the basis of further clin ical research.
Correct classification of menstrual migraine is perhaps even more relevant as 
treatment becomes increasingly costly, as may be the case if triptans are more 
w ide ly used for prophylaxis as well as acute therapy.
However, even before a definition can be developed, it is first necessary to 
confirm  the existence of menstrual migraine as a discrete entity.
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1.1.1. PAPER 1: MIGRAINE AND MENSTRUATION: A PILOT STUDY 
OBJECTIVES
The objectives of this study were to determine the prevalence of migraine 
associated w ith  menstruation in an outpatient population and to use the data to 
develop a prelim inary definition for menstrual migraine.
METHODS 
Patients and methods
Women attending the City of London Migraine C lin ic were asked to keep a 
record of their migraine attacks and menstrual periods as a routine part of their 
treatment programme. During a 6-month period, diary cards from women w ith 
migraine w ith aura and/ or migraine w ithout aura were collected at their fo llow - 
up visits, typ ica lly  three months after their first appointment. M igraine was 
defined in accordance w ith  the IHS criteria.(Headache Classification Committee 
of the International Headache Society, 1988)
The data were collated and analysed. Records kept by women using hormonal 
treatments such as hormonal contraception or hormone replacement therapy, or 
who were breastfeeding, were excluded from the data analyses. M igraine 
preceding and fo llow ing  day 1 (i.e. the first day of the bleeding) of each menstrual 
cycle were recorded on charts for individual women. In this way, headaches 
associated w ith  each phase of the menstrual cycle could be easily identified for 
each woman. On the basis that the luteal phase is a relatively constant 14 days, 
migraine occurring at the time of ovulation w ould thus be expected around day 
-14 even in women who did not have a regular 28-day cycle.(Speroff & Fritz, 
2004) The results were also summated on a single chart of all cycles for all 
women.
RESULTS
Over three hundred women were asked to keep records at their first visit to the 
c lin ic. Fifty-five women aged between 1 7 and 50 years (mean 35.8 ± SD 9.0 
years) kept complete records of migraine attacks over three menstrual cycles and
were not using hormonal treatments. Eleven women had migraine with  aura 
(20%) and 44 had migraine without aura (80%).
Figure 3 shows all migraine attacks recorded by the 55 women over three 
complete menstrual cycles. There was a marked increase in migraine incidence 
around the first day of menstruation (i.e. the start of the bleeding). There was no 
increased incidence at the estimated time of ovulation (day -14). Attacks recorded 
at each end of the chart are due to the variability in the length of menstrual 
cycles.
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Six of the women (10.9%) had migraine attacks occurring only at the time of 
menstruation and at no other time. O f these, four (7.2%) had attacks in all 3 
cycles recorded which occurred only between days -2 to +3 of the cycle (i.e. two 
days before menstruation and the first three days of bleeding). The other 2 
patients had migraine attacks occurring also on day -4 and day +4.
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FIGURE 4 : Ex a m p l e  o f  In c id e n c e  o f  M ig r a in e  O v e r  T h r ee  C yc le s  in  a  W o m a n  W it h  P u r e
M e n s t r u a l  M ig r a in e
O nly one woman had attacks of migraine w ith in the -2 to +3 period as well as at 
the estimated time of ovulation (day -14). However, attacks associated w ith 
menstruation occurred in all 3 cycles, whereas the attack at ovulation was only 
recorded in one cycle and could have occurred by chance.
All 7 women had migraine without aura.
When the individual graphs for each woman were studied, 37 women (67.3%) 
had attacks during all stages of the menstrual cycle over the three cycles studied. 
O f these, 19 (34.5% of total) had an increased number of attacks w ith in  the 
period defined for 'menstrual' migraine; 18 (32.7%) had attacks throughout the 
cycle but w ith  no increase in number during the defined period; 14 (25.5%) had
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no attacks w ith in  the defined period during the three cycles. O f the women who 
had both migraine with and without aura and increased incidence of migraine 
between days -2 to +3, menstrual attacks were w ithout aura.
DISCUSSION
In a study such as this it is d ifficu lt to overcome the problems of self-selection as 
only a small number of women were motivated enough to keep a clear record of 
all attacks and many charts were inadequately completed.
However, the effect of menstruation on migraine was most apparent between the 
days -2 to +3 of the menstrual cycle. On this basis pure menstrual migraine could 
be defined as:
'M igraine attacks which occur on or between days -2 to +3 o f the 
menstrual cycle and at no other tim e.'
Using this definition, the prevalence of pure menstrual migraine in this population 
was 7.2% across three consecutive menstrual cycles.
This compares to 14.1% found by Epstein et al. when the replies to a 
questionnaire completed adequately by 92 women still menstruating were 
analysed and checked by interview.(Epstein eta l., 1975) These women claimed a 
regular relationship of their attacks of migraine to the menstrual cycle although 
this was not confirmed against prospective records. The original questionnaire 
was sent to all women over the age of 14 who had attended the Oxford Migraine 
C lin ic over a 3-year period, so the replies were from a self-selected population.
Digre and Damasio found 8% of women w ith  migraine had menstrual migraine 
using their definition of 'a common migraine that occurs during the week before 
or the week of menstruation, the women being headache free for the remainder of 
the cycle'.(D igre & Damasio, 1987) They also included women who they 
considered to have migraine at ovulation as well as during the menstrual flow . In 
the present study, there was no clear association between attacks of migraine and 
ovulation.
For the majority of women, migraine attacks could occur at any time of the 
month, as well as being more prevalent around the time of menstruation. On this 
basis 'menstrually-related migraine' could be defined as:
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'M igraine attacks which occur regularly on or between days -2 to +3 o f the 
menstrual cycle w ith additional attacks at other times o f the cycle.'
Migraine attacks are triggered by several factors and menstruation must act as an 
additional trigger at that time. This may or may not be a specifically hormonal 
effect due to a direct action of the hormones or secondary to changes in the 
hypothalam ic-pituitary axis. The effects on other biochemical pathways or even 
the effect of other trigger factors (dietary, sensory, stress, etc.) may also play a 
role. It w ould seem that there are only a few women for whom  menstruation is 
the sole trigger of their attacks of migraine.
SUMMARY OF FINDINGS
Migraine was most prevalent on or between two days before the onset of 
menstruation and the first three days of bleeding (day 1 ±2 days). Using this as a 
definition for menstrual migraine, four categories of women were identified:
1. Those w ith  pure 'menstrual' migraine (7.2%);
2. Those w ith  'menstrually-related' migraine (34.5%);
3. Those whose attacks occur throughout the menstrual cycle but w ith  no 
increase at the time of menstruation (32.7%);
4. Those whose attacks do not occur at the time of menstruation (25.5%).
Menstrual attacks were typ ica lly w ithout aura, even in women who also had 
migraine with  aura. No link between migraine and ovulation was identified.
FURTHER WORK
It was felt that further studies are required to identify the specific groups and to 
analyse any further differences between the groups in the light of previous studies. 
For example, patients identified as having 'menstrual' migraine need to be studied 
for a much longer period to assess whether or not the temporal relationship of 
attacks to menstruation continues. Also the finding that all four women with pure 
menstrual migraine had migraine without aura needs to be corroborated w ith 
larger study numbers. The effect of other trigger factors needs to be studied - a 
greater link w ith  menstruation may be found by removing as many triggers as
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possible (e.g. excluding dietary triggers, eating regular meals, reducing caffeine 
intake, etc.).
A larger series is needed to enable a firm statement to be made about the duration 
of increased susceptibility. This susceptibility could then be correlated w ith 
known hormonal changes and the effect of ovulation, which may have been 
masked in such a small group as mentioned above.
The identification of the four distinct groups may well have an implication for the 
treatment of migraine in women. For example, it is most likely that hormonal 
treatment w ill be effective for the group w ith pure menstrual migraine and may 
help the group w ith menstrually-related migraine. It is un like ly that hormonal 
treatment w ill help those whose attacks are not related to menstruation. Further 
controlled studies w ill need to be undertaken to support this hypothesis.
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1.1.2. PAPER II: DEFINING MENSTRUAL MIGRAINE: A REVIEW
The results presented in Paper I provide evidence for the existence of menstrual 
migraine, suggesting that menstrual attacks are most likely to be migraine w ithout 
aura and occur on or between days -2 to +3 of the cycle.
In considering a definition, a review of published definitions was undertaken.
Figure 5 shows the different timings for attacks described as 'menstrual' migraine. 
The interval during which menstrual migraine attacks could occur ranged from a 
3-day interval to a 15-day interval.(O 'Dea & Davis, 1990; Lichten e ta/., 1991)
The tim ing for these intervals varies. In some definitions attacks are premenstrual 
(before the onset of menstruation) or perimenstrual (before and during 
menstruation); others define attacks during menstruation only or include 
ovulation.
Table 1 shows that definitions w ith similar time intervals may still differ from one 
another. Some researchers included attacks at any stage of the cycle provided that 
attacks occurred regularly w ith in  the specified interval for menstrual migraine. For 
others, the definition was only met when attacks fall solely w ith in  the specified 
interval on every occasion w ith no attacks at other times of the cycle. It is 
important to distinguish between the two since a pure hormonal mechanism is 
likely to be involved only in women w ith pure menstrual migraine. In contrast, 
additional non-hormonal factors w ill be acting in women w ith  additional non- 
menstrual attacks. If studies are to uncover the mechanisms responsible for 
menstrual migraine, it is necessary to study women in whom hormonal events are 
the sole association.
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FIGURE 5 : V A R IA T IO N  OF DEFINITIONS FOR 'M EN STR U AL' M IGRAINE BASED O N  AVERAGE D U R ATIO N  OF FIVE DAYS OF MENSTRUAL BLEEDING
AUTHORS PREDEFINED OR 
RETROSPECTIVE 
DEFINITION
TIGHTEST DEFINITION TYPE OF MIGRAINE DOES DEFINITION  
ALLOW ATTACKS AT 
OTHER TIMES?
Benedetto et al (1987) Predefined Migraine that occurs only prior to, during, or at the end of 
menstruation and/or at the time of ovulation
Common or classical 
(Ad Hoc)
No
□  ’Alessandro et al (1983) Predefined Migraine only or predom inantly during menses Not specified Yes
Dalton (1973) C lin ical
assessment
Attacks of severe disabling headaches always recurring at the 
same phase o f each menstrual cycle...highest daily incidence 
was on the two days immediately preceding menstruation
Not specified Yes
N.B. Included women 
taking oral 
contraception
de Lignieres et al (1986) Predefined Common migraine occurring exclusively just before or during 
menstruation (day -2 to last day of menses)
Common No
Dennerstein et al (1988) Predefined Regular migraine in the paramenstruum Any Yes
Diamond (1 984) Not specified Exclusively at menses Not specified Not specified
Digre and Damasio (1987) Not specified Common migraine that only occurs during the week before or 
the week of menstruation; the woman is headache free for the 
remainder of the cycle
Common (Ad Hoc) No
Epstein et al (1975) Predefined Migraine confined to just before or during the period o f blood 
loss
Not specified No
Facchinetti et al (1990 Predefined Migraine attacks normally starting -2 and -1 days before 
menses, lasting until 2nd day of the menstrual flow
Any (ad hoc) Yes
Note: 'com m on' and 'classical' m igraine was diagnosed according the Ad Hoc criteria for migraine, w hich predates the IHS classification.(Ad Hoc Committee of the
NIH, 1962) The terms are equivalent to 'm igraine w ithout aura' and 'm igraine w ith aura' respectively
TABLE 1: D e f in it io n s  f o r  M e n s t r u a f  M ig r a in e
Facchinetti et al (1993) Predefined M igraine attacks that occurred between day -2 and day +3 in 
relation to the onset of the menstrual flow
Common (IHS) ?No
Facchinetti et al (1995) Predefined M igraine attacks occurring -3 to +5 days relative to the start of 
menstruation
Not specified Not specified
Gallagher (1989) Predefined A migraine attack almost exclusively associated w ith  the 
menstrual cycle
Not specified Not specified
Gross et al (1995) Predefined A retrospective diagnosis o f >80% of attacks occurring during 
the menstrual w indow  (day -3 to +5) in the past 6 months
Migraine ± aura (IHS) Yes
Lichten et al (1991) Predefined 'Horm onal m igraine': migraines during the luteal phase of the 
menstrual cycle - most typ ica lly  w ith in  7-10 days prior to 
menses: includes 'menstrual m igraine': headache during 
menstrual phase only - after 2nd fu ll day of menstruation
Any (Ad Hoc) Not specified
Lundberg (1986) Not specified The migraine attack is often associated w ith  a particular day of 
the menstrual cycle that is characteristic for each woman. It 
com m only occurs just before the menstrual period, often 
together w ith  the premenstrual syndrome...M igraine attacks 
may also occur at the time o f ovulation and during or 
immediately after menstruation
Not specified Not specified
MacGregor et al (1990) C lin ical
assessment
M igraine attacks w hich regularly occur on or between days -2 
and +3 of the menstrual cycle and at no other time
Common (IHS) No
Magos et al (1983) Predefined Regular attacks immediately before or during menstruation Classical and common 
(WFN)
Not specified
Note: 'com m on' and 'classical' m igraine was diagnosed according the Ad Hoc criteria for migraine, which predates the IHS classification.(Ad Hoc Committee of the
NIH, 1962) The terms are equivalent to 'm igraine w ithou t aura' and 'm igraine w ith  aura' respectively
TABLE 1: D e f in it io n s  f o r  m e n s t r u a l  m ig r a in e
u j
U l
Martignoni et al (1987) Review article Menstrual migraine most com m only appears just prior to the 
onset of the period (premenstrual migraine) but it may also 
occur during or after the actual flow . Sometimes it also occurs 
at the time of ovulation
Common Not specified
Mathew (1986) No defin ition Common Not specified
Nattero et al (1977) Predefined M igraine a few days before the onset of menstruation Not specified Not specified
Nattero et al (1989) Predefined Onset o f the migraine crisis exclusively prior to, during, or at 
the end o f menstruation
Classical or common 
(Ad Hoc)
No
Nattero et al (1991) Predefined M igraine exclusively prior to, during, or at the end of 
menstruation and....also at the time of ovulation
Any No
O 'Dea et al (1990) Predefined During the luteal phase of the menstrual cycle (between 
ovulation and menstruation)...associated w ith  the 
premenstruum distinct from sporadic migraine
Not specified Not specified
Pfaffenrath (1993) Predefined M igraine attacks occurring exclusively between 2 days prior to 
onset and first day after the offset of the menses
Not specified No
Pradalier (1994) Predefined IHS defin ition: 90 per cent of attacks occur between 2 days 
before menses and the last day o f menses
?Migraine w ithout aura 
(IHS)
Yes (10%)
Riemasch-Becker (1994) Predefined M igraine onset between 2 days before or during menstruation Not specified Yes
Sances et al (1989) Predefined M igraine attacks linked w ith  menstrual cyclic ity Not specified Not specified
Sances et al (1991) Predefined A form  o f periodical headache that often fails to improve w ith 
usual prophylactic treatments
Not specified Not specified
Schoenen (1985) Predefined Exclusively perimenstrual Not specified No
Note: 'com m on' and 'classical' m igraine was diagnosed according the Ad Hoc criteria for migraine, which predates the IHS classification.(Ad Hoc Committee of the
NIH, 1962) The terms are equivalent to 'm igraine w ithout aura' and 'm igraine w ith aura' respectively
TABLE 1 : D EFIN IT IO N S FOR MENSTRUAL MIGRAINE
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Solbach et al (1984) Predefined Any migraine headache w hich occurs 3 days prior to 
menstrual flow , during tim e of flow , or 3 days fo llow ing
Predominantly classical or 
common
Not specified
Solbach and Waymer 
(1993)
Predefined Attacks during a 5 day period from 1 day before start of 
menstrual flow  through the first 4 days of flow
Migraine w ith  or w ithout 
aura (IHS)
Yes
Somerville
(1971,1972,1975)
Predefined One predictable attack o f m igraine per month always 
confined to premenstrual or menstrual phases
Severe and throbbing 
headache, lasting several 
hours accompanied by 
nausea and photophobia ± 
visual or sensory symptoms
No
Szekely et al (1986) Predefined Headache occurring regularly w ith in  plus or minus one 
week of day one o f menstruation
Headache Not specified
Waters and O 'Connor 
(1971)
Clin ical
assessment
Incidence of migraine attacks tw ice as frequent during 
menstruation and non migraine headaches more than 
tw ice as frequent during menstruation - highest 
incidence during 1 st few days of menstruation.
Unilateral headache, 
warning before headache, 
accompanying nausea
Yes
Note: 'com m on' and 'classical' m igraine was diagnosed according the Ad Hoc criteria for migraine, w hich predates the IHS classification.(Ad Hoc Commitee o f the 
NIH, 1962) The terms are equivalent to 'm igraine w ithou t aura' and 'm igraine w ith  aura' respectively
TABLE 1 : D e f in it io n s  f o r  m e n s t r u a l m ig r a in e
oj\ i
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Table 1 also shows the type of migraine for each definition. In the majority of 
cases any type of migraine is allowed, or the type of migraine is not specified.
Stricter definitions confine attacks to those of migraine w ithout aura but again, the 
time interval ranges enormously from approximately 7 days to approximately 14 
days.(de Lignieres et al., 1986; Digre & Damasio, 1987)
In some cases the definition is very loose, e.g. 'm igraine attacks exclusively prior 
to, during, or at the end of menstruation, and... also at the time of ovu la tion1; 'a 
migraine attack almost exclusively associated w ith the menstrual cycle1; 'a form 
of periodical headache that often fails to improve w ith  usual prophylactic 
treatment1.(Gallagher, 1989; Nattero et al., 1991; Sances et al., 1991) Such 
definitions are unhelpful for c lin ica l practice or further research.
The strictest definition for 'menstrual' migraine was the one used by de Lignieres 
et al. and Smits et al.: 'attacks of migraine w ithout aura occurring not earlier than 
two days before menstruation and not later than the last day of the menses w ith 
no other headache attacks during the rest of the cycle.' The attacks had to be 
regular, always occurring at the same time in the menstrual period, and to have 
occurred during each of the 12 cycles preceding the study. Further, the duration 
of menstrual cycles had to be consistent, not differing in length by more than two 
days for all 12 cycles.(de Lignieres et al., 1986; Smits et al., 1994)
TOWARDS A DEFINITION FOR MENSTRUAL MIGRAINE
If a definition is to be developed, several points need to be considered:
D id the researchers diagnose migraine accurately?
Many of the studies were undertaken before the introduction of the IF4S diagnostic 
criteria and migraine may not have been diagnosed accurately. Correct diagnosis 
of migraine is essential - several studies have noted an increase in non-migraine 
headaches perimenstrually, particularly in women who fu lfil criteria for the 
premenstrual syndrome.(Waters & O 'Connor, 1971; Metcalf, 1988; Keenan & 
Lindamer, 1992)
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At what stage of the menstrual cycle is migraine most likely to occur and what 
type of migraine?
The majority of studies using a definition for menstrual migraine were undertaken 
to assess different treatments. The definition was predetermined w ithout prior 
evaluation of the natural incidence of migraine across the menstrual cycle.
The results o f Paper I suggest that migraine incidence peaks on or between day -2 
and day +3 of the cycle. Further, menstrual attacks were without aura.
In a study undertaken in a specialist c lin ic, Dalton studied 52 women w ith 
menstrual migraine, defined as attacks of severe disabling headaches, always 
recurring at the same phase of each menstrual cycle.(Dalton, 1973) O f 512 
attacks recorded, 36% occurred during the four days immediately before 
menstruation and 30% occurred during the first four days of menstruation. The 
peak incidence was two days immediately before the onset of menstruation.
There was no association w ith ovulation.
In a com m unity based study Waters and O 'Connor, analysed data from 11 7 
women aged between 20 and 64 years.(Waters & O 'Connor, 1971) In 
menstruating women, the highest incidence of migraine was reported during the 
first few days of menstruation. O f 42 women whose diary cards were analysed 
over two menstrual cycles, the incidence of migraine was about tw ice as frequent 
during menstruation compared to the rest of the cycle. There was no association 
w ith  ovulation.
Johannes et al. studied a group of women who were participating in a large 
population-based prevalence survey of headache.(Johannes et al., 1995) Seventy- 
four women aged between 22 and 29 kept diary records of all their headaches for 
up to 1 6 weeks. The authors noted a 60% increase in migraine without aura 
during the first three days of menstruation. Flowever, they did not analyse 
severity. A ll women in the study had experienced at least one attack of migraine 
w ith aura during their lifetime. They were required to have at least two migraine 
attacks per month, thus the study included women for whom menstruation was 
not the sole trigger. No increase in any headache type was noted during the 
premenstrual phase or in relation to the estimated tim e of ovulation; however, 22 
of the 74 subjects (30%) were using oral contraception during the study period.
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Although the investigators stated that this was not found to be a significant 
covariant, the mechanism of attacks linked to the normal hormonal cycle may 
differ from attacks linked to the w ithdrawal bleed associated w ith  combined oral 
contraceptive use.
In a population-based diary card study Stewart et al examined data from 81 
women each contributing a mean of 89.1 diary days (total 7219 days).(Stewart et 
al., 2000) They found migraine without aura was more likely to occur two days 
before the onset of menstruation and on the first two days of menstruation. There 
was no association between menstruation and migraine with  aura. They did not 
state whether or not any women were taking oral contraceptives.
Taken together, these studies confirm the tim ing of increased incidence of 
migraine on or between day -2 to +3 and provide further evidence that such 
attacks are w ithout aura.
Can menstrual migraine be diagnosed subjectively or is objective diary data 
required?
Few studies paid attention to documented evidence of 'menstrual' migraine, 
usually relying on the patient history, or at most assessing only one or two months 
of diary cards. Patients' self-assessment of menstrual migraine is unreliable, an 
example being women saying that they only get migraine w ith their periods when 
their diary cards show attacks occurring at any stage of the menstrual cycle. 
Patients often report that their attacks occur "when I ovulate" - despite the fact 
that they are taking the combined hormonal contraceptives, w hich inh ib it 
ovulation. Therefore studies obtaining data by questionnaire only, relying on 
subjective reporting of a link between migraine and menstruation, w ill lead to an 
overestimation of the association.
This concern was confirmed by the results from a prospective trial of oral 
sumatriptan 100mg in the treatment of menstrual migraine.(Dowson ef a/., 2005) 
Women who stated that more than 80% of their attacks occurred between -3  to 
+5 days from the onset of menstruation participated in a double-blind, placebo- 
controlled crossover study, conducted over four menstrual cycles. Prospective 
diaries reviewed at the end of the study revealed that only 11 % of participants 
met the inclusion criteria.
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The importance of keeping accurate diary information must be stressed to the 
patient. Waters and O 'Connor stated: 'A ll 11 7 women who were examined 
c lin ica lly  made some attempt to keep diaries of their headaches but the degree of 
co-operation was extremely variable'.(Waters & O 'Connor, 1 971) In Paper I 
presented above, more than 300 women were asked to keep records for three 
months, but only 55 kept diary cards that were complete and suitable for analysis.
Should attacks associated with  ' periods' resulting from withdrawal o f exogenous 
hormones (e.g. combined hormonal contraceptives or cyclical hormone 
replacement therapy (HRT)) be included in the definition?
The progestogen w ithdrawal bleed occurring during the hormone-free interval of 
combined hormonal contraceptives or cyclical HRT is not the same as a 
menstrual bleed resulting from the ovarian cycle, although both are often 
described as 'menstrual'. The endogenous menstrual cycle is the result of 
complex hormonal changes in the hypothalam ic-pituitary-ovarian axis leading to 
ovulation. Menstruation follows the decline in hormones towards the end of the 
cycle. In contrast, ovulation is suppressed by use of combined hormonal 
contraceptives. This is important when considering whether the migraine is 
associated solely w ith  a menstrual 'bleed' or by hormonal changes, as the 
mechanism(s) o f migraine may be different in these distinct cases even if the 
tim ing of attacks is the same. Research should clearly separate these 
subpopulations in order to account for potential differences in pathophysiology.
How many cycles o f data should be collected to confirm the diagnosis?
An additional factor is the number of cycles over which these attacks should 
occur. Clearly, a woman who has exclusive attacks in the defined interval over 
six cycles is more likely to have menstrual migraine than a women who only has 
half her attacks occurring during the defined interval over fewer cycles. However, 
not all women can provide complete diary data for six cycles in advance of a 
clin ical trial. A m inim um  of three cycles of data is likely to provide adequate 
information.
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SUMMARY OF FINDINGS
A review of the literature revealed that there is no consensus for a definition for 
menstrual migraine. Researchers have used a number of different interpretations 
for the term, making it d ifficu lt to compare the data. The review confirms the 
findings in Paper I, that the incidence of migraine increases on or between day -2 
and day +3 of the menstrual cycle and that menstrual attacks are without aura, 
even in women who have migraine with aura. Since attacks at the time of 
menstruation could be a chance occurrence, a definite association should be 
confirmed over several cycles. Balancing the need for accurate data against the 
inconvenience of keeping diaries, it is reasonable to suggest that menstrual 
attacks occurring in at least two out of three of menstrual cycles is sufficient 
evidence to confirm  the association.
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1.1.3. PAPER III: HEADACHES AND HORMONES: SUBJECTIVE 
VERSUS OBJECTIVE ASSESSMENT
Having identified that migraine is more prevalent around day 1 of menstruation, a 
study was undertaken to assess the relationship that women consider exists 
between their migraine attacks and the menstrual cycle.
The subjective account was compared to a prospective record kept by the women 
of their migraine attacks and menstrual cycle. The hypothesis was that self- 
assessment is unreliable and w ill lead to an overestimation of prevalence of 
menstrual migraine.
OBJECTIVES
The objective of this study was to compare the subjective assessment of the 
effects of menstruation on headaches and migraine against objective diary card 
data.
PATIENTS AND METHODS
One doctor interviewed a consecutive series of 100 women diagnosed w ith 
migraine w ith  aura and/or migraine w ithout aura when they attended the City of 
London M igraine C linic. The women were asked specific questions regarding the 
effect of menstruation on their attacks of migraine and other headaches.
Based on the results of this questionnaire, the women were then divided into two 
groups:
Group 1: Those who thought that their attacks of migraine were related to 
menstruation;
Group 2: Those who did not th ink there was any relationship between migraine 
and menstruation.
A ll menstruating women were asked to keep a record of their migraine attacks 
and menstrual cycles over the fo llow ing three menstrual cycles. In this way their 
initial self-assessment of migraine attacks associated w ith  menstruation could be 
compared w ith  a prospective record.
For each woman, the number of migraine attacks that occurred on each day of 
the three menstrual cycles were recorded on a chart. As in Paper I, attacks were
44
charted both preceding and fo llow ing day 1 of the menstrual cycle (day 1 = the 
first day of bleeding). In this way the relationship of migraine attacks to each 
phase of the menstrual cycle could be studied. Attacks around the estimated time 
of ovulation could be identified around day -14, even if the cycles were irregular, 
as the luteal phase is relatively constant.(Speroff et al, 1989)
RESULTS
O f the 100 women interviewed, 22 (age 38.9+/- SD 12.9) had migraine with aura 
and 78 (age 38.0 +/- SD 11.7) had migraine w ithout aura.
Eighty-four women were still menstruating and were not using hormonal 
treatment. Eleven women were post menopausal and 5 had had an hysterectomy 
w ith  conservation of the ovaries.
Self-assessment
O f the menstruating women: 42 women (7 migraine with  aura (16.7%), 35 
migraine without aura (83.3%)) thought that their migraine attacks were related to 
menstruation (Group One); 41 women (11 migraine w ith  aura (26.8%), 30 
migraine w ithout aura (73.2%)) did not think that their migraine attacks were 
related to menstruation (Group Two); one woman was uncertain of the presence 
of any link between migraine and menstruation.
Sixty-five women reported headaches of any kind (including migraine) occurring 
around the time of menstruation, all 42 (100%) in Group One and 23 (56.1%) in 
Group Two. One woman (2.4%) in Group One reported non-migraine headaches 
compared to 8 of the 23 women (34.8%) in Group Two. Nine women (21.4%) in 
Group One reported an increase in migraine at menstruation compared to only 2 
women (8.7%) in Group Two.
Migraine and menstruation diary
Twenty women (24.1%) kept an accurate record over three consecutive menstrual 
cycles, 16 (2 migraine with aura, 14 migraine w ithout aura) from Group One and 
4 (all migraine w ithout aura) from Group Two.
A marked increase in migraine was noted to cluster around day 1 of the cycle 
(first day of bleeding). There was no increase in incidence of migraine at the
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expected time of ovulation (day -14).
Pure menstrual migraine was defined as 'migraine attacks which occur regularly 
on or between days -2 to +3 of the menstrual cycle and at no other tim e1, as 
proposed in Paper I.(MacGregor et al., 1990) O nly three women (15%) fu lfilled 
these criteria, all from Group One. All three women had migraine w ithout aura.
'Menstrually-related' migraine was defined as 'm igraine attacks which occur 
regularly on or between days -2 to +3 of the menstrual cycle w ith additional 
attacks at other times of the cycle'.(MacGregor et al., 1990) Three women 
(1 5.0%) fu lfilled  these criteria and were all from Group One. All had migraine 
w ithout aura.
The remaining ten women from Group One (8 migraine without aura, 2 migraine 
with aura) and one woman from Group Two, had attacks throughout the 
menstrual cycle w ith no increase at the time of menstruation. None of the other 
three women in Group Two had any attacks on or between days -2 and +3 over 
all three cycles.
Most women from Group One had been quite specific in the questionnaire 
regarding the tim ing of their attacks e.g. "always 5 days before my period", "only 
during my period". This relationship was not borne out by the diaries of the 13 
women from Group One who did not have menstrual migraine but was accurate 
for the three women w ith pure menstrual migraine.
DISCUSSION
The findings of this study support the results of Paper I. They emphasise the 
requirement of definitive criteria for 'menstrual' migraine and 'menstrually- 
related' migraine and the need for prospective records to make the diagnosis, 
rather than relying on subjective reporting of a menstrual association.
Previous studies have reported that between 26-60% of women w ith migraine 
relate a periodicity of their headaches to their menstrual cycles.(Epstein et al,
1975; Edelson, 1985; Nattero, 1982; Lance, 1982; Dalton, 1976) This compares 
w ith our find ing of 50.6%. Epstein et al. (1975) defined true 'menstrual' migraine 
as attacks confined to just before or during the period of blood loss which 
occurred in 14% of menstruating women, w ith a further 12% having additional
attacks at other times. O ur findings of 1 5% and 1 5% respectively were similar. 
Women who completed our prospective study were a self-selected group who 
knew that a connection between migraine and menstruation was being studied. 
Unfortunately data in this part of the study was highly selected as so few women 
kept complete diary cards for the three months. O ur previous study on a larger 
number of women who kept records as part of their routine treatment showed that 
7.2% of women had 'menstrual' migraine and 34.5% had 'menstrually-related' 
migraine.(MacGregor ef a/v 1990)
SUMMARY OF FINDINGS
%
In this study the subjective link between migraine and menstruation as reported 
by women questioned often failed to match prospective records of migraine and 
menstruation. This discrepancy casts considerable doubt on some previous 
published research in which the diagnosis of 'menstrual' migraine was based 
upon subjective history or retrospective questionnaires. Information obtained at 
interview is of lim ited value in identifying women in whom a definite link 
between migraine and menstruation exists, although this study suggests that it 
does correctly identify women in whom there is no such link.
Suggested definitions for 'menstrual' migraine and 'menstrually-related' migraine 
are based on the clin ica l observation that women have more migraine attacks on 
or between days -2 to +3 of the cycle. Universally agreed criteria are necessary 
for the comparison of studies and specific treatment regimes.
These findings confirm  that the terms pure menstrual migraine and menstrually- 
related migraine should only be used when strict criteria are fu lfilled, enabling 
future studies to explore the pathophysiology of 'menstrual' migraine w ith  fewer 
confounding triggers. Such criteria should also be met before specific hormonal 
treatment is considered.
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1.2. ASSESSING THE CLINICAL DIFFERENCES BETWEEN 
MENSTRUAL MIGRAINE AND NON-MENSTRUAL ATTACKS
If menstrual migraine is distinct entity, there should be identifiable characteristics 
that distinguish such attacks from other types of migraine. Although it is generally 
considered that attacks of menstrual migraine are more severe and less responsive 
to treatment compared to non-menstrual attacks, there are lim ited data to support 
this c lin ica l observation. Most studies have retrospectively analysed data from 
large c lin ica l trials of acute treatment w ith triptans, comparing all attacks 
occurring in association with menstruation with non-menstrual attacks. Very few 
studies have focused specifically on women diagnosed w ith pure menstrual or 
menstrually-related migraine.
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1.2.1. PAPER IV: PREVALENCE OF MIGRAINE ON EACH DAY OF 
THE NATURAL MENSTRUAL CYCLE
This study was undertaken to assess the association between migraine and 
menstruation over a larger number of cycles, in a larger number of women, in 
whom an accurate diagnosis of migraine has been made, than has previously 
been studied. Further, the data were subjected to a w ith in-wom an analysis rather 
than the usual between-women comparisons.
OBJECTIVES
The objectives of this study were to assess when migraine was most likely to 
occur during the menstrual cycle and if migraine at the time of menstruation 
differs in severity and the presence or absence of nausea or vom iting versus 
attacks at other times of the cycle.
METHODS
Women w ith  migraine attending the City of London M igraine C lin ic kept diary 
cards as part of their routine management. On the diary cards both headaches 
and migraine were recorded, together w ith severity (mild, moderate, or severe), 
presence of aura and nausea or vomiting.
Fully completed diary cards recording migraine attacks and menstruation over a 
m inim um  of three menstrual cycles in women who had migraine w ith and/or 
w ithout aura were analysed.
A database was designed specifically for the study using M icrosoft Access. One 
individual entered all the data, in order to ensure consistency of interpretation. 
Based on information from each woman's diary cards it was judged whether she 
suffered a headache or a migraine. Where there was any doubt about the nature 
of any headache episode, we assessed the accompanying symptoms or contacted 
the patient directly for clarification.
Because it was not known when in the cycle each woman began her diary, 
migraine attacks occurring before the first recorded period were not included in 
the analysis. Also, the date of the last period for each woman was not recorded so 
it was assumed that the length of the last recorded cycle w ould be 28 days.
Migraine attacks occurring more than 23 days from the last known period date 
were excluded in order to avoid including migraine attacks in the last cycle 
which may have occurred in the 5 days before the fo llow ing  period.
DEFINITIONS
The fo llow ing  definitions were used for the analysis:
o  The pre-menstruation interval: the five days immediately before the first 
day of menstruation (days -5  to -1).
o  The post-menstruation interval: the first day of menstruation and the five 
days immediately afterwards (days 1 to 6).
o  'A ll other times' included the days that did not fall w ith in  either the pre- or 
post-menstruation interval, i.e., all days of the cycle other than day 1 of 
menstruation ± 5 days.
Additional analyses were based on the two days before menstruation (days -1 and 
-2 ) and the first day of menstruation plus subsequent tw o days of bleeding (days 
+ 1 to +3).
ANALYSES
Migraine was counted as each day on which the woman reported migraine. For 
each woman the risk of migraine during the pre-menstruation and during the 
post-menstruation intervals was compared to the risk o f migraine at all other times 
of her cycle and the relative risk calculated.
Since diary data for the final cycle for most women was incomplete, a statistical 
model was developed to handle the data consistently. This is illustrated in Figure 
6, w hich shows how each day was determined to be pre- or post menstruation or 
all other times for one woman who provided a diary for three consecutive cycles, 
w ith an incomplete third cycle. The final cycle was assumed to last 28 days, on 
the basis of mean duration, although it is recognised that there is marked 
individual variation.(Speroff & Fritz, 2004)
In this example, over the three recorded cycles, there were two known pre­
menstruation intervals from day -5 to day -1 (of 10 days in total) during which 
there were two migraine attacks, three known post-menstruation intervals from
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day +1 to day +6 (of 1 8 days in total) during which there were nine migraine 
attacks, and 49 days at all other times during which there were 11 migraine 
attacks. For this woman the relative risk of having a migraine attack in the pre­
menstruation interval was 0.89 (2/10 -f 11/49). The relative risk of having an 
attack in the post-menstruation period was 2.23 (9/18 -r 11/49). This approach 
was, therefore, a w ithin-wom an comparison and w ould a llow  for her own 
migraine pattern during the course of her cycles.
If there were no migraine days for both the pre-menstruation interval and at other 
times (or both the post-menstruation interval and at other times) a relative risk was 
not calculated.
Relative risks were pooled across all women using an exact method which allows 
for small occurrences, providing a 95% confidence interval and p-value.(Martin & 
Austin, 2000)
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RESULTS
Diary cards from 165 women were reviewed. Six women were excluded because 
each had data for one cycle only and four women were excluded because the 
data were not from consecutive cycles. The analysis presented here is thus based 
on 1 55 women. There was a total of 693 cycles; 1 7% of women provided data for 
2 cycles, 37% for 3 cycles, 16% for 4 cycles and 30% for 5 or more cycles.
O f the 1 55 women, date of birth was available for 143. The median age of these 
women was 44 years (range 1 5 to 58).
All women used symptomatic medication. Although this varied between 
individuals, it was comparatively consistent w ith in  individuals. O nly six women 
were using prophylactic therapy.
The cycle length was 29 ± 4 days (mean ± SD). Although the range was 19-44 
days, 95% of women had a cycle length between 21 and 37 days.
Severity of migraine and whether there was nausea or vom iting was only 
recorded by 81 women: 33% of women (27/81) reported migraine w ith vom iting 
at some point, and 91% (74/81) w ith nausea.
Table 2 shows the total occurrence of migraine days, the number that were mild, 
moderate or severe, and the number that were associated w ith nausea or 
vomiting.
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Severity Migraine associated 
w ith:
No. of 
days w ith 
migraine
M ild Moderate Severe Nausea Vom iting
Pre-menstruation 
(5 days before 
menstruation)
322 31 56 47 78 10
Post-menstruation 
(1st day of bleeding 
+5 days)
889 85 136 138 210 32
All other times 1160 151 196 149 266 30
Total 2371 267 388 334 554 72
TABLE 2 :T H E  TO TAL OCCURRENCE OF MIG RAIN E DAYS, THE NUM BER TH A T WERE SEVERE, MODERATE OR 
M IL D , A N D  THE NUM BER ASSOCIATED W IT H  NAUSEA OR V O M IT IN G
Figure 7 shows the number of attacks occurring on each day of the menstrual 
cycle, based on 126 women who had three consecutive cycles. The first day of 
bleeding was used as the reference point from which all other migraine days were 
compared. The frequency of migraines increased as menstruation was 
approached, w ith  the highest frequency occurring on the first day of menstruation 
(day 1), and decreasing after. There was no association between migraine and the 
expected time of ovulation (day -14).
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Table 3 shows the pooled relative risk of migraine during the pre-menstruation 
interval and post-menstruation interval compared to all other times of the cycle.
In the five days preceding menstruation women were 25% more likely to have a 
migraine (relative risk 1.25). This increased to 71 % in the two days before 
menstruation (relative risk 1.71). The chance of migraine was more than two-fold 
on the first day of menstruation and during the five days afterwards (relative risk 
2.19). The risk was highest on the first day of menstruation and the fo llow ing two 
days (relative risk 2.50). All the results were highly statistically significant.
Figure 8 shows the individual relative risk of migraine for each woman during the 
two days before menstruation. The horizontal line, relative risk of 1, indicates no 
difference in the occurrence of migraines during the menstrual cycle compared to 
at other times; 78% of women (11 7/1 50) had a relative risk that exceeded one 
(indicating increased risk during the pre-menstruation interval).
Figure 9 shows the individual relative risk of migraine for each woman during the 
first three days of menstruation; 76% of women (11 7/1 54) had a relative risk that 
exceeded one.
Table 4 shows the pooled relative risk of migraine according to severity. Severe 
attacks were more likely to occur during the pre-menstruation (relative risk 1.43) 
and post-menstruation intervals (relative risk 2.63) compared to all other times of 
the cycle. There was a trend from m ild to severe in both the pre-menstruation and 
post-menstruation intervals, providing further weight that migraines tend to be 
more severe just before or after the first day of menstruation. Again, the risk was 
always highest in the post-menstruation interval than the pre-menstruation one. 
The risks were also greater when migraine attacks were restricted to the tw o days 
before or after (and including) the first day of menstruation. Women were more 
likely to have a severe migraine on the first day of menstruation or during the 
fo llow ing two days (relative risk 3.41) compared to other times of her cycle.
Again there was a trend from m ild to severe. Results for the post-menstruation 
interval were highly statistically significant, and those results for severe migraines 
during the pre-menstruation interval were also generally significant.
1sl day of menstruation ± 5 days
Relative 95% Statistical Number of
risk confidence significance women*
interval
1st day of menstruation ± 2 days
Relative risk 95% Statistical Number of
confidence significance women*
interval
Pre-menstruation 1.25
Post- 2.19
menstruation
All other times* 1.00
1.10-1.42 p<0.001 150
2.01-2.40 p<0.0001 155
1.71
2.50
1.00
1.45-2.01
2.24-2.77
p<0.0001
p<0.0001
150
154
Pre-menstruation is the 5 (or 2) days before menstruation; post-menstruation is the 1st day of bleeding and the subsequent 5 (or 2) days
* The number of women on whom the relative risk is based
* 'A ll other times' is defined as the days of the cycle other than day 1 of menstruation ± 5 days
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Ln
CO
151 day of menstruation ± 5 days 1st day of menstruation ± 2 days
Severity of migraine Relative
risk
95%
confidence
interval
Statistical
significance
Number
of
women*
Relative
risk
95%
confidence
interval
Statistical
significance
Number
of
women*
Pre-menstruation
M ild 0.97 0.63-1.43 P=0.95 43 1.39 0.78-2.28 P =0.27 42
Moderate 1.26 0.92-1.71 P =0.1 5 58 1.54 0.98-2.31 P =0.06 57
Severe 1.43 1.00-2.00 P =0.05 58 2.06 1.29-3.13 P =0.003 55
All other times 1.00 - - - 1.00* - - -
Post-menstruation
M ild 1.62 1.22-2.12 P <0.001 48 1.54 1.05-2.19 P =0.03 42
Moderate 1.91 1.52-2.40 P <0.0001 66 1.89 1.41-2.51 P <0.0001 62
Severe 2.63 2.07-3.35 P <0.0001 59 3.41 2.58-4.47 P <0.0001 59
All other times* 1.00 - - - 1.00 - - -
Pre-menstruation is the 5 (or 2) days before menstruation; post-menstruation is the 1si day of bleeding and the subsequent 5 (or 2) days
* The number of women on whom the relative risk is based
* 'A ll other times' is defined as the days of the cycle other than day 1 of menstruation ± 5 days
TABLE 4: The POOLED RELATIVE RISK OF M ILD , MODERATE OR SEVERE MIGRAINE O N  OR BETWEEN D A Y  1 ±5 A N D  O N  OR BETWEEN DAY 1 ±2
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Table 5 shows the pooled relative risk of migraine associated w ith vom iting or 
nausea. Most women had migraine w ith nausea and migraine w ith vom iting was 
less common. Both types of migraine were more likely to occur close to 
menstruation, w ith highly statistically significant results observed for the post­
menstruation interval (day 1 to day 6 of the cycle). Women were almost five times 
more likely to have a migraine associated w ith vom iting on or during days 1 to 3 
of menstruation (relative risk 4.69).
Migraine 
associated with
1st day of menstruation ± 5 days
Relative 95% Statistical Number of
risk confidence significance women*
interval
1st day of menstruation ± 2 days
Relative 95% Statistical Number of
risk confidence significance women*
interval
Vomiting:
Pre-menstruation 1.55
Post-menstruation 3.09
All other times 1.00
0.67-3.24
1.82-5.28
P =0.33 
P <0.0001
21
24
2.62
4.69
1.00 "
0.87-6.31
2.62-8.31
P =0.09 
P <0.0001
19
22
Nausea:
Pre-menstruation 1.29
Post-menstruation 2.18
All other times* 1.00
0.98-1.66
1.81-2.63
P =0.07 68
P <0.0001 70
1.84
2.60
1.00
1.30-2.53
2.08-3.23
P <0.0001 
P <0.0001
66
69
Pre-menstruation is the 5 (or 2) days before menstruation; post-menstruation is the 1st day of bleeding and the subsequent 5 (or 2) days
* The number of women on whom the relative risk is based
* 'A ll other times' is defined as the days of the cycle other than day 1 of menstruation ± 5 days
TABLE 5 : T h e  POOLED RELATIVE RISK OF M IG RAINE ASSOCIATED W ITH  V O M IT IN G  OR NAUSEA O N  OR BETWEEN DAY 1 ± 5  A N D  O N  OR BETWEEN DAY 1 ± 2
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DISCUSSION
The results of this observational study confirm a clear association between 
migraine and menstruation. Migraine was more likely to occur during a five-day 
w indow  from two days before to two days after the first day of menstruation (days 
-2  to +3). The w ithin-wom an analysis showed that menstrual attacks also tended 
to be more severe and associated with nausea and vom iting at this time compared 
to attacks at other times of the cycle. The greatest effect of menstruation on 
migraine was during the first three days of the cycle.
These results are similar to previously published diary card studies showing that 
the peak time for migraine during the menstrual cycle is on or between two days 
before the start of menstruation and the first three days of bleeding.(Waters & 
O'Connor, 1971; Dalton, 1973; MacGregor et al., 1990; Johannes et al.f 1995; 
Stewart et al., 2000) Although the present study suggests that days +4 to +6 are 
also associated w ith increased risk of migraine, all migraine days were analysed 
whereas our 1990 study analysed only the first day of each migraine attack.
The strengths of the present study are the larger population, greater number of 
cycles, the confirmed diagnosis for each migraine attack, the accuracy of diary 
card data, and use of w ithin-wom an analysis.
We were unable to look at the association between migraine aura and 
menstruation. Women had been asked to complete the diaries as part of their 
clin ical management rather than as participants in a c lin ica l trial and it was noted 
that some women confused premonitory symptoms w ith  aura. Although the true 
diagnosis of each attack could be established by direct questioning in the majority 
of cases, it was not always possible to be sure, particularly for women who had 
attacks w ith  and w ithout aura. Hence we considered that these data were 
potentially too unreliable for an analysis to be meaningful.
A potential weakness is that these data are from women attending a specialist 
headache c lin ic  and cannot be extrapolated to the general population of women 
w ith migraine. However, these data are likely to represent women seeking 
medical help for migraine. Although a community based study would need to be 
undertaken to confirm this, previous studies in both community and c lin ic  based
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populations have shown similar results.(Waters & O 'Connor, 1971; Dalton, 1973; 
MacGregor et al., 1990; Johannes et al., 1995; Stewart et al., 2000; Couturier et 
al., 2003)
SUMMARY OF FINDINGS
Migraine w ith menstruation is a significant problem for many women, who also 
report that menstrual attacks are of longer duration, more severe and less 
responsive to treatment compared to attacks at other times of the cycle. The 
present diary based observational study confirms that migraine is most likely to 
occur during the two days before menstruation and the first three days of 
bleeding, and that these attacks tend to be more severe than non-menstrual 
attacks. There was no association between migraine and ovulation.
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1.2.2. ADDITIONAL EVIDENCE OF CLINICAL DIFFERENCES 
BETWEEN MENSTRUAL MIGRAINE AND NON-MENSTRUAL 
ATTACKS: A REVIEW
Based on incidence alone, menstrual migraine could be classified as a sub­
category of migraine w ithout aura with a predictable 'trigger'. On this basis, there 
would be no need for a specific definition.
In support of this, published reviews of data from large databases generated in 
clin ical trials suggest that all seven of the commercially available triptans work as 
well for menstrual attacks as they do for attacks at other times of the month, 
which suggests there is no need for specific definition w ith respect to treatment 
strategies.(Solbach & Waymer, 1993; Facchinetti e ta /., 1995; Gross e ta/., 1995; 
Silberstein ef a/., 1999; MacGregor & Keywood, 2000; Massiou e ta/., 2000; 
Silberstein et a/., 2000; Silberstein et a/., 2002; Nett et a/., 2003; Loder et a/.,
2004; Massiou et a/., 2005) Flowever, the analyses were based on all attacks 
occurring during menstruation versus non-menstrual attacks and not based on 
attacks in women diagnosed w ith menstrual migraine.
In contrast, the results from Paper IV suggest that w ith in  individual women there 
are clin ica l differences between menstrual migraine and non-menstrual attacks. 
Other published research in women diagnosed w ith menstrual migraine 
according to the proposed definitions confirms that menstrual attacks of migraine 
are more severe than non-menstrual attacks but also that they last longer, are less 
responsive to treatment, and more prone to relapse.( Allais et al., 2006; Couturier 
et al., 2003; Dowson et al., 2005; Granella et al., 2004; Visser et al., 1996)
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In a prospective placebo-controlled study of 115 women, data from 53 women 
identified w ith menstrually-related migraine suggested that sumatriptan was less 
effective for menstrual attacks compared to non-menstrual attacks (Figure 
10).(Gross et al., 1995; Dowson et al., 2005)
■ sumatriptan 100mg
■  placebo
attacks inside menstrual attacks outside menstrual 
window window
FIGURE 10: EFFICACY OF SUM ATRIPTAN 1 0 0 M G  4 HOURS POST TREATMENT O N  ATTACKS INSIDE A N D  
OUTSIDE THE MENSTRUAL W IN D 0 W .(G R 0 S S  ET A L ., 1 995; D O W S O N  £7 A L ,  2005)
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Granella et al. noted that pain-free at 2 hours fo llow ing  treatment was less likely 
to be achieved for menstrual versus non-menstrual attacks (Figure 11) and 
menstrual attacks lasted longer than non-menstrual attacks (Table 6).(Granella et 
al., 2004)
3
2
1
0.7 0.67
0.41
o
days -2 to -1 days +1 to +2 days +3 to +7
FIGURE 1 1 : 2 HR PAIN-FREE: MENSTRUAL ATTACKS (DAYS -2 TO  +3) VS. ALL OTHER TIMES OF THE
c y c l e . ( G r a n e l l a  e t a l ., 2004)
Day of menstrual cycle* Attack duration (hrs) 
(mean ± 95% Cl)
Significance
Days -2 to -1 29.6 ± 24.1 P< 0.0001
Days +1 to +2 33.7 ± 24.8 P< 0.0001
Days +3 to +7 24.0 ± 21.8 P= 0.002
All other times 16.3 ± 15.1
* relative to 1 st day o f bleeding (Day +1)
TABLE 6 : D U R A T IO N  OF M IG RAINE AT DIFFERENT STAGES OF THE MENSTRUAL CYCLE (G R A N E LLA  ET A L .,
2004)
67
Granella et al. also found that fo llow ing treatment, menstrual attacks were more 
likely to relapse than non-menstrual attacks (Figure 12).(Granella et a l 2004)
3
2.15
2
1.96
1.01
1
o
days -2 to -1 days +1 to +2 days +3 to +7
FIGURE 12: R e l a p s e  in  24 h o u r s : m e n s t r u a l  a t t a c k s  (d a y s  -2 t o  +3) vs. a l l  o t h e r  t im e s  o f  t h e
c y c l e . ( G r a n e l l a e t a l ., 2004)
Similarly, Allais et al. reported that although acute triptan therapy for menstrual 
migraine provided effective pain-free relief at 2 hours in most women, a sustained 
pain-free state was achieved by fewer than 30% of patients.(Allais et al., 2006)
SUMMARY OF FINDINGS
In contrast to post-hoc analyses of treatment trials, specific studies of women with 
menstrual migraine confirm the clin ica l impression that menstrual attacks are 
more severe, less responsive to symptomatic treatment and more prone to relapse 
compared to non-menstrual attacks. They also highlight the importance of the 
c lin ica lly  relevant w ithin-wom an analyses of menstrual versus non-menstrual 
attacks, assessing intra-individual variation rather than inter-individual variation.
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1.3. CONCLUSIONS FROM PART ONE
From all the data presented thus far, the fo llow ing points can be concluded:
1. There is no agreed definition for menstrual migraine; clin ical trials have used a 
variety of definitions, making it d ifficu lt to compare data.
2. In women w ith migraine, attacks are more likely to occur during a five-day 
w indow  from two days before to two days after the first day of menstruation (days 
-2  to +3).
3. Migraine at this time of the cycle is typ ically w ithout aura, even in women who 
have migraine with aura.
4. W ithin-wom an analyses showed that menstrual attacks are more severe and 
more likely to be associated w ith nausea and vom iting compared to attacks at 
other times of the cycle; the greatest effect of menstruation on migraine is during 
the first three days of the cycle.
5. Other published data suggest that menstrual attacks are longer, less responsive 
to treatment, and more prone to relapse compared to non-menstrual attacks.
6. Subjective assessment overestimates the association between migraine and 
menstruation and accurate diary data is mandatory to confirm  the diagnosis.
It could be argued that menstrual migraine does not require a discrete definition 
and should be considered as migraine w ithout aura. Menstruation is just an 
additional trigger to others such as missed or delayed meals, dehydration, lack of 
sleep, etc.
Fiowever, evidence supports the hypothesis that menstrual migraine is a distinct 
c lin ical entity since menstrual attacks are c lin ica lly  different from attacks at other 
times of the cycle.
To ensure the association w ith menstruation is not a chance occurrence, it is 
necessary to ensure that the association is consistent over several cycles. As a 
m inimum, it seems reasonable that the association could be confirmed if 
menstrual attacks occur in at least two out of three menstrual cycles.
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On the basis of the above findings, the fo llow ing definitions for pure menstrual 
migraine and menstrually-related migraine were proposed to encompass the 
clin ica l entity of menstrual migraine:
Pure menstrual migraine
Attacks o f migraine w ithout aura occurring exclusively on or between days- 
2 to +3 o f menstruation in at least two out o f three menstrual cycles and at 
no other times o f the cycle
Menstrually-related migraine
Attacks o f migraine w ithout aura occurring on or between days -2 to +3 o f 
menstruation in at least two out o f three menstrual cycles w ith additional 
attacks o f migraine with or w ithout aura at other times o f the cycle
These definitions were submitted to Headache Classification Committee of the 
International Headache Society for consideration and are included in the second 
edition of the International Classification of Headache Disorders.(Headache 
Classification Subcommittee of the International Headache Society (IHS), 2004) At 
present, they are in the appendix rather than part of the main classification, in 
consideration of the need for additional confirmatory research and 
epidemiological evidence. An agreed definition is essential to ensure that 
comparable populations are studied, so that we can elucidate the 
pathophysiology and improve management. Research w ill also enable further 
refinement of the definitions.
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1.4. AN INTERNATIONAL CLASSIFICATION FOR MENSTRUAL 
MIGRAINE
A t.1.1 Pure menstrual migraine without aura
Diagnostic criteria:
A. Attacks, in a menstruating woman, fu lfilling  criteria for migraine w ithout aura
B. Attacks occur exclusively on day 1 ±2 (i.e., days -2 to +3)1 of menstruation2 in 
at least two out of three menstrual cycles and at no other times of the cycle
A1.1.2 Menstrually-related migraine without aura
Diagnostic criteria:
A. Attacks, in a menstruating woman, fu lfilling  criteria for migraine w ithout aura
B. Attacks occur on day 1 ±2 (i.e, days -2 to +3)1 of menstruation2 in at least two 
out of three menstrual cycles and additionally at other times of the cycle
Notes:
1. The first day o f menstruation is day 1 and the preceding day is day -1; there is no day 0
2. For the purposes o f this classification, menstruation is considered to be endom etrial bleeding 
resulting from  either the normal menstrual cycle or from  the w ithdraw al o f exogenous 
progestogens, as in the case of combined oral contraceptives and cyclica l hormone replacement 
therapy
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PART 2:
MENSTRUAL MIGRAINE IS ASSOCIATED WITH OESTROGEN
'WITHDRAWAL'
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2.1 MIGRAINE AND OESTROGEN 'WITHDRAWAL' DURING THE 
NATURAL MENSTRUAL CYCLE
2.1.1. EVIDENCE FOR THE ASSOCIATION BETWEEN MIGRAINE 
AND OESTROGEN 'WITHDRAWAL' DURING THE NATURAL 
MENSTRUAL CYCLE: A REVIEW
The inconsistency of definitions for 'menstrual' migraine has made it impossible 
to establish the true significance of the results of biochemical and hormonal 
studies previously published. The steroid hormones involved in the menstrual 
cycle, particularly oestrogen and progesterone, are the obvious targets for 
research. Studies comparing levels of these hormones in women w ith  'menstrual' 
migraine versus controls have not identified any convincing differences.(Epstein et 
al., 1975) However, such findings do not exclude sensitivity to normal endocrine 
changes of the ovarian cycle as a 'trigger' for attacks.
THE MENSTRUAL CYCLE
The average menstrual cycle lasts 28 days - counted from the first day of one 
menstrual period to the start of the next - but this can vary considerably in 
individuals.
The cycle can be divided into three stages: the fo llicu la r phase, ovulation, and the 
luteal phase (Figure 13).
Menses Menses
1 14 28 Day of cycle
Follicular Phase Ovulation Luteal Phase
4 ► -4-----►■4---------------------  ►
FIGURE 13: T h e  t h r e e  s t a g e s  o f  t h e  m e n s t r u a l  c y c l e
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The fo llicu lar phase is the first part of the cycle. At the start of each cycle, 
hormones from the hypothalamus stimulate the pituitary gland to secrete fo llic le  
stimulating hormone (FShU® (Figure 14). This stimulates the ovaries and five to 
twenty follicles rapidly start to grow. By about day six of the cycle, a single 
fo llic le  in one of the ovaries grows faster, w hile  the others regress.
The developing follicles produce oestrogen®. Rising oestrogen levels feedback to 
the pituitary gland, to reduce the secretion of FSH and trigger luteinizing hormone 
(LHJ®. Ovulation takes place as a surge of LH causes the fo llic le  to rupture, 
releasing the mature egg®.
The luteal phase is the time between ovulation and menstruation. It consistently 
lasts close to 14 days.(Speroff & Fritz, 2004) Under the control of LH, the empty 
fo llic le  transforms into the corpus luteum, which produces progesterone and a 
second rise of oestrogen®. Therefore progesterone is only present in the luteal 
phase of ovulatory cycles. High hormone levels cause the production of fo llic le  
stimulating hormone and luteinizing hormone to fa ll® . If there is no pregnancy, 
the corpus luteum rapidly degenerates, nine to eleven days after ovulation and 
levels of oestrogen and progesterone fall. The fall in progesterone causes the 
menstrual bleed®.
Given the increased incidence of migraine at this time of the cycle, the luteal fall 
in oestrogen and progesterone merits further examination.
follicular phase ovulation luteal phase
Pituitary
gland
® FSH
ovary
2) oestrogen
® oestrogen/ 
progesterone
® ovulation corpus
luteum
© FSH/LH
® menstruation
variable length '14 days
FIGURE 1 4 :  T h e  p it u it a r y - o v a r i a n  a x is : f o l l ic u l a r , o v u l a t o r y , a n d  l u t e a l  p h a s e s
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OESTROGEN AND PROGESTERONE IN MENSTRUAL MIGRAINE
Progesterone
Insufficient progesterone in the luteal phase was first considered to be responsible 
for the occurrence of menstrual migraine.(Gray, 1 941; Singh & Singh, 1947)
A more recent study of 14 volunteers, 11 of whom had menstrual migraine, 
suggested that luteal progesterone levels were significantly associated w ith 
headache activity.(Beckham et al., 1992) However, the number of patients was 
small and samples were taken only at four points during a single menstrual cycle.
Somerville also considered that progesterone 'w ithdraw al' was a likely 
mechanism for menstrual migraine. He used progesterone supplements to treat six 
women who had attacks of migraine during the late luteal phase. Menstruation 
was delayed in four of these women. Five experienced migraine at their 
customary time, unrelated to plasma progesterone levels (Figure 1 5).(Somerville, 
1971, 1972a)
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days from onset of menstruation progesterone injection
FIGURE 1 5: The EFFECT OF TREATMENT W ITH  PROGESTERONE O N  MENSTRUAL M IG RAINE.(SO M ER VILLE,
1971, 1972a )
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Somerville also studied the effects of exogenous progesterone in women in whom 
high serum levels of exogenous oestrogen had inhibited ovulation. Neither the 
administration of progesterone nor its subsequent 'w ithdraw al' resulted in 
migraine.
In contrast, continuous progestogen treatments at doses sufficient to suppress the 
endogenous menstrual cycle, have been effective in preventing menstrual 
migraine.(Bradley ef a/., 1968; Somerville & Carey, 1970)
Oestrogen
The evidence is more in favour of menstrual attacks being associated, at least in 
some women, w ith falling levels or 'w ithdrawal' of oestrogen. Somerville went on 
to examine the effects of oestrogen on menstrual migraine, studying 14 women 
each of whom had a predictable attack of migraine every month, always confined 
to the premenstrual or menstrual phases.(Somerville, 1972b, 1975b, a) Each 
subject had confirmed menstrual migraine for at least six successive cycles 
immediately prior to the study. A review of his data shows that all the subjects 
had attacks occurring on or between day 1 ±3 of the menstrual cycle. On the basis 
of his observations, Somerville suggested that migraine could be triggered by the 
sudden w ithdrawal of oestrogen fo llow ing high oestrogen levels. He also noted 
that a period of oestrogen 'prim ing' w ith several days of exposure to high 
oestrogen levels is a necessary precursor. This w ould explain why migraine 
attacks are not associated w ith ovulation. In contrast to sustained higher 
oestrogen levels in the luteal phase, oestrogen levels are relatively low in the 
fo llicu lar phase and do not 'prime' the system sufficie , l / rar the drop in 
oestrogen immediately post ovulation to have an effect.
If the oestrogen 'w ithdraw al' hypothesis is correct, stabilising oestrogen 
fluctuations by maintaining high, stable levels, should prevent migraine.
In favour of this, Somerville showed that migraine could be postponed by 
maintaining high plasma oestradiol levels w ith an intramuscular injection of long- 
acting oestradiol valerate in oil; migraine subsequently occurred when the plasma 
oestradiol fell (Figure 16).
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FIGURE 16: Pl a s m a  o e s t r a d io l  c o n c e n t r a t io n s  d u r in g  t h e  p r e m e n s t r u a l  a n d  m e n s t r u a l  phases
OF NORMAL AND OESTRADIOL-TREATED CYCLES IN ONE W O M A N  WITH REGULAR MENSTRUAL
m i g r a i n e .(So m e r v i l l e , 1 9 7 2 b )
Somerville also tried a short-acting oestrogen, which did not produce the same 
results, confirm ing his suggestion that prolonged oestrogen exposure is necessary 
for 'w ithdraw al' to trigger migraine. Further attempts to control oestrogen 
fluctuations w ith oral oestradiol valerate and conjugated equine oestrogens, 
failed.(Somerville, 1975b) These formulations did not significantly affect plasma 
oestradiol levels, which is likely to account for their failure to prevent migraine.
Several other studies support Somerville's oestrogen w ithdrawal theory. Epstein et 
a!., noted that the extent of decline from peak to trough oestrogen was greater in 
all 14 women w ith  migraine in their study compared to 8 women in the control 
group who did not have migraine.(Epstein et al., 1975) They concluded that 
variation in hormonal activity might be a potentially relevant factor in all women
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with migraine; factors additional to the hormonal environment could account for 
the development of 'menstrual' attacks. Lichten et al., studied 28 postmenopausal 
women challenged w ith oestrogen confirming that a drop in serum oestrogen 
could precipitate migraine attacks and that a period of oestrogen prim ing was a 
necessary prerequisite.(Lichten ef a/., 1996)
Oestrogen 'withdrawal' in the absence of progesterone
Several studies suggest that oestrogen 'w ithdraw al' migraine is independent of 
progesterone.
Somerville studied two postmenopausal women w ith a past history of menstrual 
migraine but who had been free of migraine since the menopause. Migraine was 
associated w ith the fall in oestrogen fo llow ing depot oestradiol, despite plasma 
progesterone concentrations never exceeding 1 ng/mL.(Somerville, 1972a)
Similarly, when postmenopausal women were challenged w ith oestrogen in the 
study by Lichten eta l., oestrogen 'w ithdraw al' migraine occurred in the absence 
of progesterone and a period of oestrogen prim ing was a necessary 
prerequisite.(Lichten eta/., 1996)
Additional clinical evidence for oestrogen 'withdrawal'
Women taking the combined oral contraceptive p ill can experience migraine 
attacks during the pill-free week, when ethinyloestradiol falls after 21 days of p ill- 
taking. (W hitty eta/., 1966) In women using hormone replacement therapy, 
migraine attacks occurred during the week free from oestrogen in the old regime 
of 21 days on treatment, 7 days off.(Kudrow, 1975) In a placebo-controlled 
double-blind crossover study of hysterectomised women w ith bilateral 
oophorectomies, increased frequency of headache was reported fo llow ing 
courses of oestrogen.(Dennerstein et a/., 1978) M igraine attacks also occur 
directly postpartum, a time when oestrogen levels plummet.(Stein, 1981) These 
findings provide further evidence for oestrogen 'w ithdraw al' migraine and 
together w ith the studies in postmenopausal women, suggest that ovulation is not 
a necessary precursor.
However, these studies were undertaken on small numbers of women over few 
cycles. Larger studies were warranted to confirm these findings.
79
2.1.2. PAPER V: INCIDENCE OF MIGRAINE RELATIVE TO 
MENSTRUAL CYCLE PHASES OF RISING AND FALLING 
OESTROGEN
This longitudinal study was undertaken to assess the association between 
migraine and urinary oestrogen levels on each day of the menstrual cycle. All 
women were diagnosed with menstrual migraine and were not using exogenous 
hormones.
OBJECTIVES
The objectives of the study were to assess the association between migraine and 
urinary hormone levels, w ith particular reference to rising and falling phases of 
oestrogen, and to  test the hypothesis that oestrogen 'w ithdraw al' triggers 
migraine in the late luteal phase of the menstrual cycle.
METHODS
Participants were selected from women attending the City of London Migraine 
C linic who had been keeping diary card records of migraine and menstruation. 
They were eligible for inclusion into the study if they had pure menstrual 
migraine or menstrually-related migraine, and had regular menstrual cycles (21- 
35 days).
Eligibility was based on prospective diary information recorded for at least three 
months, to confirm menstrual migraine or menstrually-related migraine. Women 
w ith additional non-migraine headaches could participate provided that they 
could distinguish these headaches from migraine. Non-hormonal migraine 
prophylaxis could be continued provided that the dose remained stable during 
the study period.
Women were not eligible if: headaches (including migraine headaches) occurred 
more often than three days a week on average, i.e. more than 12 days per month; 
analgesics or acute headache medications were used regularly on more than 
three days a week; they were pregnant, or intended to become pregnant during 
the study period (women used non-hormonal contraception), or were 
breastfeeding; had evidence of impaired liver or kidney function; had evidence of
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polycystic ovarian syndrome (unless they had regular menstrual periods); used 
hormonal contraception, hormone replacement therapy or other hormonal 
treatment w ith in  six months prior to the start of the study or at any time during the 
study period; used treatments that might affect the menstrual cycle such as a diet 
high in soy, or use of soy/isoflavane supplements; be taking tetracycline (which 
affects LH assay) or had any medical or psychiatric condition that might have 
been affected adversely by use of oestrogen supplements or which would 
preclude participation in the study.
All women gave informed consent and were reviewed monthly, either by 
telephone or by a c lin ic  visit. All study documents were approved by an 
independent Ethics Committee.
DEFINITIONS
Pure menstrual migraine was defined as migraine attacks on or between day 1 of 
menstruation ± 2 days (i.e. on or between days -2  to +3 of the cycle assuming 
day 1 is the first day of menstruation and that there is no day 0) in at least two out 
of three cycles, w ith no migraine at other times of the cycle.
Menstrually-related migraine was defined as up to four attacks of migraine per 
month of which one must occur on or between day 1 of menstruation ± 2 days in 
at least two out of three cycles.
INTERVENTIONS
Diary Cards
Women were provided w ith a diary card for each month on which the fo llow ing 
information about each migraine attack was recorded, as it occurred: date and 
time of onset of symptoms; peak severity (mild, moderate or severe); duration of 
attack (to nearest day); associated symptoms (nausea, photophobia and 
phonophobia); aura, if present; medication (name, dose, time taken). If there was 
doubt about the nature of any headache episode, the patient was contacted for 
clarification.
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Urine Samples
Daily early morning urine (EMU) samples were collected on each morning of the 
study, in universal vials containing sodium azide (0.1%) as a preservative. During 
the collection period, women sent their samples to the laboratory weekly where 
specimens were aliquoted and stored at 4°C until analyses were carried out.
Hormonal Analyses
Urine samples were analysed for oestrone-3-glucuronide (EiG) and pregnanediol 
3-glucuronide (PdG), urinary metabolites of oestradiol and progesterone, together 
w ith luteinizing hormone (LH), and follicle-stim ulating hormone (FSH) using an 
AutoDelfia® (Perkin Elmer Life Sciences, Cambridge, UK). LH was used to confirm 
ovulation, while FSH allowed classification of menopause status.(Miro et al., 
2004c) A standard curve comprising six standards (in triplicate) and three quality 
control samples were run for each assay. Twenty-five replicates of each standard 
were run as samples and the concentration of each was determined using 
Multicalc®. The lowest detectable concentration of the assays was determined to 
be 0.09 IU/L (LH); 0.1 7IU/L (FSH); 0.1 ng/ml (EiG); and 0.07pg/ml (PdG). Samples 
were analysed in duplicate.
Urinary EiG reflects the changes of plasma oestradiol.(Catalan et al., 1989) Early 
morning urine samples were convenient and the excretion pattern of EiG in EMU 
is similar to the pattern obtained for 24-hour urine samples.(World Health 
Organization, 1983) Because of this, concentrations can be expressed in 
mass/volume instead of mass steroid/creatinine ratio.(Adlercreutz et al., 1982) 
Further, creatinine adjustment is not essential for the study of menstrual cycle 
urinary hormones based on daily sampling.(Miro et al., 2004a) Data were shifted 
back one day for comparison with the diary card data, since morning collection 
of EiG and PdG reflect serum hormone levels 12-24 hours earlier.(Munro eta l., 
1991)
STATISTICAL METHODS
Rather than divid ing the menstrual cycles into the standard fo llicular, ovulatory 
and luteal phases, each menstrual cycle was divided into phases of rising and 
falling oestrogen. Hence there were two phases of rising oestrogen (the first
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during the early fo llicu lar phase; the second during the early luteal phase) and 
two phases of oestrogen 'w ithdrawal' (the first occurring during early luteal phase; 
the second during late luteal phase) identified as follows (Figure 1 7):
Phase 1: fo llicu lar phase rising oestrogen - from the fo llicu lar EiG nadir to the 
ovulatory peak.
Phase 2: post-ovulatory falling oestrogen - from the ovulatory peak to the post­
ovulatory nadir.
Phase 3: luteal phase rising oestrogen - from the post-ovulatory nadir to the luteal 
EiG peak.
Phase 4: late luteal/early fo llicu lar falling oestrogen - from the luteal EiG peak to 
the EiG nadir of the next cycle.
Oestrogen phase: 1 :rising 2 :fa I ling 3:rising 
+»<------
4:falling
OP
LP
PON
FN1 FN2
MENSESMENSES
FollicularMenstrual cycle phase: Luteal Follicular
O vulation
Phase 1: fo llicu la r phase rising oestrogen - from fo llicu la r EiG nadir (FN1) to ovulatory peak (OP); Phase 2: post-ovulatory fa lling 
oestrogen -from ovulatory peak (OP) to post-ovulatory nadir (PON); Phase 3 : luteal phase rising oestrogen - from the post-ovulatory nad 
(PON) to the luteal EiG peak (LP); Phase 4: late luteal/early fo llicu la r fa lling oestrogen - from the luteal EiG peak to the EiG nadir o f the 
next cycle (FN2)
FN1= fo llicu la r nadir of cycle 1; OP = ovulatory peak; PON = post-ovulatory nadir; LP = luteal peak; FN2 = fo llicu la r nadir o f cycle 2
F IG U R E  1 7 :  E x a m p le  o f  r i s i n g  a n d  f a l l i n g  p h ases  o f  O e s t r o n e - 3 - g l u c u r o n i d e  (EiG) a c r o s s  o n e  m e n s t r u a l  c y c le
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A migraine attack was counted as consecutive days of migraine. An interval of 48 
hours freedom from symptoms defined discrete attacks.(International Headache 
Society C linical Trials Subcommittee, 2000) A migraine day was each day on 
which a woman reported migraine.
For each cycle the total number of migraine attacks in each phase was 
determined. The expected number, assuming random occurrence, was calculated 
as the total number times the ratio of the phase length to the cycle length. The 
expected and observed numbers in each phase were then cumulated over all 
cycles.
The EiG slopes and EiG concentrations on the first day of each migraine attack 
and the preceding 5 days were analysed in order to asses whether migraine was 
related to rate of change EiG, or if a critical threshold existed (Figure 1 8).
ovulatory E,G peak
luteal EtG peak
drop
slope
F IG U R E  1 8 :  Sc h e m a t ic  t o  s h o w  h o w  s l o p e  a n d  d r o p  o f  E i G  w e r e  m e a s u r e d
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For each woman, the risk of migraine during the pre- or post-menstruation period 
(day 1 ±2) was compared w ith the risk of migraine at all other times of her cycle, 
and the relative risk calculated. The relative risks were then combined across all 
women using a method that allows for small occurrences and provides a p-value 
and 95% confidence interval.(MacGregor & Flackshaw, 2004)
RESULTS
Forty women w ith diary evidence of pure menstrual migraine or menstrually- 
related migraine in two out of three cycles, and who fu lfilled the e lig ib ility  
criteria, were recruited into the study. Two women were excluded from the data 
analysis: one experienced cycles longer than the maximum 42 day cycle length 
acceptable for inclusion in the study; another w ith pre-study diaries confirm ing 
migraine w ith menstruation did not experience menstrual attacks during the study 
period. Therefore the final analyses were undertaken on data from 38 women.
Patient Characteristics
The mean age of the women was 43 (range 29-50) years; 87% were over age 35 
and 29% were over age 45. All women had migraine w ithout aura; one woman 
also had attacks of migraine with aura but all her menstrual attacks were w ithout 
aura. Most women had menstrually-related migraine; one woman had pure 
menstrual migraine.
Nine women (24%) used analgesics alone for symptomatic treatment: 21(55%) 
used analgesics and triptans, 6 (1 6%) used triptans alone, 2 (5%) used ergots.
Nine women (24%) were taking daily non-hormonal prophylaxis: 3 amitripytline;
3 beta-blockers, 1 pizotifen, 1 am itriptyline and atenolol, 1 fluoxetine and 
pizotifen. There were no differences in demographic data or migraine frequency 
between these women and women who were not using prophylaxis.
Characteristics of migraine attacks
There was a total of 476 migraine days during the study. Women experienced a 
mean of 1.86 migraine attacks per cycle and 3.98 migraine days per cycle.
Migraine was more likely to occur on day 1 ±2 compared to all other times of the 
cycle (RR 1.45 [95%CI 1.17-1.79], p<0.001). Further, these attacks were more 
likely to be moderate or severe (RR 1.35 [95%CI 1.03-1.74], P=0.03) and
8 6
associated w ith  nausea (RR 1.46 [95%CI 1.04-2.001, P = 0.03) or vom iting  (RR 
2.56 [95%CI 1.05-5.78J, P=0.04).
Association between migraine and urinary hormone levels
Cycle day, EiG levels, PdG levels, menstruation, and m igraine days as co llected 
for all wom en are represented in Figures 19 and 20. These show in form ation from 
tw o wom en: one w ith  pure menstrual m igraine and one w ith  m enstrually-related 
m igraine. This highlights the in tra -ind iv idua l variation in horm one levels and 
tim ing  o f m igraine over consecutive cycles.
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M igra ine incidence was inversely related to rising and fa lling  phases o f oestrogen 
(Table 7). The differences between phases were h igh ly s ign ificant (p<0.0013). 
Phase 4 (late luteal/early fo llicu la r fa lling  oestrogen) had the highest incidence of 
m igraine com pared to the expected incidence. In contrast, phases o f rising 
oestrogen (phase 1 and phase 3) had the lowest incidence o f m igraine com pared 
to the expected incidence. There was no significant d ifference between expected 
and observed num ber o f m igraine attacks at the tim e o f post-ovulatory fa lling  
oestrogen (phase 2).
Observed no. o f 
m igraine attacks
Expected no. of 
m igraine attacks
x 2
Phase 1: fo llicu la r phase 52 64.4 2.39
rising oestrogen
Phase 2: post-ovulatory 
fa lling  oestrogen
40 42.4 0.13
Phase 3: luteal phase 23 33.5 3.29
rising oestrogen
Phase 4: late luteal/early 
fo llicu la r fa lling  oestrogen
90 64.7 9.87
TOTAL 15.68
Overall p<0.0013 for observed versus expected
TABLE 7 : OBSERVED A N D  EXPECTED FREQUENCY OF M IG RAIN E D U R IN G  DIFFERENT PHASES OF THE
MENSTRUAL CYCLE
Figure 21 shows the poo led incidence of m igraine corre lated w ith  urinary EiG 
and PdG on each cycle  day of 120 cycles from  38 w om en. The incidence of 
m igraine began to rise three days before the first fu ll day o f b leeding (day -3 ), 
associated w ith  fa lling  levels o f EiG. Peak incidence was on the first fu ll day of 
b leeding (day +1) and the preceding day (day -1 ). The median cycle day o f the 
EiG nadir was day +2. As EiG began to rise, the incidence o f m igraine declined.
The mean peak luteal phase EiG was 32.8ng/m L.
FIGURE 21:
Day of cycle
I n c id e n c e  o f  m ig r a in e ,  u r i n a r y  O e s t r o n e - 3 - g l u c u r o n i d e  (Ei G) a n d  p r e g n a n e d i o l - 3 - g l u c u r o n i d e  (Pd G) l e v e ls  o n  e a c h  d a y  o f
THE MENSTRUAL CYCLE IN 1 2 0  CYCLES FROM 3 8  W O M E N
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FIGURE 22: A n a ly s is  o f  r a t e  o f  c h a n g e  a n d  c r i t i c a l  t h r e s h o l d  o f  o e s t r o g e n
The data were also assessed for critica l 'threshold ' and rate o f change o f EiG, both 
for ind iv iduals and as pooled data. Figure 22 shows an exam ple o f EiG slope 
plotted against EiG level data from  one patient. Each po in t represents one day. If 
that day is a m igraine event it is coloured red. If it is rate o f change that matters 
m igraine events w ou ld  tend to fall be low  the slope = 0 line. If it is a critica l 
threshold that matters then m igraine events should tend to be on the left.
Analysis o f pooled data did not reveal any re lationship between the concentration 
of EiG on the day on w h ich  m igraine occurred in the late luteal phase, or on any 
of the five preceding days. Neither was there any apparent relationship between 
the rate o f change of EiG on the day on w h ich  m igraine occurred in the late luteal 
phase, or on any o f the five preceding days.
DISCUSSION
This study is the first to assess m igraine during both rising and fa lling  levels of 
oestrogen across the menstrual cycle. The strengths o f this study are the careful 
diagnosis of m igraine for each attack, the larger num ber o f wom en, and da ily  
horm one levels assessed over several consecutive cycles.
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The results confirm previous studies showing that migraine is significantly more 
likely to occur in association with falling oestrogen in the late luteal/early 
fo llicu lar phase of the menstrual cycle. This supports the hypothesis of oestrogen 
'w ithdrawal' triggering migraine. A new finding, which has not been assessed in 
earlier studies, is that migraine was significantly less likely to occur during phases 
of rising oestrogen. Although this study identified day -1 as the day of peak 
migraine incidence, day +1 was classified as the first FULL day of bleeding and in 
most cases menstruation had started on the day before. Hence these findings are 
compatible w ith the results of previous studies that identified peak migraine 
incidence at the start of bleeding.
Ovulation was confirmed by urinary hormone analyses. As in the diary card 
studies, there was no significant association between migraine and ovulation. 
Since only luteal oestrogen 'w ithdrawal' but not ovulatory oestrogen 'w ithdrawal' 
was associated with migraine, this supports the suggestion that a period of 
sustained high oestrogen prim ing is a necessary precursor.(Somerville, 1972b, 
1975a, b)
The age of the study population is of note (mean age is 43 years). The clin ical 
impression is that the menstrual trigger for migraine affects women entering the 
perimenopause more than younger age groups. Although there was no control 
population, this is supported by results of other studies of women not using 
hormonal contraception. In one study, the mean age of women in the menstrual 
migraine group was 37 years, whereas the mean age of women who had migraine 
unrelated to menstruation was 29 years.(Epstein et al., 1975)
The failure to identify a critical 'threshold' for oestrogen associated w ith migraine 
in the late luteal phase is in line w ith the theory that fa lling levels are more 
important than absolute levels.(Somerville, 1972b) There was no evidence of an 
association between the rate of change of oestrogen 'w ithdraw al' and migraine. 
Other researchers have also failed to find a correlation w ith critical threshold or 
rate of change.(Martin et al., 2005) However, they may still be important at an 
individual level although it would be necessary to have many more cycles of 
individual data to analyse this. Further, urinary EiG levels may not be sensitive 
enough to establish a difference.
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If oestrogen 'w ithdrawal' is an important mechanism, why does it not trigger 
migraine in all women? The mean peak luteal phase urinary EiG level of 32.8 
ng/mL is worth noting as it is significantly higher than the expected mean urinary 
peak luteal phase EiG levels of 14.9 ng/mL for normal fertile cycling women 
reported in population studies matched by menopause status.(Miro et al.,2004b) 
Other researchers noted raised serum concentrations of both oestrogen and 
progestogen in women w ith migraine, most striking in the late luteal 
phase.(Epstein et al., 1975) But high luteal phase oestrogen may just reflect the 
age of the population, as the perimenopause can be associated w ith high 
oestrogen levels.(Santoro et al., 1996) High baseline oestrogen would result in a 
greater luteal drop, which might account for the increased prevalence of 
menstrual attacks of migraine at this time.
Biological predisposition may also be relevant. A study of postmenopausal 
women found that despite similar serum oestradiol levels, only postmenopausal 
women w ith a premenopausal history of migraine associated w ith menstruation 
developed migraine as oestrogen levels declined, fo llow ing a single depot 
oestradiol injection.(Lichten eta l., 1996) In contrast, women with no 
premenopausal migraine did not develop migraine. This would be interesting to 
study in more depth in future research, particularly in light of a recent study of 
women w ith migraine and chronic daily headache, the results o f which suggest 
that headaches are influenced by hormone fluctuations even in women w ithout 
an apparent association w ith menstruation.(Martin et al., 2003)
SUMMARY OF FINDINGS
In women diagnosed w ith menstrual migraine, migraine incidence was 
significantly higher during the late luteal/early fo llicu lar phase of falling oestrogen 
and significantly lower during rising phases of oestrogen, compared to the 
expected number of attacks. The early luteal post-ovulatory fall in oestrogen had 
no effect on migraine incidence. As previously reported, menstrual attacks were 
more severe and more likely to be associated w ith nausea or vom iting compared 
to non-menstrual attacks.
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2.2. MIGRAINE AND OESTROGEN 'WITHDRAWAL' IN WOMEN 
USING COMBINED ORAL CONTRACEPTIVES: A REVIEW
Very little is known about the effects of combined oral contraceptives (COCs) on 
migraine. The methodology of studies assessing the effect of COCs on migraine 
has been inconsistent and few studies attempt to differentiate between headache 
and migraine.
HEADACHE AND COCS
Headache is a common side effect of COC use, w ith  initial exacerbation in the 
early cycles of use followed by resolution with continued use.(Sluglett & Lawson, 
1967; Brill eta/., 1990; Ernst eta/., 2002)
O f 3679 women starting COCs for the first time using 20pg ethinyloestradiol and 
150pg desogestrel, 36% reported headache at baseline.(Ernst et a/., 2002) After 
three cycles, 14% reported that headache had worsened, 57% reported 
improvement and 28% reported no change. New onset of headache affected only
0.5%.
In a study of 3267 women starting a COC containing 30pg ethinyloestradiol and 
75pg gestodene, 46% were first time COC users and 54% were switching from 
another brand.(Brill et a/., 1990) O f the 16% of women w ith headache at 
baseline, 63% reported improvement over the 18-cycle study. New onset of 
headache was reported by 8.8% of women in cycles 1 to 3, 3.9% in cycles 4 to 6, 
3.9% in cycles 10-12, and 2% in cycles 16 to 18. Unfortunately, there was no 
analysis of new users versus switchers.
In addition, frequency of headache may depend on the type of progestogen and 
the dose of oestrogen used. Studies of COCs containing 30pg ethinyloestradiol 
and levonorgestrel, a second generation progestogen, noted headache in 
approximately 10% of all cycles.(Guillebaud, 1983) It might appear that use of 
COCs containing third generation progestogens is associated w ith headache as 
reviews of studies using COCs containing 30pg ethinyloestradiol and 150pg 
desogestrel found headache to affect only 5% of women during the sixth 
cycle.(Fotherby, 1995) However, this could be accounted for by differences in
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study design as other studies have not found any differential effect from 
progestogens.(Cullberg, 1972; Dunson eta l., 1993; Koetsawang eta l., 1995)
Dose of ethinyloestradiol may be relevant as women using 20fjg ethinyloestradiol 
and 1 50|jg desogestrel reported fewer than 2% by the sixth cycle.(Fotherby, 1992)
MIGRAINE AND COCS
Few studies have specifically assessed migraine in COC users. The majority of 
publications assess high dose COCs containing at least 50pg ethinyloestradiol and 
pre-date the IHS diagnostic criteria. Migraine improves in a significant proportion 
of women and many report no change in migraine frequency or severity.(Whitty 
eta l., 1966; Phillips, 1968; Larsson-Cohn & Lundberg, 1970; Kudrow, 1975; 
Dalton, 1976; Ryan, 1978; Granella eta l., 1993; Cupini e ta l., 1995)
As w ith headache, migraine, typically w ithout aura, occurs during the hormone- 
free interval.(Whitty eta l., 1966; Phillips, 1968; Ryan, 1978; Horowski & Runge,
1986; MacGregor & Hackshaw, 2002)
The prevalence of headache and migraine among women using COCs was 
examined in a large, cross-sectional population-based study in Norway of 13,944 
women.(Aegidius et al., 2006) There was a significant association between use of 
COCs and migraine (30pg ethinyloestradiol OR 1.4 [95% Cl 1.2 to 1.7], 
P<0.001) and for non-migrainous headache (30pg ethinyloestradiol, OR 1.2 
[95% Cl 1.0 to 1 A ], P=0.025). In contrast, there was no significant association 
between progestogen-only pills and migraine (OR 1.3, 95% Cl 0.9-1.8, P=0.1 56) 
or headache (OR 1.0 [95% Cl 0.8-1.3], P=0.1).
A c lin ic  based case-control study reviewed 39 women with migraine w ith  aura 
and 83 women with migraine w ithout aura who had used COCs.(Granella et al., 
2000) Migraine w ith aura was reported as worsening in 56.4% of cases compared 
to 25.3% of women with migraine w ithout aura (OR 3.8 [95% Cl 1.6-9.3]). There 
was no change in 38.5% of women with migraine w ith  aura compared to 67.5% 
of women w ith migraine w ithout aura (OR 0.3 [95% Cl 0.1 -0.7]). Improvement 
was reported by 5.1 % of women w ith migraine w ith  aura compared to 7.2% of 
women w ith migraine w ithout aura (OR 0.7 [95% Cl 0.1 -4.1 ]).
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A review of 36 women w ith migraine with aura and 86 women with migraine 
w ithout aura using COCs attending a headache c lin ic  noted 50% of women with 
migraine w ith aura reported worsening of migraine w ith COC use compared to 
34.8% of women w ith  migraine w ithout aura.(Cupini et al., 1995) There was no 
change in 27.7% of women w ith migraine w ith aura compared to 44.1 % of 
women w ith migraine w ithout aura. Improvement was reported by 0% of women 
w ith migraine w ith aura compared to 4.6% of women w ith migraine w ithout 
aura. New onset of migraine was reported by 22.2% of women w ith migraine 
w ith aura and 16.2% of women w ith migraine w ithout aura. In both groups, 
worsening during COC intake was more likely than improvement (P<0.0001).
HEADACHE AND MIGRAINE DURING THE PILL-FREE INTERVAL
If headache occurs, it is typically during the hormone-free interval.(Sulak et al., 
2000; LaGuardia et al., 2005; Sulak et al., 2007) These symptoms are most likely 
to result from withdrawal of ethinyloestradiol, sim ilar to the oestrogen 
'w ithdraw al' mechanism for menstrual migraine in the endogenous hormone 
cycle.
Although there are no published studies of migraine during the pill-free interval, 
these data provide circumstantial evidence for oestrogen 'w ithdraw al' as a 
putative mechanism.
2.3. CONCLUSIONS FROM PART TWO
The obvious hormones potentially involved in the pathophysiology of menstrual 
migraine are oestrogen and progesterone. A review of the literature suggested that 
the natural drop in oestrogen in the luteal phase of the menstrual cycles is 
associated w ith menstrual migraine.
From the data presented above, the fo llow ing points can be concluded:
1. Compared to the expected number of attacks there was an inverse relationship 
between migraine incidence and oestrogen; the fo llicu lar phase rising oestrogen 
was associated w ith reduced risk of migraine and late luteal oestrogen 
'w ithdraw al' was associated w ith increased risk of migraine.
2. Post-ovulatory fa lling oestrogen had no effect on risk of migraine.
3. An association between late luteal progesterone 'w ithdraw al' and migraine 
cannot be discounted, although there is evidence from published studies by other 
researchers to suggest that progesterone plays only a m inimal part, if any, in 
menstrual migraine.
4. Although there are no studies on migraine, headache associated w ith 
combined hormonal contraceptive use typically occurs during the hormone free 
interval, providing circumstantial evidence for the role of oestrogen 'w ithdrawal' 
as a mechanism.
These findings support the hypothesis that menstrual migraine and headache 
during the hormone free interval of combined hormonal contraceptives are 
associated w ith oestrogen 'w ithdrawal'.
97
PART THREE:
MENSTRUAL MIGRAINE CAN BE PREVENTED WITH OESTRADIOL
SUPPLEMENTS
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3.1. IDENTIFYING THE OPTIMAL DOSE AND TIMING OF 
OESTRADIOL SUPPLEMENTS FOR PREVENTION OF OESTROGEN 
'WITHDRAWAL' DURING THE NATURAL MENSTRUAL CYCLE
3.1.1. IDENTIFYING THE OPTIMAL DOSE
A review of the literature confirms that stabilising oestrogen levels, either high or 
low, can prevent oestrogen 'w ithdraw al' migraine.
Somerville inhibited the endogenous menstrual cycle w ith  100mg oestradiol 
implants. The resultant fluctuating serum levels of oestradiol were associated with 
severe menstrual disturbance and worsening of migraine.(Somerville, 1975a). In 
contrast, Magos et al. showed that implant doses large enough to suppress 
ovulation and produce constant plasma oestrogen levels achieved a 96% 
response rate: 46% of women became completely headache-free, 37.5% reported 
almost complete symptomatic relief, and 12.5% reported partial benefit.(Magos et 
al., 1983) However, such treatment is impractical for most women as it involves 
an (albeit minor) outpatient procedure and is not readily reversible. Implants 
slowly release oestradiol at constant levels over approximately six months 
although their effect can be sustained for up to two years. Further, progestogens, 
which are mandatory to prevent endometrial hyperplasia, can induce 
migraine.(Magos et al., 1986)
Treatments that reduce oestrogen levels have been successful in the treatment of 
migraine: danazol is used to maintain steady, low levels of oestrogen; tamoxifen 
modifies the dynamics of oestrogen by its anti-oestrogen activity; and 
gonadotrophin releasing hormone analogues provoke a 'medical' 
menopause. (O'Dea & Davis, 1990; Holdaway eta l., 1991; Lichten eta l., 1991; 
Murray & Muse, 1997; Mathew & Fung, 1999)
An alternative strategy is to prevent the late luteal oestrogen fall using exogenous 
oestrogen perimenstrually, rather than throughout the cycle. There have been 
several small studies comparing oestradiol supplements w ith placebo. Those 
based on 25pg or 50pg oestradiol patches seemed to have little effect in reducing 
the occurrence of menstrual or menstrually-related migraine.(Pfaffenrath, 1993; 
Pradalier et al., 1994; Smits et al., 1994) However, there was a clear benefit in
trials using higher doses of 100|jg oestradiol patches or 1.5mg oestradiol gel.(de 
Lignieres et al., 1986; Dennerstein et al., 1988; Pradalier et al., 1994) The 
suggestion from these studies is that 25pg and 50pg oestradiol patches are not 
effective in preventing migraine as they result in suboptimal doses of oestrogen, 
achieving mean oestradiol serum levels of 25pg/ml and 40pg/ml respectively. In 
contrast, the 100pg oestradiol patch and 1.5mg oestradiol gel produce higher 
mean plasma oestradiol levels around 75-80pg/ml, equivalent to mid-luteal phase 
endogenous oestradiol levels.
On the basis of these findings, the optimal dose for perimenstrual prophylaxis 
appears to be either 10Opg oestradiol patches, which are replaced every 3-4 days, 
or 1.5mg oestradiol gel, used daily.
100
3.1.2. IDENTIFYING THE OPTIMAL TIMING OF OESTROGEN 
SUPPLEMENTS
Having identified that oestrogen 'w ithdrawal' is associated w ith increased risk of 
migraine, the next step was to assess if migraine could be prevented w ith 
oestrogen supplements. However, to ensure the optimal outcome, tim ing of 
oestrogen needed careful consideration.
Author Start of treatment Type of oestrogen Dose Duration
Somerville
(1972)
de Lignieres 
e ta l. (1986)
Dennerstein 
e ta l. (1988)
Pfaffenrath
(1993)
Smits et al. 
(1993) 
Pradalier 
et al. (1994)
3-10 days before 
expected onset of 
menstruation
48 hours before the 
earliest expected 
onset of migraine
at 2 days prior to 
expected migraine
2 days prior to 
suspected onset of 
migraine
Day -2 
Day -4
oestradioI valerate 5-10 mg in N/A
i.m.
oestradiol gel
oestradiol gel
single or
divided
doses
1.5mg 7 days
1.5mg 7 days
oestradiol patches 50pg not stated
oestradiol patches 50pg 8 days
oestradiol patches 25/1 OOpg 8 days
TABLE 8: TIMING AND DOSE OF OESTROGEN SUPPLEMENTS FOR PREVENTION OF MENSTRUAL MIGRAINE
In previous studies (Table 8), oestrogen supplements have been timed based on 
the first day menstruation or the anticipated start of menstrual migraine, both of 
which are subject to variability and can be d ifficu lt to predict accurately.
This may not be the optimum time to bridge the late luteal drop in oestrogen, 
which starts from the time of peak luteal phase levels and continues until 
oestrogen levels start to rise in the fo llicu lar phase of the fo llow ing cycle.
From Paper V data, peak luteal EiG occurred on day -6 of the cycle and the 
fo llicu lar EiG m inimum was on day +2 of the cycle (Figure 23 and Figure 24).
No
. 
of 
cy
cle
s
110
Days from E 1G peak to end of cyde
FIGURE 2 3 :  C y c le  d a y  o f  lu t e a l  EiG peak  n = 3 8
40
cyde day of E1C minimum
FIGURE 2 4 : C ycle  d a y  OF EiG m in im u m  n = 3 8
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To ensure adequate oestrogen levels over the 'prone' time we considered that the 
optimal time to start supplements would be from six days before the first fu ll day 
of bleeding up to and including the second full day of bleeding (Figure 25). This 
was based on the fo llow ing assumptions:
o Peak luteal EiG was on day -6 and migraine incidence began to increase 
on day -3.
o It would take three days to reach stable oestradiol levels.(Kuhl, 1990)
o Stable oestradiol levels would continue from day -3 through day +2 when 
oestradiol was stopped.
o There would be a gradual decline in oestradiol over around three to five 
days fo llow ing gel use.(Kuhl, 1990) This would a llow  sufficient time for 
fo llicu lar phase endogenous oestrogen levels to rise.
day of cycle
FIGURE 2 5 : T im i n g  o f  o e s t r a d io l  s u p p l e m e n t s  in  r e l a t io n  t o  e n d o g e n o u s  o e s t r o g e n
The remaining problem was how to establish accurate tim ing of treatment.
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3.2. PAPER VI: A METHOD TO PREDICT MENSTRUAL MIGRAINE 
AND OPTIMISE TIMING OF TREATMENT OF PERIMENSTRUAL 
PROPHYLAXIS
None of the published trials using premenstrual prophylaxis raised any concerns 
about the difficu lty of tim ing treatment accurately.
Treatments have varied from use of standard prophylactics given perimenstrually 
such as pizotifen or propranolol, through to NSAIDs such as naproxen, and 
perimenstrual oestrogen supplements.(de Lignieres et al., 1986; Dennerstein eta l., 
1988; Sances et al., 1990; Pfaffenrath, 1993; Pradalier et al., 1994; Smits et al., 
1994; Kornstein & Parker, 1997)
More recently, interest has focused on perimenstrual prophylaxis w ith triptans, 
originally developed for the acute treatment of migraine. Sumatriptan, naratriptan 
and frovatriptan have been studied for perimenstrual prophylaxis, starting 
treatment 2-3 days before the expected onset of migraine.(Newman et al., 1998; 
Newman et al., 2001; Silberstein et al., 2004; Tuchman et al., 2005; Mannix et 
al., 2007; Brandes et al.)
Although these studies did not report correct tim ing of prophylaxis as an issue, the 
patient populations entering such clin ical trials may differ from women seeking 
treatment in clin ical practice. For example, many of these studies have included 
women experiencing migraine in the pill-free interval o f combined oral 
contraceptives. These women w ill experience regular 28-day cycles, so that it is 
easy to predict the tim ing of attacks and perimenstrual treatment.
In c lin ica l practice, the largest group consulting for migraine is women in their 
late 30s or 40s, who are approaching the menopause.(Stewart et al., 1991) Given 
the normal variation in the length of the menstrual cycle and the variation in the 
tim ing of menstrual attacks from cycle to cycle, predicting the time to start 
prophylaxis can be difficult.
Further, patient recall of menstrual cycles and migraine correlates poorly w ith 
objective information.(Waters & O'Connor, 1971; Lipton e ta l., 1992; MacGregor 
eta l., 1997) Although diary cards can resolve this problem in part, the natural
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variation in cycle length w ith in individual women can mean that identifying the 
optimum time to start premenstrual prophylaxis is somewhat hit-and-miss.
Reviewing 492 menstrual cycles from 31 women participating in clin ical trials of 
a triptan for perimenstrual prophylaxis, cycle length varied by 9.9 ± 7.5 days. 
Tim ing of prophylaxis was accurately predicted in 63/232 (26.7%) cycles of 
treatment. The discrepancy of actual versus predicted menstruation was 1.9 ± 2.5 
(range -12 to 1 7) days (unpublished data).
The peak time for migraine during the menstrual cycle is on or between two days 
before the start of menstruation and the first three days of bleeding.(Waters & 
O'Connor, 1971; Dalton, 1973; MacGregor et al., 1990; Johannes et al., 1995; 
Stewart et al., 2000; MacGregor & Hackshaw, 2004) Therefore, rather than 
predicting the expected day of migraine in order to commence perimenstrual 
prophylaxis, a more sensible approach would be to predict the first day of 
menstruation and time prophylaxis relative to this, continuing treatment 
throughout the vulnerable period.
Menstruation consistently occurs close to 14 days fo llow ing  ovulation.(Speroff & 
Fritz, 2004) On this basis, some studies have measured the ovulatory rise in 
temperature in order to predict ovulation and time perimenstrual 
prophylaxis.(Szekely et al., 1989) Temperature can be affected by many factors, 
not least use of analgesics for migraine, which can inh ib it the small postovulatory 
rise in basal body temperature. Another indicator of ovulation is the change in the 
quantity and quality of cervical mucous (Billings method).(Billings, 1964) These 
two methods are often combined so that a deficiency in one method is balanced 
by the advantage of the other, thereby resulting in greater efficiency. However, 
the chore of observations and charting is an unwanted inconvenience for many 
women and long-term compliance is unlikely.
A simple method that predicts menstruation reliably w ould enable many women 
w ith pure menstrual and menstrually-related migraine to predict menstrual attacks 
and time perimenstrual prophylaxis more accurately, over consecutive cycles of 
treatment.
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The Clearblue Easy Fertility Monitor (Unipath Diagnostics Inc, Waltham, MA) is a 
home ovulation test that simultaneously detects luteinizing hormone (LH) and 
oestrone-3-glucuronide (EiG) in early morning urine, thus identifying the likely 
time of ovulation.(Behre et al., 2000)
To test the accuracy and acceptability of this device in migraine, a trial was 
undertaken using the monitor to predict the start day of perimenstrual oestrogen 
prophylaxis in women w ith menstrual migraine.
OBJECTIVES
The objectives of this study were to assess the accuracy and the suitability of the 
fertility monitor in the management of menstrual migraine by:
o Assessing the accuracy of ovulation prediction using the monitor 
compared to urinary hormone analyses; 
o Assessing the accuracy of using a simple algorithm to calculate optimal 
tim ing of perimenstrual supplements for the prevention of menstrual 
attacks of migraine; 
o Assessing patient acceptability of the monitor.
METHODS
The trial was conducted fo llow ing Good Clinical Practice (GCP) and w ith the 
Declaration of Helsinki (1964), as amended in South Africa (1996). A ll study 
documents were approved by an independent Ethics Committee.
INCLUSION AND EXCLUSION CRITERIA
Diagnosis of migraine w ith and w ithout aura was in accordance with IHS 
criteria.(Headache Classification Committee of the International Headache 
Society, 1988)
Pure menstrual migraine was defined as migraine on or between days -2  to +3 
(assuming day 1 is the first day of menstruation and that there is no day 0) in at 
least 2/3 cycles w ith no migraine at other times of the cycle.
Menstrually-related migraine was defined as up to four attacks of migraine per 
month of which one must occur on or between days -2  to +3 in at least 2/3 
cycles.
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Eligibility was based on diary-card review to confirm pure menstrual or 
menstrually-related migraine. Women were not e lig ible if they: had 
headaches/migraine more often than three days a week; used symptomatic 
medications regularly on more than three days a week; were pregnant, or 
intended to become pregnant during the study (women used non-hormonal 
contraception); were breastfeeding; had impaired liver or kidney function; had 
polycystic ovarian syndrome; used any hormonal treatment w ith in  the previous 
six months; used tetracycline; consumed a high soy diet or took soy/isoflavane 
supplements; had any medical or psychiatric condition that might be affected 
adversely by oestrogen supplements or which w ould preclude participation.
INTERVENTIONS
Eligible women who gave informed consent were given a monitor, test sticks, and 
packs for daily urine collection. They kept headache diary cards, recording 
symptoms and treatments taken. After three baseline cycles, women used 
perimenstrual oestradiol gel or placebo for six treatment cycles.
Home study procedures 
Urine samples
The first morning urine samples were collected in universal vials containing 
sodium azide (0.1%), a preservative.
Fertility monitor
The hand-held monitor (Figure 26) comes w ith disposable dual-assay urine test 
sticks and is designed for use by women w ith cycle lengths of 21-42 days. It 
detects ovulation by tracking changes in urinary levels of two female sex 
hormones in early morning urine:
o oestrone-3-glucuronide (EiG), levels of which correspond to plasma levels 
of oestradiol w ith a rise during the fo llicu lar phase of the menstrual cycle 
triggering a surge in luteinizing hormone, 
o luteinizing hormone (LEI), the surge of which occurs 24-36 hours prior to 
ovulation.(Behre et al., 2000)
F IG U R E  2 6 :  T h e  C l e a r b l u e  Ea s y  F e r t il it y  M o n i t o r  ( U n ip a t h  D ia g n o s t ic s  In c )
On the m orn ing after the start of the first period after entering the study, each 
wom an pressed th e 'm ' button to in itia te that cycle o f use. The wom en were 
instructed to look at the m onitor every m orn ing and, through its display, the 
m onitor guided them through each cycle (Figure 27). The m onito r requires one 
test, using a disposable dual-assay urine stick, every day fo r 10 to 20 days, 
depending on the length o f the menstrual cycle and the tim ing  o f the LH surge. 
The test stick is held for 3 seconds in the collected urine sample and inserted into 
the m onitor, w h ich  displays the result w ith in  five m inutes. In the first cycle, the 
first test is requested on day 6. In subsequent cycles the m on ito r calculates the 
start day depending on the accum ulated in form ation about the ind iv idua l user's 
cycles.
Oestradiol and placebo gel
W om en calculated the start day of treatment by coun ting  the first day that they 
saw the peak fe rtility  symbol as Day 1. They were instructed to use the gel on 
Day 10 (first day of LH surge + 9 days) continu ing  un til the second fu ll day of 
bleeding, i.e. day 2 o f the next cycle.
Monitor display:
.
Fertility:
□  low
□  high 
■  peak
.
LH surge + 9
nnnnnnnnnnni IIII III Innnnnnnnnnnnnnn
1 3 5 7 9 1 1 13 15 17 19 21 23 25 27 29 1 3
Cycle day Gel app lica tion 
<  ►
LH surge
FIGURE 27: GRAPHICAL REPRESENTATION OF USING THE FERTILITY MONITOR TO TRACK LUTEINIZING HORMONE (LH) SURGE AND START OF TREATMENT
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Laboratory study procedures
Women sent their urine samples to the laboratory each week. Samples were 
analyzed in duplicate for EiG, LH, pregnanediol 3-glucuronide (PdG) and fo llic le- 
stimulating hormone (FSH).
Outcomes assessed were:
o The duration of luteal and fo llicu lar phases;
o The accuracy of using the LH surge as a marker for tim ing oestradiol 
intervention;
o The percentage of LH surges confirmed by laboratory analysis that were 
detected by the Fertility monitor; 
o Subjective comments on method acceptability.
RESULTS
O f 40 women recording three baseline cycles, one woman had had no menstrual 
attacks of migraine, one had cycle lengths outside the monitor range, and one 
w ithdrew consent to use oestrogen. O f 37 women entering the six-cycle treatment 
phase: one w ithdrew to conceive; four had incomplete data; and five had cycle 
lengths consistently outside the monitor range. In these five women, cycle lengths 
of ovulatory cycles during the study ranged from 15 to 72 days. The fo llicu lar 
phase ranged from 4 to 55 days but the luteal phase was more constant, ranging 
from 10 to 19 days. O f the 46 cycles studied during the treatment phase, 1 7 
(37%) had no urinary LH peak, i.e. these cycles were anovulatory. If ovulation did 
not occur, women were alerted by the lack of 'egg' symbol on the monitor that 
cycle and so deferred treatment until the next ovulatory cycle.
The mean age of the women was 43 (range 29-50) years and 30% were over 45. 
During the six-cycle treatment phase the cycle length in one woman ranged from 
15 to 42 days but otherwise the cycle length of ovulatory cycles ranged 20 and 
37 days, w ith a median length of 28 days (Figure 28). The fo llicu lar phase ranged 
from 7 to 22 days (5 to 22 in the woman mentioned above), w ith a median length 
of 15 days. The luteal phase was more consistent w ith in  individual women, 
ranging from 7 to 18 days in all 27 women, w ith a median length of 14 days. O f 
the 221 cycles during treatment, 29 (14%) were anovulatory.
Follicular Phase
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Day relative to LH Peak
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Top: mean hormone levels across the cycle. Middle: percentage of women (y-axis) versus cycle length in days (x-axis). Bottom: follicular 
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In all but two women the algorithm of the LH surge + 9 days accurately calculated 
6 days before the first day of menstruation in the majority of cycles. These two 
women had consistently short luteal phases necessitating a different algorithm.
W ith respect to the LH surge, analyses were undertaken on the 182 ovulatory 
cycles in 27 women completing the study. O f these cycles, 8 were outside the 
normal testing range for the monitor. O f the remaining cycles, the LH surge was 
not detected in 1 7 cycles, due to poor LH surge (2.9%) or a missed LH surge 
(6.7%) (as confirmed by laboratory analysis). In all cycles, the monitor detected 
90.2% of LH surges w ith in the range of the monitor (Figure 29).
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FIGURE 2 9 : M o n it o r  Pe r f o r m a n c e : LH Su r g e  C ycle  D a y  ( M o n it o r ) v s . LH Peak  C ycle  D a y  (u r in e
ANALYSIS). LH, LUTEINIZING HORMONE
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Regarding method acceptability, 35 women responded to a questionnaire inviting 
comments about the study (APPENDIX 2). Thirty-three women (94%) found the 
monitor useful and provided the fo llow ing comments:
"I found I could judge the 'danger period' for migraine very accurately"
"You could adjust your life-style because you had more of an idea when 
migraine would occur... it helped plot more accurately [than diaries"
"I found just being totally tuned in to where my body was in its monthly 
cycle helped me to 'manage' attacks. For instance, I felt more confident as 
to whether I could or could not risk a glass of w ine !"
77% of women wanted to continue using the monitor as a treatment aid:
"I missed the monitor a lot when the trial ended - slightly irregular cycles 
mean I have to guess a lot..."
"Very easy to use - it became part of my daily routine, I even used it 
camping!"
"Useful to remind me IF I should be taking oestrogen gel" (woman with 
some anovulatory cycles)
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DISCUSSION
The monitor was easy to use and accurately identified ovulation, enabling 
prediction of menstruation and tim ing of perimenstrual migraine prophylaxis. This 
was despite variation in cycle length, which largely resulted from variation in 
fo llicu lar phase length; fo llow ing ovulation, the luteal phase was relatively 
constant. The monitor was designed for use by women w ith cycle lengths of 21 to 
42 days, which led to exclusion of five women w ith cycle lengths outside this 
range. For such women, using test sticks every day of the cycle until ovulation 
rather than selected days, would circumvent this problem.
Because the luteal phase is consistently 14 days, the treatment algorithm correctly 
predicted 6 days before the onset of menstruation in 25 of the 27 women 
completing the study per-protocol. Two women had short luteal phases and the 
algorithm had to be modified. In practice, written instructions could enable 
women to calculate their own algorithm. The software could easily be modified 
to calculate the algorithm automatically, based on data collected about the users' 
own luteal phase, showing a symbol to identify the start day of perimenstrual 
prophylaxis.
For women treated by a health-care professional there is also the option to 
download the monitor's memory onto a small data card for transfer to a home 
computer for display and storage. Data cards can also collect information on 
events, such as migraine attacks.
When using oestrogen supplements, the benefit of confirm ing ovulation is that 
women can avoid using oestrogen supplements in anovulatory cycles, in which 
no progesterone is produced. These cycles are more common in women 
approaching the menopause and the 'unopposed' endogenous oestrogen 
increases the risk of endometrial hyperplasia and cancer.
The monitor can be used to time non-hormonal and even non-drug treatments 
used perimenstrually. Predicting menstruation also enables women to avoid 
additional migraine triggers around their 'prone' time and has obvious advantages 
for early intervention with symptomatic treatments.
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SUMMARY OF FINDINGS
A home-use fertility monitor was used to time perimenstrual prophylaxis in 
women w ith menstrual or menstrually-related migraine. There was considerable 
inter- and intra-variability in cycle length, mostly due to fo llicu lar phase 
differences; the post-ovulatory luteal phase was relatively constant. The monitor 
accurately identified ovulation in over 90% of cycles, enabling prediction of 
menstruation and precise tim ing of perimenstrual prophylaxis. Ninety-seven 
percent of women found the monitor useful in predicting menstrual migraine 
attacks.
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3.3. PAPER VII: PREVENTION OF MENSTRUAL MIGRAINE WITH 
PERIMENSTRUAL OESTRADIOL
This study aimed to assess the effect of perimenstrual oestradiol on the incidence 
of menstrual migraine when used in conjunction w ith the fertility monitor. By 
identifying peak fertility associated w ith ovulation, the monitor could predict 
menstruation and hence be used to indicate when to apply the gel.(MacGregor et 
al., 2005; Behre et al., 2000) Further, by collecting early morning urine, the effect 
of oestradiol supplements on migraine could be correlated w ith changes in 
hormone levels both during and after use, which has not been assessed in 
previous studies. The effect of oestradiol on the length of the fo llicu lar and luteal 
phases was also examined.
OBJECTIVE
Based on the hypothesis that migraine attacks in the late luteal phase are 
associated w ith oestrogen 'w ithdrawal', the objective of the study was to assess 
the effect of perimenstrual percutaneous oestradiol on migraine in the late luteal 
phase of the menstrual cycle in women w ith menstrual or menstrually-related 
migraine. The main outcome was migraine occurrence defined as the number of 
days on which there was a migraine attack.
METHODS
Subjects
Women attending the City of London Migraine C lin ic and who had participated 
in the earlier observational study of the association between oestrogen and 
migraine (Paper V) were invited to participate in this randomised placebo- 
controlled crossover study. They were eligible for inclusion if they had pure 
menstrual migraine or menstrually-related migraine, and had regular menstrual 
cycles (21-35 days). Women who had additional non-migraine headaches could 
participate provided that they could distinguish these headaches from migraine. 
Non-hormonal migraine prophylaxis could be continued provided that the dose 
remained stable during the study period.
Women were not eligible for the study if: headaches and/or migraine occurred 
more often than three days a week on average; analgesics or acute headache
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medications were used regularly on more than three days a week; they were 
pregnant, or intended to become pregnant during the study period, or were 
breastfeeding; had evidence of impaired liver or kidney function; had evidence of 
polycystic ovarian syndrome (unless they had regular menstrual periods); used 
hormonal contraception, hormone replacement therapy or other hormonal 
treatment w ith in six months prior to the start of the study or at any time during the 
study period; used treatments that might affect the menstrual cycle such as 
tetracycline, a diet high in soy, or use of soy/isoflavane supplements; or had any 
medical or psychiatric condition that might have been affected adversely by use 
of oestrogen supplements or which would preclude participation in the study. All 
women were required to provide informed consent.
Definitions
Menstrual migraine was defined as migraine attacks on or between day 1 of 
menstruation ± 2 days (i.e. on or between days -2  to +3 of the cycle assuming 
day 1 is the first day of menstruation and that there is no day 0) in at least two out 
of three cycles w ith no migraine at other times of the cycle. Menstrually-related 
migraine was defined as up to four attacks of migraine per month of which one 
must occur on or between day 1 of menstruation ± 2 days in at least tw o out of 
three cycles.
Migraine data
Migraine data, as it occurred, was recorded on a diary card for each month, and 
included date and time of onset of symptoms; peak severity (mild, moderate or 
severe); duration of attack (to nearest day); associated symptoms (nausea, 
photophobia and phonophobia); aura, if present; medication (name, dose, time 
taken).
Adverse events
Adverse events were recorded on the diary cards as they occurred. If women 
were concerned about any unusual symptoms that they experienced, they were 
instructed to contact the c lin ic  or telephone a 24-hour emergency contact 
number.
117
Fertility Monitor
The system comprises a hand-held monitor (Figure 26) and disposable dual-assay 
urine test sticks and was designed for use by women w ith cycle lengths of 21-42 
days (Clearblue Easy Fertility Monitor - Unipath Diagnostics Inc., Waltham, MA). 
The test sticks simultaneously detect luteinizing hormone (LH) and oestrone-3- 
glucuronide (EiG) in early morning urine, which identify ovulation. This has been 
previously described in detail.(Behre eta/., 2000) Women conducted a test each 
day as requested by the monitor by using a sample of early morning urine. By 
this method the women identified the day of LH surge in each cycle by the 
appearance of the peak fertility symbol on the monitor screen enabling them to 
calculate when to start using the perimenstrual supplements. Each woman 
performed at least 10 tests per cycle.
Urine Samples
Women collected early morning urine (EMU) samples on each morning of the 
study. Samples were collected in universal vials containing sodium azide (0.1%) 
as a preservative. During the collection period, women sent their samples to the 
laboratory weekly. At the laboratory, urine specimens were aliquoted and stored 
at 4°C until analyses were carried out.
Hormonal Analyses
Samples were analysed for oestrone-3-glucuronide (EiG) and pregnanediol 3- 
glucuronide (PdG), which are the urinary metabolites of oestradiol and 
progesterone, together w ith luteinizing hormone (LH), and follicle-stimulating 
hormone (FSH) using an AutoDelfia® (Perkin Elmer Life Sciences, Cambridge,
UK). LH was assayed to confirm ovulation and to compare urinary analyses with 
monitor performance, reported in a separate study. FSH was assayed and, 
together w ith the other hormones, enabled classification of menopause status.
Analyses were conducted with highly specific in-house developed antibodies, as 
previously described.(Miro et al., 2004c) A standard curve comprising six 
standards (in triplicate) and three quality control samples were run for each assay. 
Twenty-five replicates of each standard were run as samples and the 
concentration of each was determined using Multicalc®. The lowest detectable
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concentration of the assays was determined to be 0.09 IU/L (LH); 0.1 7IU/L (FSH);
0.1 ng/ml (EiG); and 0.07pg/ml (PdG). Samples were assayed in duplicate.
Urinary EiG reflects the changes of plasma oestradiol (E2).(Catalan et al., 1989)
Early morning urine (EMU) samples were convenient and the excretion pattern of 
EiG in EMU is similar to the pattern obtained for 24-hour urine samples.(World 
Health Organization, 1983) Because of this, concentrations can be expressed in 
mass/volume instead of mass steroid/creatinine ratio.(Adlercreutz et al., 1982)
Further, there is evidence that creatinine adjustment is not essential for the study 
of menstrual cycle urinary hormones based on daily sampling.(Miro et al., 2004c)
The urinary data were shifted back one day for comparison w ith the diary card 
data, since morning collection of EiG and PdG reflect serum hormone levels 12- 
24 hours earlier.(Munro et al., 1991)
Oestrogen supplements
The dispensing pump delivers unit doses of 0.5g of gel containing 0.5mg of 
oestradiol. Three pump doses (1.5mg oestradiol) were used daily applied to the 
upper arms (avoiding the breasts) or thighs, on a large clean dry area of skin that 
had not been covered with any creams or talcum powder. This could be morning 
or evening, providing that this tim ing was consistent throughout the study.
Women were advised to wait one or two minutes before covering the area w ith 
clothing.
Each woman was given oestradiol gel for three menstrual cycles and placebo gel 
for three cycles, in a crossover trial. Supplements were started six days before the 
first fu ll day of bleeding up to and including the second full day of bleeding.
The time period from the LH surge to menses is consistently close to 14 days in 
ovulatory cycles.(Speroff & Fritz, 2004; MacGregor et al. 2005) The monitor indicated 
the LH surge with a specific symbol representing peak fertility. Women calculated 
the start day for the gel by marking on their diaries the first day that they saw the 
peak fertility symbol on the monitor as day 1. They were instructed to start using 
the gel on day 10 (day of LH surge + 9 days), approximating to six days before the 
first full day of bleeding, continuing to use it daily until, and including, the 
second fu ll day of bleeding of the next cycle. Since the monitor collected 
information w ith in a time w indow  in the morning only, if a period started later in
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the day the first cycle day would be recorded on the morning of the next day. To 
check the correct order was followed, the women were asked to write the code of 
the gel allocated for that cycle on the diary card.
The incidence of short luteal phases in the normal population is about 5- 
6%.(Lenton et al., 1984) In line with this, two women were identified w ith short 
luteal phases in the preliminary study and the tim ing of oestradiol gel was 
adjusted accordingly (six and eight days fo llow ing the LH surge, respectively).
A ll women were instructed to use the gel only if they saw the peak fertility 
symbol. Hence gel was only used during ovulatory cycles, ensuring endometrial 
protection from endogenous progesterone during treatment.
Compliance
On completion of, or fo llow ing withdrawal from the study, all unused supplies 
were accounted for and returned to the clin ic. Although the urinary EiG levels 
could test compliance with the active gel, they did not ensure compliance with 
placebo gel. Therefore we weighed the gel containers when they were dispensed 
and when they were returned to ensure that the same amount had been used from 
each container.
Blinding and randomisation
Oestradiol and matching placebo were packaged identically and the two gels 
were indistinguishable. Each woman received six gel packs, labelled A to F. 
Unipath Limited undertook blinding so that neither the investigators nor the 
women knew which was oestradiol and which was placebo. Women were 
randomly allocated to receive either oestradiol or placebo for their first cycle, and 
then given in an alternating order for the remaining five cycles. However, since 
the gels were identical and each woman received six different packs neither the 
patient nor researcher would have been able to predict the next treatment. There 
was also unlikely to be any carryover effect between the gels because there was a 
sufficiently long length of time between stopping one gel and starting the next (31 
days on average; 5-95th centile 16-75 days). Even if there were some carryover 
effect this could only be from using the oestradiol gel before the placebo gel, 
which would dilute any treatment effect.
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Sample size
The sample size was calculated based on each woman providing data for three 
placebo cycles and three oestradiol cycles. Previous data showed a mean of 3.5 
migraine days per cycle per woman with a standard deviation of 1.5.(MacGregor 
& Hackshaw, 2004) Assuming that there would be 10 migraine days over three 
cycles using placebo, a study of 36 women would have 90% power to detect a 
25% reduction in migraine days (from 10 to 7.5), at the 5% level of statistical 
significance.
Statistical analysis
Each woman recorded the start and end date of each gel. To assess the effect of 
oestradiol compared to the placebo we compared the proportion of days on 
which a migraine occurred when the woman was on oestradiol w ith the 
proportion of migraine days when she was on placebo, and estimated the 
difference (i.e. a w ithin-woman comparison). This was analysed, as in a standard 
crossover trial, with allowance for a possible period effect - that is, whether the 
effect on migraine was influenced by the ordering of the oestradiol and placebo 
gels.(Armitage & Berry, 1987)
We also estimated the relative risk, namely, the percentage reduction in migraine 
days per woman when using the oestradiol gel compared to placebo. For each 
woman the relative risk was estimated using the ratio of the proportion of days on 
which a migraine occurred (oestradiol versus placebo), and then pooled across all 
women using an exact method.(Martin & Austin, 2000) The analysis based on 
relative risks did not allow for an ordering effect of the gels, although as shown in 
the Results section, there was no evidence of such an effect.
The effect of the oestradiol gel was assessed for all women who had used at least 
one cycle of oestradiol and one of placebo. Data were also analysed for the 
subset of women who had regular menstrual cycles and had used all six gels in 
accordance w ith the protocol (referred to as "per-protocol" population). The 
analyses of urinary hormones and length of the fo llicu lar and luteal phases were 
restricted to the per-protocol population.
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Cycles between LH peaks were defined, and split into luteal and fo llicu lar phases 
by the first day of bleeding. Where an LH peak was not defined the data between 
neighbouring LH peaks was removed. For the analysis of luteal phase length, 
'oestradiol' and 'placebo' corresponded to gel application in that phase. For the 
analysis of fo llicu lar phase length 'oestradiol' and 'placebo' corresponded to gel 
application in the preceding luteal phase. Two-way analysis of variance was used 
providing a w ithin-woman comparison.
RESULTS
O f 38 women eligible to participate in the crossover study, 37 received study 
treatment and one woman withdrew from the study before treatment allocation 
(Figure 30). Two women used only one gel for one cycle and, therefore, did not 
provide any useful information for a w ithin-woman analysis.
Data were analysed for the remaining 35 women, 31 used all six allocated gels 
(three oestradiol and three placebo), two women used four gels (two oestradiol 
and two placebo), one woman used three gels (one oestradiol and two placebo) 
and one woman used two gels (one oestradiol and one placebo).
O f these 35 women, urinary hormone data for four women showed elongated 
cycles w ith evidence of delayed ovarian response indicative of the 
perimenopause.(Miro et al., 2004b) Two women had missed treatment cycles, 
one had started gel early, and one had several days of missing urine samples. 
Hence data for 27 women who had used all six gels in accordance with the 
protocol were available for per-protocol analysis.
Patient characteristics are shown in Table 9 and Table 10.
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EXCLUDED: N=2
N o t  m e e t in g  in c lu s io n  c r ite r ia
EXCLUDED: N=1
W ith d r e w  c o n s e n t to  use  g e l
EXCLUDED: USED ONLY 1 GEL:
W ith d r e w  as w is h e d  to  c o n c e iv e :  
P e r im e n o p a u s a l h o rm o n e  p r o f i le :
ANALYSED
N=38
Menstrual or menstrually-related migraine 
N=40
PATIENT DIARY REVIEW
2/3 pre-study cycles 
w ith migraine on day 1 ±2 days
ALLOCATED AND RECEIVED 
INTERVENTION
N=37
6 cycle cross-over 
oestradiol/placebo
ANALYSED
All women who used at least 1 oestradiol 
and 1 placebo gel 
N=35
Excluded from per-protocol analysis: n=8 
M is u s e d  g e l:  n =  1 
M is s e d  t re a tm e n t c y c le s :  n = 2  
M is s in g  u r in e  s a m p le s : n =  7 
P e r im e n o p a u s a l h o rm o n e  p r o f i le :  n = 4
Per-protocol
N=27
FIGURE 30: P a r t i c i p a n t  F l o w
123
All women 
recruited
(n=38)
All women in 
the crossover 
study (n=35)
Per protocol
(n=27)*
Mean age (years) 43 43 43
Range (years) 2 9 -5 0 2 9 -5 0 2 9 -5 0
Over 45  (%) 29 29 30
Over 35 (%) 87 86 89
Type of headache (n)
Migraine w ithout aura 37 34 26
Migraine w ith & w ithout aura 1 1 1
Association with menstruation (n)
pure menstrual migraine 1 1 1
menstrually-related migraine 37 34 26
* w o m e n  w i t h  r e g u la r  m e n s t r u a l  c y c le s  w h o  u s e d  a l l  6  g e ls  in  a c c o r d a n c e  w i t h  t h e  p r o t o c o l
TABLE 9 : SELECTED PATIENT CHARACTERISTICS
All women 
recruited
(n=38)
All women in 
the crossover 
study (n=35)
Per protocol
(n=27)*
Acute treatment (n) 38 35 27
analgesics only 9 8 7
triptans only 6 5 4
ergots only 1 1 0
analgesics and triptans 21 2 0 15
analgesics and ergots 1 1 1
Prophylactic treatment (n) g * * g * * y * *
am itriptyline 4 4 2
beta-blocker 4 4 4
fluoxetine 1 1 1
pizotifen 2 2 2
* w o m e n  w i t h  r e g u la r  m e n s t r u a l  c y c le s  w h o  u s e d  a l l  6  g e ls  in  a c c o r d a n c e  w i t h  th e  p r o t o c o l  
* *  2  w o m e n  e a c h  t o o k  t w o  p r o p h y la c t i c  a g e n ts
TABLE 10: M ig r a in e  d r u g s  u s e d  b y  w o m e n  d u r i n g  t h e  s t u d y
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Effect of oestradiol gel on migraine frequency and severity subsequent to gel use
In all, there were 133 migraine days whilst women were using oestradiol and 1 71 
when using placebo, a difference that is statistically significant (P=0.03). The 
within-woman analysis based on the difference in the proportion of gel-days on 
which a migraine occurred (active vs placebo gel), after allow ing for a possible 
period effect, yielded a difference in percentage points of -3.6% [95% Cl -8 .8  to 
1.6%], in favour of the oestradiol gel. The difference was almost statistically 
significant (P-0.08). There was no evidence of an effect of the order of oestradiol 
and placebo gels (P=0.43).
Figure 31 shows the individual relative risk of having a migraine day using 
oestradiol compared to placebo for each of the 35 women.
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FIGURE 31 : R e la t iv e  r i s k  (RR) o f  m ig r a in e  u s in g  o e s t r a d i o l  g e l  v s .  p la c e b o  g e l  (n=34) 125
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Table 11 shows the average relative risk for the group of 35 women. Oestradiol 
was associated w ith a statistically significant 22% reduction in migraine days per 
woman; RR 0.78 [95% Cl 0.62 to 0.99]. These attacks were also less severe 
(P=0.03) and there was evidence that they were associated w ith less nausea, 
although this difference was not statistically significant. The effect was sim ilar if 
the data were restricted to the per-protocol population (n=27) there was a 22% 
reduction in migraine days (RR 0.78 [95% Cl 0.60 to 1.01 ], P=0.06).
RR [95%CI] P-value Total no. of 
migraine days
All migraine 0.78 [0.62 to 0.99] 0.04 304
Severe or moderate 0.73 [0.54 to 0.97] 0.03 206
migraine
Migraine w ith nausea 0.75 [0.52 to 1.06] 0.10 139
Migraine w ith vomiting 0.86 [0.33 to 2.19] 0.90 22
TABLE 11 : R e la t iv e  r i s k  (RR) o f  m ig r a in e  u s in g  o e s t r a d i o l  v s .  p la c e b o
Table 12 shows the effect of gel on migraine occurring on days 1 ±2 of the cycle 
in all women. The results are consistent w ith those in Table 11, in that oestradiol 
was associated w ith a reduction in migraine days. However, since the time period 
is narrower, the results are based on fewer events and the difference was not 
statistically significant. No results are presented on migraine w ith vom iting since 
only four women experienced vomiting.
RR [95%CI] P-value Total no, of 
migraine days
All migraine 0.85 [0.58 to 1.43] 0.42 120
Severe or moderate 0.77 [0.48 to 1.24] 0.31 78
migraine
Migraine w ith nausea 0.93 [0.49 to 1.76] 0.92 44
TABLE 12: R e la t iv e  r i s k  (R R ) o f  m ig r a in e  o n  d a y  1 ±2 u s in g  o e s t r a d i o l  v s .  p la c e b o
There was, however, evidence of an increase in migraine occurrence in the five 
days immediately fo llow ing oestradiol use compared to placebo, RR 1.40 [95%
Cl 1.03 to 1.92], P=0.03. The relative risk of having a moderate or severe attack 
was 1.40, [95% Cl 0.97 to 2.05] but this was not statistically significant, P=0.07. 
O f the 22 women who benefited from using the oestradiol gel (they had fewer 
migraines compared to using placebo), 1 5 experienced post-gel migraine (they 
had more migraine days during the 5 days after the oestradiol gel compared to the 
5 days after placebo). This effect appeared to disappear after 5 days; the relative 
risk of having a migraine between 5 and 10 days after gel use was 1.04 [95% Cl 
0.67-1.62], P=0.92.
Effect of oestradiol gel on urinary hormones
Oestradiol gel increased basal EiG, delaying the EiG fall in some cases until early 
in the subsequent cycle. Figure 32 shows the overlaid oestradiol levels from 
active versus placebo or untreated cycles from one woman. This gives an 
example of the effect of gel on urinary EiG, w ith the 'double hump' created by 
endogenous luteal phase EiG followed by a rise in EiG associated w ith exogenous 
gel use, and subsequent delay in oestrogen 'w ithdraw al'. A further example from 
a single cycle is shown in Figure 33.
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The EiG concentration fo llow ing the end of gel use is shown in Figure 34. EiG 
levels remained elevated above those associated w ith placebo cycles for four 
days, a difference that was significant for the first three days (p<0.0001). The 
mean difference from placebo cycles was 1 6ng/ml and the mean rate of decline 
of EiG was 4ng/ml per day.
Peak incidence of migraine was 3 days fo llow ing the end of gel use is shown in 
Figure 35.
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FIGURE 34: DIFFERENCE BETWEEN MEAN E,G LEVELS ON OESTRADIOL GEL COMPARED TO PLACEBO GEL 
FOLLOWING THE LAST DAY OF GEL USE; PER-PROTOCOL POPULATION (N=27)
Days after last day of gel treatment
FIGURE 35: INCIDENCE OF MIGRAINE FOLLOWING THE LAST DAY OF GEL TREATMENT (N=21 )
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Effect of oestradiol on the length of the follicular and luteal phases
Oestradiol was associated with a significant increase in the length of the fo llicu lar 
phase (mean 13.90 days [95% Cl 13.25 to 14.54] compared to placebo (mean 
12.51 days [95% Cl 11.85 to 13.16], P=0.003 versus oestradiol). Oestradiol had 
no effect on the length of the luteal phase (mean 14.26 days [95% Cl 13.89 to 
14.63] for oestradiol; mean 14.46 days [95% Cl 14.09 to 14.84] for placebo).
Adverse events
No serious adverse events were reported. There were two possible treatment- 
related events. One woman reported stomach pains and nausea unrelated to 
migraine associated with the first cycle of active gel; she later w ithdrew for 
personal reasons, unrelated to the study. One woman reported diarrhoea and 
vomiting associated with the first cycle of active gel but did not experience 
similar symptoms with the other two cycles using active gel.
Compliance
Compliance throughout the study was excellent w ith no women lost to follow-up. 
There were missing urine samples for only 2.6% of days over the course of the 
study. There were no discrepancies in the weights of gels returned compared to 
the expected weights fo llow ing gel use, confirming compliance with use of the 
study medication.
DISCUSSION
These results confirm that perimenstrual oestrogen supplements can reduce the 
severity and duration of menstrual attacks of migraine during treatment. This is in 
keeping with other studies using a similar dose of oestrogen to achieve serum 
oestradiol levels of at least 60pg/mL.(Dennerstein et al., 1988; de Lignieres & 
Bousser, 1992; Pradalier eta/., 1994)
If oestrogen withdrawal is the sole mechanism of 'menstrual' migraine, stabilising 
oestrogen levels should be 100% effective for these attacks. The fact that this 
treatment does not produce such a favourable outcome could be due to several 
reasons:
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o The dose of oestrogen used failed to achieve stable plasma levels. This is 
important as menstruating women may produce a surge of endogenous 
oestrogen over and above the levels of oestrogen maintained by the 
exogenous treatment. Such fluctuations may be sufficient to trigger 
migraine.
o  O nly one patient had pure menstrual migraine in this study. Compared to 
pure menstrual migraine, menstrually-related migraine is only partially 
hormone dependent and may be less responsive to oestrogen treatment. 
(Dennerstein etal., 1988)
o Other mechanisms (hormonal and/or non-hormonal) are acting in addition 
to oestrogen withdrawal.
o Oestrogen withdrawal is not the direct mechanism of 'menstrual' migraine.
However, the benefits are offset by an increase in migraine fo llow ing gel use, 
associated w ith an iatrogenic delayed oestrogen 'w ithdrawal'. Reviewing the 
previous studies, Somerville identified delayed migraine in single cases over 
single cycles.(Somerville, 1972b, 1975a, b) De Lignieres noted only one of 
eighteen patients had migraine three days after stopping oestradiol.(de Lignieres et 
a!., 1986) Other clinical studies have not commented on this, possibly because 
the post-treatment phase was not analysed since data only compared the time 
periods during which oestradiol or placebo oestrogen was applied.(Dennerstein et 
a i,  1988; Pradalier etal., 1988; Pfaffenrath, 1993; Smits etal., 1994)
Possible reasons for the occurrence of post-gel oestrogen 'w ithdrawal' migraine 
are that:
o The dose of oestradiol was inadequate.
o The duration of treatment was too short and, in some women, oestradiol 
treatment was stopped before fo llicular oestrogen had started to rise; had 
active treatment been continued until follicular-phase oestrogen levels 
were rising, it is possible that post-treatment headaches might have been 
avoided.
o Exogenous oestrogen inhibited the fo llicular rise of endogenous oestrogen. 
This latter possibility is consistent with the observation that the fo llicu lar
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phase was extended by over 1 day in oestradiol treated cycle. This might 
be tempered by tapering the dose of exogenous oestrogen gradually over 
several days into the early fo llicular phase.
It seems unlikely that the dose used was inadequate, provided that the women 
used it correctly. Women were instructed to use the gel anywhere below the 
waist and, at the first visit, were shown the approximate size of area to cover. 
Variation in the area of gel application could have a significant effect on serum 
oestradiol levels.(Kuhl, 1990) Compliance checks, weighing the containers, 
suggested that the correct amounts of gel were used. A review of the individual 
graphs of EiG levels (APPENDIX 3) shows that most women did achieve the 
'double-hump' although not always consistently. Further, the dose used in this 
study was the same dose that had been effective in earlier studies.(de Lignieres et 
al.f 1986)
The duration of use of oestrogen supplements in the trial had been based on the 
expected perimenstrual increase in migraine, starting two days before the onset of 
menstruation.(MacGregor, 1996) Supplements were started around six days 
before the first full day of menstruation, coinciding w ith  the mean luteal EiG peak 
and allow ing three days to achieve steady state levels. Based on our findings, 
tailoring the start of oestrogen supplements to each individual, based on an 
analysis of individual variation in the day on which menstrual attacks occur 
would be optimal.
Extending the duration of use of oestrogen supplements until endogenous 
oestrogen had risen might prevent post-supplement oestrogen 'w ithdrawal' 
migraine. In this study, oestradiol was used until day 2 of the cycle based on 
analysis of the pre-treatment study cycles, which showed that median cycle day 
of the EiG nadir was day 2. However, there was w ide inter- and intra-individual 
variation and in some women the EiG nadir did not occur until day 6 or even 
later (Figure 36). In such cycles, post-gel oestrogen 'w ithdraw al' would not be 
tempered by endogenous oestrogen and could account for the post-gel increase 
in migraine. Similar to tailoring the start day of oestrogen supplements, future 
studies could tailor the duration of oestrogen supplements to individual variation 
in cycle day of the EiG minimum.
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It is interesting to note that post-treatment headache has been reported in trials of 
perimenstrual prophylaxis w ith triptans. Two randomized controlled trials of 
naratriptan for short-term prevention of menstrual migraine, reported significant 
rebound headache.(Mannix et al.f 2007) This has not been seen in similar trials 
w ith frovatriptan. This may in fact be related to differences in pharmacokinetic 
properties, particularly since frovatriptan has a significantly longer half-life than 
all other triptans.(Buchan et at., 2002)
Compliance in our study was high. This reflects the interest and commitment of 
the women hoping to identify the cause and potential treatment of a condition 
that results in considerable morbidity. However, some women were concerned 
that oestrogen supplements had similar adverse effects as hormone replacement 
therapy (HRT). It is important to inform women that supplementing oestrogen 
perimenstrually is not the same as taking HRT. There is no evidence that use of 
exogenous oestrogen, even if given continuously in higher doses necessary for 
contraception, increases the risk of breast cancer when given to premenopausal 
women.(Marchbanks et al., 2002) Similarly, there is no evidence that HRT 
increases the risk of breast cancer when used premenopausally by menstruating 
women with a normally timed menopause.
A more relevant risk is the potential effect of oestrogen supplements on the 
endometrium if used during anovulatory cycles, during which there is no 
progesterone to protect the endometrium. If 'unopposed' oestrogen is continued 
over a long period of time, there is increased risk of endometrial hyperplasia and 
cancer, although the absolute risk of acquiring these disorders is small. This is of 
particular concern given the age of women presenting w ith menstrual or 
menstrually-related migraine, as typified in this study. The specific strengths of the 
present study are the population size, daily hormone analysis over several cycles, 
confirmed diagnosis for each migraine attack, accuracy of diary card data, and 
use of w ithin-woman analysis. The main potential weakness is that women 
attending a specialist headache clin ic might not represent the general population 
of women requiring treatment for menstrual attacks of migraine. However, 
previous studies in both community and clin ic based populations have shown a
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similar prevalence of menstrual migraine.(MacGregor et al., 1997; Couturier et 
al., 2003)
Future studies should assess the optimal dose and duration of oestrogen 
supplements to avoid deferring oestrogen 'w ithdraw al' migraine.
SUMMARY OF FINDINGS
Percutaneous oestradiol was associated with a 22% reduction in migraine days 
(RR 0.78 [95%CI 0.62 to 0.99], P=0.04); these attacks were less severe and less 
likely to be associated with nausea. This was fo llowed by a significant 40% 
increase in migraine in the 5 days fo llow ing oestradiol compared to placebo (RR 
1.40 [95%CI 1.03 to 1.92], P=0.03).
Although perimenstrual percutaneous oestradiol showed benefit during treatment, 
this was offset by deferred oestrogen withdrawal after the gel was stopped, 
triggering post-dosing migraine.
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3.4. PREVENTION OF OESTROGEN 'WITHDRAWAL' MIGRAINE IN 
WOMEN USING COMBINED HORMONAL CONTRACEPTIVES
3.4.1. PREVENTION OF MIGRAINE IN THE HORMONE-FREE 
INTERVAL OF COMBINED HORMONAL CONTRACEPTIVES: A 
REVIEW
If oestrogen withdrawal is a mechanism for menstrual migraine, it follows that 
attacks of migraine during the hormone-free interval of combined hormonal 
contraceptives (CHCs) might be associated with a sim ilar mechanism and thus be 
prevented with oestrogen supplements.
Few studies have assessed this strategy. One study, published in 1968 as a letter, 
attempted to treat headaches (not distinguished from migraine) in the pill-free 
interval of combined oral contraceptives (COCs), using oral
ethinyloestradiol.(Eichner, 1968) Improvement was seen in 34 of 50 women given 
5-20pg ethinyloestradiol during the pill-free interval but there was no response to 
placebo. No comment was made on whether one dose was more effective than 
any other dose. Flowever, the study is subject to a number of criticisms, not least 
because it was neither randomised nor double-blind.
An open-label study of 11 women using 0.9mg conjugated equine oestrogens on 
each day of the pill-free interval of a COC containing 20pg ethinyloestradiol 
reported a mean 77.9% reduction in the number of headache days.(Calhoun, 
2004)
Other studies of headache in the hormone-free interval have achieved similar 
outcomes by replacing the 21/7 regime with an extended or continuous regime. A 
randomized clinical trial was conducted with 239 women at nine clinical 
research sites to compare bleeding profile, headache frequency, and subject 
satisfaction with the transdermal contraceptive (norelgestromin/ethinyloestradiol 
transdermal system) used in an extended regime (84 days) w ith a traditional, 28- 
day cyclic regime. In a majority of women studied, compared w ith cyclic use, 
extended use of transdermal norelgestromin/ethinyloestradiol delayed menses and 
reduced the total incidence of mean headache days during the hormone-free 
interval.(LaGuardia etal., 2005)
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In an open label single-centre prospective study, standard 21/7 cycles of a COC 
containing 3mg of drospirenone and 30pg of ethinyloestradiol were fo llowed by a 
168-day continuous regime. O f the 114 patients who began the trial, 111 
completed the 21 /7-day cycle portion of the study. Based on the headaches 
scales, there were significant differences in headache severity among the 28 days 
of the standard 21/7 cycles (P< 0.001). Greater headache severity occurred on 
days 25 through 28 during the 7-day placebo interval of the 21/7 cycles (P<0.05). 
O f the 111 patients who completed the 21/7 phase of the study, 102 (92%) 
completed the 168-day continuous COC regime. Women w ith higher total 
headache scores demonstrated a significant reduction in daily headaches 
beginning in the first 28 days of continuous pill-taking (P< 0.0001), which 
persisted throughout entire 168 days. In contrast, headache in women w ith lower 
total headache scores remained unchanged throughout the continuous regime (P= 
0.79). Impact of headaches on work, family, and social functions also improved 
on the continuous regime in six of eight measures assessed by weekly headache 
questionnaires (P< 0.05).(Sulak et al., 2007)
CURRENT PRACTICE FOR PREVENTION OF MIGRAINE DURING THE PILL- 
FREE INTERVAL
If oestrogen 'w ithdrawal' is the mechanism for migraine arising in the pill-free 
interval, minimising the decline in oestrogen during the pill-free interval should 
prevent attacks.
Such attacks may be resolved by altering the ratio of oestrogen to progestogen or, 
more commonly, by bicycling or tricycling the p ill (taking two or three packets 
consecutively before breaking for a pill-free interval) reducing the number of p ill- 
free intervals, and thus the number of migraine attacks, from 13 to five per 
year.(Whitty etal., 1966) Continuous COC use is an option used increasingly and 
is licensed in some countries, although unscheduled bleeding can be a 
problem.(Edelman et al., 2006)
However, some women prefer to have a regular 'period'. Using natural oestrogen 
such as oestradiol during the pill-free interval could, if the oestrogen withdrawal 
theory is correct, prevent attacks of migraine at this stage of the p ill cycle whilst 
a llow ing women to experience a withdrawal bleed.
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3.4.2. PAPER VIII: PREVENTION OF MIGRAINE DURING THE PILL 
FREE INTERVAL OF COMBINED ORAL CONTRACEPTIVES USING 
OESTRADIOL SUPPLEMENTS
OBJECTIVES
The aim of this study was to determine whether the use of natural oestrogen 
supplements used during the pill-free interval could reduce the occurrence of 
migraine headache and associated symptoms.
METHODS
The East London and City Research Ethics Committee approved the protocol. 
Women who fulfilled the entry criteria were invited to participate in a double­
blind placebo-controlled randomised crossover study in which each woman was 
given oestrogen patches (Evorel™ 50pg) or matching placebo, each to be used 
during the pill-free interval of 4 pill cycles allocated at random (2 cycles using 
oestrogen, 2 using placebo). This enabled a w ithin-wom an analysis of the data to 
be possible.
Most patients were recruited from outpatient clinics at the City of London 
Migraine C linic and at St Bartholomew's Hospital Sexual Health Clinic. A couple 
of patients were also recruited fo llow ing advertisements placed in the waiting 
room at the Margaret Pyke Family Planning Centre and in other local fam ily 
planning clinics. As recruitment was poor, advertisements were also placed in 
local newspapers but, despite a good response, few suitable subjects were 
identified. All women were reviewed at the City of London Migraine C lin ic before 
inclusion in the study. In order to fulfil the entry criteria, women had to be aged 
over 18 years and suffering from recurrent attacks of migraine w ithout aura during 
the pill-free interval. They had had migraine w ithout aura for at least one year, 
had been using the same COCs for at least six months prior to entering the study, 
and had no contraindications to their continuing use of COCs. All women entered 
gave informed consent and were free to w ithdraw at any stage of the study for any 
reason.
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A full medical and headache history was taken from all women, who were then 
given a neurological and general physical examination. All information was 
recorded on the case report forms. Women were then randomly allocated to 
receive oestrogen or placebo patches that were to be used during the pill-free 
interval. Two patches were provided for each cycle: the first was to be used on 
the evening of the last day of the p ill cycle, replaced w ith the second patch on the 
morning of the fourth day of the pill-free interval, and removed on the first day of 
the next p ill cycle. Diary cards were provided which highlighted the correct time 
for patch changes. Women were instructed to record any headache or migraine 
occurring at any time during the four month study on diary cards, using a verbal 
rating scale for severity. Associated symptoms of nausea, vom iting and 
photophobia were also recorded, as was use of medication for acute treatment. 
Women were seen at the City of London Migraine C lin ic after the first 2 cycles to 
check blood pressure and to monitor adverse events, and at the end of the 4th 
cycle for a third and final assessment. Trial medication was issued for two cycles 
at the first and second visits.
The fo llow ing outcomes were assessed during the two pill-free intervals for each 
treatment and placebo regime:
o The number of pill-free intervals (0,1 or 2) during which at least one 
migraine occurred;
o The number of days during which a migraine occurred (0 to 14) over the 
two weeks;
o The number of migraines that were considered to be mild, moderate or 
severe;
o The number of days of migraine (0 to 14) over two weeks that were 
accompanied by nausea;
o The number of days of migraine (0 to 14) over two weeks that were 
accompanied by vomiting;
o The number of days of migraine (0 to 14) over two weeks that were 
accompanied by photophobia.
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Sample size calculation and statistical methods
A crossover trial of 20 women would have over 90% power to show a difference 
of 50% reduction in the outcomes assessed.
Non-parametric tests (W ilcoxon one-sample test) were used to compare the 
median within-person differences and t-tests for comparing the mean.
RESULTS
We were unable to meet our recruitment target of 20 patients. Fourteen women, 
median age 33 years (range 24-42), w ith a median onset of migraine w ithout aura 
at age 19 years (range 7 to 41) were recruited over a two-year period. The type of 
COC taken by each woman is listed in Table 13. Eight women took 3rd generation 
COCs (all monophasic) and six took 2nd generation COCs (4 monophasic and 2 
triphasic).
Patient No: COC type
1 EE 30pg /  gestodene 75pg
2 EE 35pg /  cyproterone acetate 2mg
3 EE 20pg /  desogestrel 150pg
4 EE 3 5 pg / norgestimate 250pg
5 EE 35pg / norethisterone 0.5-1 mg
6 EE 30-40pg/ levonorgestrel 50-125pg
7 EE 30pg /  levonorgestrel 1 50pg
8 EE 35pg /  cyproterone acetate 2mg
9 EE 20pg /  desogestrel 150pg
10 EE 30pg /  desogestrel 1 50pg
11 EE 30pg /  levonorgestrel 1 50pg
12 EE 30pg /  levonorgestrel 1 50pg
13 EE 20pg /  desogestrel 150pg
14 EE 30pg /  levonorgestrel 1 50pg
EE = ethinyloestradiol
TABLE 13: T ype o f  COC u s e d  by  e a c h  p a t ie n t
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Thirteen women had taken their current COC for at least six months, and one 
woman (Patient no. 13) had taken her COC for three months.
Attacks of migraine were typically reported as starting on the third day of the p ill- 
free interval (Figure 37)
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FIGURE 37: F irs t d a y  o f  h e a d a c h e  d u r in g  th e  p i l l - f r e e  in t e r v a l  (PFI) in 50 c y c le s
Twelve women completed the study w ith full data for analysis. One woman 
w ithdrew  for lack of effect after treating two cycles (one w ith oestrogen one with 
placebo) and another w ithdrew consent before treating.
O nly two adverse events were reported that could be attributable to the study 
medication. Patient no. 6, who was taking a triphasic COC, reported no 
withdrawal bleed and no headaches or migraine in the two pill-free intervals 
using oestrogen patches. In day 5 of the each of the pill-free interval in which she 
used placebo, she experienced a withdrawal bleed and an associated migraine 
attack.
Day of PFI
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Patient no. 14, who was taking a monophasic COC, experienced w ithdrawal 
bleeds starting on day 4 of the pill-free interval for both placebo cycles and on 
day 3 and day 4 of the pill-free interval in the two oestrogen cycles. She reported 
that the withdrawal bleed was much lighter than usual during the two oestrogen 
cycles.
The only other adverse event was reported by patient no. 5 who was taking a 
triphasic COC and who experienced early bleeding on day 19 or 20 of the p ill 
cycle during every cycle in the study. This event was predated participation in the 
study.
The effect oestrogen on the first day of the w ithdrawal bleed was analysed.
Bearing in mind the lim ited number of cycles, there was a tendency for oestrogen 
use to be associated with a delayed withdrawal bleed (Figure 38 and Figure 39).
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FIGURE 38: FIRST DAY OF WITHDRAWAL BLEED IN THE PILL FREE INTERVAL (PFI) IN W OMEN USING PLACEBO
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FIGURE 39: F irst d a y  o f  w it h d r a w a l  bleed  in  t h e  pill free  in t e r v a l  (PFI) in  w o m e n  u s in g
OESTROGEN
There was no evidence to suggest that women had fewer migraine attacks during 
pill-free intervals after using 50pg oestrogen patches compared to placebo 
{P-0.55). Ten of the 13 women had the same number of pill-free intervals w ith 
migraine whether they were using oestrogen or not, tw o women had fewer 
weeks, and one woman had more weeks (Table 14).
W ith respect to the number of days where the women had migraine during the 
pill-free interval, there was a suggestion that when the women were using 50pg 
oestrogen patches, they had fewer days of migraine than when they were using 
placebo (median difference -0 .5  days [95% Cl -2 .0  to 1.5]), but the results were 
not statistically significantly different (P=0.55) (Table 14).
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Patient
no.
No. of p ill free weeks (0-2) No. o f migraines (0-14)
E2 P Difference E2 P Difference
1 2 2 0 3 4 -1
2 1 1 0 1 1 0
3 1 2 -1 3 5 -2
4 2 2 0 6 9 -3
5 2 2 0 6 11 -5
6 § 2 -2 1 3 -3
7 1 1 0 2 1 0
8 2 2 0 4 5 1
9 2 2 0 5 5 0
10 2 1 1 10 3 7
11 1 1 0 2 1 1
12 2 2 0 11 8 3
13 2 2 0 2 2 0
Median - - 0 - - -0.5
E2: oestrogen patches, P: placebo patches, Difference: E2 minus P
TABLE 1 4: No. OF PILL FREE WEEKS WHEN MIGRAINE OCCURRED AND NO. OF MIGRAINES DURING EACH
2-W EEK PERIOD FOR TREATMENT AND PLACEBO
146
The frequencies of mild, moderate or severe migraines in women using 50|jg 
oestrogen patches or placebo are shown in Table 1 5. The overall severity of 
migraine was assessed using a weighted difference score which suggested that 
women using oestrogen tended to have less severe migraine but the difference 
was not statistically significantly different (mean score -1 .0  P=0.67, median score 
-1 .0  P=0.53).
No. of migraines which were: 
M ild  Moderate Severe
Patient
no.
E2 P Difference E2 P Difference E2 P Difference Weighted
difference
score
1 1 3 -2 1 1 0 1 0 1 1
2 1 1 0 0 0 0 0 0 0 0
3 2 4 -2 1 1 0 0 0 0 -2
4 0 0 0 1 1 0 5 8 -3 -9
5 3 2 1 1 3 -2 2 6 -4 -15
6 0 1 -1 0 0 0 0 2 -2 -7
7 1 0 1 0 0 0 0 1 -1 -2
8 1 0 1 2 4 -2 1 1 0 -3
9 2 2 0 3 2 1 0 1 -1 -1
10 4 3 1 1 0 1 5 0 5 18
11 0 0 0 0 1 -1 2 0 2 4
12 5 2 3 6 6 0 0 0 0 3
13 0 1 -1 2 1 1 0 0 0 1
Median _ - 0 _ _ 0 _ _ 0 -1
E2: oestrogen patches, P: placebo patches, Difference: E2 m inus P
A weighted difference score for each woman was obtained by m ultip ly ing  the difference in the 
number of m ild migraines w ith  a score o f 1, moderate m igraines m u ltip lied  by 2 and severe 
migraines m u ltip lied  by 3; the total score for each wom an is the sum.
TABLE 1 5: N o. OF DAYS (0 TO 1 4) WHEN SEVERITY OF MIGRAINE WAS MILD, MODERATE OR SEVERE;
WEIGHTED DIFFERENCE SCORE IS ALSO SHOW N
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There was a suggestion that women using 50|jg oestrogen patches experienced 
more nausea with migraine than when using placebo (median difference 0.5 days 
[95% Cl 0 to 1.0]) but the difference was not statistically significant (P=0.35) 
(Table 16). If the analysis excluded women who did not report any nausea (5 
women), then the median difference was 1.0 day (95% Cl -1 to 2.5), P=0.34.
Only two women experienced vomiting either using 50pg oestrogen supplements 
or placebo (I woman had two more episodes w ith  oestrogen, one had two less 
episodes) so no further comment could be made on this (Table 1 6).
There was no evidence to suggest that presence of photophobia was affected by 
oestrogen use (median difference 0, P=0.89) (Table 1 6).
No. of nausea No. of vom iting No. of photophobic
episodes episodes episodes
Patient
no.
E2 P Difference E2 p Difference E2 P Difference
1 1 0 1 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0
4 1 1 0 0 0 0 0 0 0
5 2 1 1 0 0 0 5 8 -3
6 0 3 -3 0 2 -2 0 2 -2
7 0 0 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0 0 0
9 2 1 1 0 0 0 4 5 -1
10 3 0 3 2 0 2 4 0 4
11 0 0 0 0 0 0 1 1 0
12 6 4 2 0 0 0 0 0 0
13 1 1 0 0 0 0 1 0 1
Median - - 0 - - 0 - - 0
E2: oestrogen patches, P: placebo patches, Difference: E2 m inus P
TABLE 1 6: N o. OF DAYS (0 TO 1 4) WHEN MIGRAINE WAS ACCOMPANIED BY NAUSEA, VOM ITING OR
DISLIKE OF LIGHT
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DISCUSSION
The results of this pilot study suggest that use of 50pg oestradiol patches during 
the pill-free interval of combined oral contraceptives shows a trend towards 
reducing the frequency and severity of migraine at that time. This result was not 
as good as expected. We had originally aimed for 20 eligible women to 
participate in the trial but only 14 were recruited and only 12 completed the 
study with full data for analysis. We observed less than a 50% difference in the 
outcomes assessed and, together w ith the smaller than intended sample size, this 
could explain the lack of statistical significance in our results.
The City of London Migraine Clinic is a research centre so all staff were 
experienced in undertaking clinical trials and diagnosing migraine. However, one 
of the major problems with the study was recruitment of patients, despite a long 
recruitment period. In clinical practice, migraine and headache occurring in the 
pill-free interval is common. Although many patients were identified w ith 
migraine in the pill-free interval, few were prepared to enter into a formal clinical 
trial and usually requested treatment rather than trial medication. This was 
particularly the case with younger women and it is notable that the median age of 
patients entering this study was 33 years -  older than the usual population of pill 
users.
Transdermal patches were used as these provide stable plasma levels of 
oestradiol.(Kuhl, 1990) In hindsight, the 50pg dose of oestradiol was too low and 
a 100pg dose should have been used. Several women in the present study went 
on to use 100pg oestradiol patches during the pill-free interval w ith success. A 
better trial design would have been to use combinations of placebo and 50pg 
oestradiol patches to achieve pill-free interval supplements of placebo, 50pg 
patches and 100pg patches, each for two cycles. This would have extended the 
trial by a further two cycles, which might potentially have been a problem for 
recruitment. Against this concern, the main problem w ith recruitment was getting 
women to participate in the first instance; once they were in the trial, continuance 
was good. Ideally, a 1 50pg comparative dose w ould have been useful but would 
have raised issues of the acceptability of using three patches simultaneously.
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Alternative strategies to consider include oral oestrogens during the pill-free 
interval or extended regimes of p ill taking in women diagnosed w ith migraine 
during the pill-free interval. Although trial data for efficacy in headache exists, 
placebo controlled trials in women with migraine are lacking.(Calhoun, 2004; 
LaGuardia et al., 2005; Sulak et al., 2007)
Trials designed formally to assess the comparative frequency of migraine in 
women taking COCs containing different progestogens would also be valuable as 
the results could aid the decision about the choice of COC for women with 
migraine w ithout aura.
Studies to identify other potential mechanisms of migraine in the pill-free interval 
are also recommended, as oestrogen withdrawal may be only one of several 
differing mechanisms.
SUMMARY OF FINDINGS
There was a non-significant trend for women using 50pg oestrogen supplements 
in the pill-free interval to have fewer migraines and for attacks to be less severe 
compared to women using placebo.
150
3.5. CONCLUSIONS FROM PART THREE
If the hypothesis that menstrual migraine is associated w ith oestrogen 
'w ithdrawal' is correct, it follows that menstrual migraine should be prevented 
with exogenous oestrogen supplements to inhib it the endogenous late luteal drop 
in oestrogen.
From the data presented above, the fo llow ing points can be concluded:
o The optimal dose for perimenstrual prophylaxis is 100pg oestradiol 
patches or 1.5mg oestradiol gel.
o In order to prevent the late luteal drop in oestrogen, the optimal tim ing for 
perimenstrual prophylaxis appeared to be from the luteal phase oestrogen 
peak (day -6), continuing through to the early fo llicu lar rise of endogenous 
oestrogen (day +2).
o To time perimenstrual prophylaxis effectively, it is necessary to predict the 
onset of menstruation.
o Although the median length of the menstrual cycle was 28 days in the 
women participating in our trials, there was a w ide inter- and intra­
individual range in cycle length, making it d ifficu lt to predict menstruation.
o Identification of ovulation using a fertility monitor enabled prediction of 
menstruation and accurate tim ing of oestrogen supplements, irrespective of 
cycle length.
o  Perimenstrual oestradiol supplements inhibited the late luteal drop in 
oestrogen and prevented menstrual attacks in some, but not all, women.
o The benefits of treatment were offset by a delayed oestrogen 'w ithdrawal' 
migraine in some women.
o There was a trend to suggest that migraine in the pill-free week of 
combined oral contraceptives could be prevented w ith oestradiol 
supplements although, based on the dose of oestrogen and the number of 
participants, the results were not significant. It is likely that the 50pg dose 
is too low for optimal clinical benefit.
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These findings provide limited support for the hypothesis that menstrual migraine 
can be prevented using oestradiol supplements. Reasons for the lack of clinical 
efficacy include failure to achieve adequate stable levels of oestradiol, too short a 
duration of prophylaxis so that supplements were stopped before the fo llicu lar 
rise in endogenous oestrogen, and suppression of endogenous oestrogen. Further, 
the study included women with menstrually-related migraine, in whom migraine 
is only partially hormone dependent.
Additional findings were that oestrogen 'w ithdraw al' migraine is independent of 
menstrual bleeding and is independent of other menstrual cycle hormones. Given 
that migraine can occur when oestrogen is 'w ithdraw n' during the hormone free 
interval of combined hormonal contraceptives, oestrogen 'w ithdraw al' migraine is 
also independent of ovulation.
PART 4: 
SUMMARY OF RESEARCH
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The results of the research presented in this thesis support the initial hypotheses:
1. Menstrual migraine is a discrete clinical entity
1.1. Migraine in menstruating women is most likely to occur on or 
between two days before the start of menstruation and the first three 
days of bleeding.
1.1.1. Pure menstrual migraine can be defined as 'attacks of 
migraine without aura occurring exclusively on or between 
days -2 to +3 of menstruation in at least two out of three 
menstrual cycles and at no other times of the cycle'.
1.1.2. Menstrually-related migraine can be defined as 'attacks of 
migraine w ithout aura occurring on or between days -2 to +3 
of menstruation in at least two out of three menstrual cycles 
w ith additional attacks of migraine w ith or w ithout aura at 
other times of the cycle'.
1.2. Compared to non-menstrual attacks, menstrual attacks of migraine 
are significantly more severe and associated with nausea and 
vomiting, are longer, are less responsive to treatment, and are more 
prone to relapse.
2. Menstrual migraine is associated with oestrogen 'withdrawal'
2.1. In women with menstrual or menstrually-related migraine incidence
was inversely related to rising and fa lling phases of oestrogen across 
the menstrual cycle.
2.1.1. Compared to the expected incidence, the highest incidence 
of migraine was during the late luteal/early fo llicular phase 
of falling oestrogen.
2.1.2. Compared to the expected incidence, the lowest incidence 
of migraine was during the fo llicu lar phase of rising 
oestrogen and the luteal phase of rising oestrogen.
2. There is circumstantial evidence that migraine during the hormone-
free interval of combined hormonal contraceptives is associated 
with oestrogen 'w ithdrawal'.
Menstrual migraine can be prevented with oestradiol supplements
1. In women with menstrual migraine not using exogenous hormones:
3.1.1. To maintain mid-luteal oestradiol levels, the optimal dose for 
perimenstrual prophylaxis is at least 100pg oestradiol 
patches or 1.5mg oestradiol gel.
3.1.2. Based on the tim ing of the luteal oestradiol peak and the 
fo llicular phase oestradiol nadir, the optimum tim ing for gel 
use was considered to be from 6 days before menstruation to 
the second full day of bleeding.
2. Identifying ovulation enabled accurate prediction of menstruation 
and hence accurate timing of the start of gel use.
3. In women with menstrual migraine who are not using exogenous 
hormones:
3.3.1. 1.5mg oestradiol gel used for eight days perimenstrually 
significantly reduced the frequency and severity of migraine 
during treatment compared to placebo.
3.3.2. Oestradiol treatment was fo llowed by an increase in 
migraine associated with delayed oestrogen 'w ithdrawal', 
the highest incidence on the third day fo llow ing the last day 
of treatment.
4. In women with menstrual migraine taking combined oral 
contraceptives:
3.4.1. The highest incidence of migraine was on the third day 
during the pill-free week.
3.4.2. Use of 50pg oestradiol supplements during the pill-free week 
resulted in fewer and less severe migraine attacks compared 
to placebo but the difference was not significant.
PART 5:
OPPORTUNITIES FOR FUTURE RESEARCH
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This thesis marks a waypoint in my research into the association between 
oestrogen and migraine being as much a starting point for future work as a 
summary of research to date. Along this journey I have sought to develop a 
definition for menstrual migraine in order to further research into the relevant 
mechanisms. Such delineation has enabled studies to confirm the association 
between migraine without aura and falling levels of oestrogen in the late luteal 
phase of the menstrual cycle. Notably, although I set out to find mechanisms for 
menstrual migraine, it is apparent that menstruation is only an association since 
oestrogen 'w ithdrawal' migraine can occur in the absence of menstrual bleeding 
and, indeed, in the absence of ovulation.
Although there was a clear inverse association between migraine incidence and 
oestrogen levels across the menstrual cycle, the results of supplementing 
oestrogen at the expected time of oestrogen 'w ithdraw al' were disappointing. 
Strategies to reduce post-dosing oestrogen 'w ithdrawal' need to be studied. 
C linically, starting oestrogen supplements in the late luteal phase and tapering the 
dose through the early fo llicular phase seems effective but a placebo-controlled 
study is necessary to both confirm this impression and to assess the effect on 
fo llicu lar phase endogenous oestrogen.
Given the contraceptive needs of many women w ith migraine, further research 
into the effects of hormonal contraception is warranted. There are no studies 
assessing anovulatory progestagens such as the intramuscular depot 
medroxyprogesterone acetate (DMPA), subdermal etonogestrel and oral 
desogestrel. Subdermal etonogestrel and oral desogestrel inh ib it the LH surge, but 
do not inhibit FSH.(Croxatto & Makarainen, 1998) Consequently, these methods 
are associated with fluctuating follicular phase oestrogen levels, which could act 
as a migraine trigger.(Somerville & Carey, 1970) Even with DMPA which, like 
combined hormonal contraceptives inhibits both FSH and LH, migraine is 
reported in association with breakthrough bleeding. The mechanisms for this are 
unknown although improvement is noted in women achieving 
amenorrhoea.(Somerville & Carey, 1970)
Why are some women with migraine susceptible to oestrogen 'w ithdrawal' and 
other women are not? The results presented in this thesis suggest that susceptible
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women may have high luteal phase oestrogen levels, compared to women who 
do not experience menstrual attacks. This might explain why menstrual migraine 
is more prevalent in the perimenopause, since some women experience high 
fluctuating oestrogen levels.
Future studies should confirm or refute the proposed definition of 'menstrual' 
migraine, perhaps by analysing the peak incidence of migraine during the 
menstrual cycle in a larger number of migraineurs. Prospective records of 
migraine and menstrual periods would need to be recorded in different age 
groups of women who were not on any form of hormonal treatment or 
prophylactic migraine treatment. The duration of records should be for a 
minimum of three cycles. Longer records would be preferable but many women 
may not maintain accurate records over lengthy study periods. If sufficient data 
are collected it would be possible to analyse other subgroups, e.g. women with 
exclusively premenstrual attacks or those w ith attacks exclusively occurring at the 
time of the menstrual flow, to assess differences. Further, the type of migraine and 
duration of attacks in 'menstrual' migraineurs could be examined.
Are attacks of 'menstrual' migraine always w ithout aura? Women who have both 
types of migraine are more likely to have migraine w ithout aura associated with 
oestrogen 'w ithdrawal' and attacks with aura at other times of the cycle. Research 
not presented in this thesis suggests that migraine with  aura occurs at times of 
high oestrogen levels, such as when taking combined hormonal contraceptives or 
hormone replacement therapy, and during pregnancy.(MacGregor & Guillebaud, 
1998; MacGregor, 1999a; MacGregor, 1999b; MacGregor, 2004, 2007a, b)
There is a need for further evidence to support or refute the concept of 'menstrual' 
migraine as a specific nosological entity. To date, most of the studies cited have 
included small numbers of women over few cycles and have combined data from 
women using hormonal treatments w ith those who are not. Further, since the 
issue is whether or not migraine at menstruation is different from non-menstrual 
attacks w ithin the same woman, studies would be more relevant if they undertook 
w ithin-woman analyses. In order better to understand the pathophysiology and to 
provide effective treatment, it is important to assess the association prospectively
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over a large number of cycles in a large number of women who have an accurate 
diagnosis of migraine.
In addition, there is the issue of whether or not migraine associated with 
withdrawal bleeding during the pill-free interval of combined oral contraceptives 
or w ith progestogen-withdrawal bleeding in women using hormone-replacement 
therapy constitutes 'menstrual' migraine. Since migraine associated with 
withdrawal bleeding resulting from hormonal contraception or hormone 
replacement therapy may have a different pathophysiology from menstrual 
migraine resulting from the hypothalamic-pituitary-ovarian cycle, these groups 
should be studied separately.
Studies should establish if there is a continuing relationship between migraine 
attacks and menstruation over a longer period of time. Most women have 
difficulty in remembering accurately the effects of hormonal events on their 
headaches and interview bias can affect the results of retrospective studies. It is 
therefore important that all evidence should be from prospective studies. Some 
women do not initia lly relate their attacks to menstruation but only notice a link 
in the perimenopause or after some specific hormonal event e.g. pregnancy or 
use of oral contraception. This may be due to subjective bias but could represent 
a true change in pathophysiology. An ideal study w ould be to fo llow  women over 
many years and assess the changes in the tim ing and type of migraine attacks 
relating to known hormonal changes. An example is the temporal relationship of 
migraine during pregnancy and post partum. The effects of hormonal events on 
non-migraine headaches also merit further study.
Then there is the question of whether the effect of oestrogen is primary or 
secondary. Regulation of the menstrual cycle is complex with ovarian steroids 
playing a limited role in the overall control. It is likely that the chemical alteration 
more directly responsible for migraine is the effect of the changing hormonal 
environment on other biochemical and metabolic pathways, rather than a direct 
effect of sex hormones.
Ovarian steroids cross the blood-brain by passive diffusion, with brain levels 
mirroring blood levels.(Aloisi, 2003) There is evidence that ovarian steroids can 
be produced w ith in the central nervous system.(Stoffel-Wagner, 1993) As
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neurosteroids, oestrogen and progesterone can influence the pain processing 
networks and vascular endothelium involved in the pathophysiology of migraine. 
Both oestrogen and progesterone also have a c lin ica lly  relevant effect on vascular 
tone.(Sarrel, 1999) Further, close interrelationships between oestrogens and brain 
neurotransmitters have been confirmed, including the catecholamines, 
norepinephrine, dopamine and the endorphins. Therefore, hormonal changes 
could trigger some alteration in activity of the hypothalamic-pituitary-adrenal 
axis, exposing susceptible women to a migraine attack. Accordingly, migraine has 
been shown to increase fo llow ing gonadotropin-releasing hormone (GnRH) 
analogue induced hypothalamic-pituitary-ovarian axis down-regulation.(Amir et 
a l, 2005)
Fluctuating levels of oestrogen and progesterone in the luteal phase of the 
menstrual cycle affect levels of brain dopamine.(Magos et al., 1985; Murialdo et 
al., 1986) Oestrogen also facilitates the glutaminergic system, potentially 
enhancing neural excitability. In contrast, progesterone appears to activate 
GABAergic systems, suppressing neuronal reactivity, and modulates the effects of 
oestrogen on the central nervous system.(Martin & Behbehani, 2006) Oestrogen 
has potent effects on the serotonergic system, increasing serotonergic tone.
Serotonin-producing neurons are sensitive to the presence or absence of ovarian 
hormones.(McEwan, 2002) Fluctuating levels of oestrogen and progesterone in 
the luteal phase of the menstrual cycle affect levels of brain serotonin and 
abnormalities of the serotonin system in menstrual migraine has been 
reviewed.(Silberstein & Merriam, 1993) This association might account for 
efficacy of perimenstrual prophylaxis w ith triptans and warrants further 
evaluation.(Newman eta/., 1998; Newman eta/., 2001; Silberstein et a/., 2004; 
Tuchman et a/., 2005; Mannix et a/., 2007; Brandes et al.) To this end, we are 
examining the association between urinary serotonin, precursors and metabolites, 
oestrogen and migraine across the menstrual cycle in women w ith pure menstrual 
or menstrually-related migraine.
That oestrogens do not affect all women w ith migraine might be explained by the 
intrinsic oestrogen receptor sensitivity of the hypothalamic neurons. Limited data 
imply that this may have a genetic basis.(Berman et al., 2006) Experimental
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studies in rats suggest that abnormalities in how oestrogen modulates neuronal 
function in migraine may be due to a mismatch between its gene-regulation and 
membrane effects. A decline in oestrogen levels modulates central sensitization, 
increasing the pain and disability of the migraine attack.(Welch et al., 2006;
Martin et al., 2007) We are currently undertaking further research to identify 
genes that may play a role in menstrual migraine.
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RESEARCH IN PROGRESS
EFFECT OF MIGRAINE, THE MENSTRUAL CYCLE, AND PERIMENSTRUAL 
OESTRADIOL SUPPLEMENTS ON THE URINARY METABOLITES SEROTONIN 
(5-HT), 5-HYDROXYINDOLE ACETIC ACID (5-HIAA) AND TRYPTOPHAN IN 
WOMEN WITH MENSTRUAL OR MENSTRUALLY-RELATED MIGRAINE
Experimental and physiological studies have suggested a relationship between 
serotonin (5HT) and menstrual cycle hormones.(Martin & Behbehani, 2006)
Given the implication of 5HT in migraine, and the benefits of perimenstrual 
triptan prophylaxis, this association with oestrogen may be important to our 
understanding of the pathophysiology of menstrual migraine. However, human 
data are lacking
We are undertaking a p ilot study to assess urinary 5HT, 5-hydroxyindoleacetic 
acid (5HIAA) - the metabolite of 5HT, and tryptophan - a precursor for serotonin, 
across natural menstrual cycles in women with menstrual migraine. The effects of 
perimenstrual oestrogen supplements on urinary 5HT, 5HIAA and tryptophan w ill 
also be assessed.
The hypotheses are that:
1. Changes in urinary 5HT, 5HIAA and tryptophan parallel changes in urinary 
oestrogen metabolites.
2. Urinary 5HT, 5HIAA and tryptophan increase in direct temporal relationship to 
migraine attacks.
Urine samples from Studies V, VI, and VII were frozen at -20C and are available 
for further analysis. Samples from five women, randomly selected from the study 
of 38 women who completed the oestrogen and menstrual migraine studies, w ill 
be analysed for serotonin and 5HIAA. For each woman, daily samples from the 
three placebo and three oestrogen treated cycles w ill be analysed. Approximately 
180 samples w ill be analysed for each woman, i.e. approximately 900 samples in 
total.
For the first hypothesis, data w ill be analysed separately for each woman and 
pooled with respect to urinary 5HT, 5HIAA and tryptophan levels. These results, 
across each day of the menstrual cycle, w ill be compared with existing data on
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oestrogen levels from the same samples to assess any correlation between urinary 
oestrogen and urinary 5HT, 5HTIAA and tryptophan across treated and untreated 
cycles.
For the second hypothesis, urinary 5HT, 5F1IAA and tryptophan levels for each 
woman w ill compared to diary data, previously collected, regarding the tim ing of 
migraine attacks to assess any migraine specific changes in serotonin metabolism.
Depending on the outcome of this initial study, we may extend the study to 
analyse the samples from the remaining 33 women who participated in the 
original studies.
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THE GENETICS OF MENSTRUAL MIGRAINE
The ovarian hormones play a complex role in the central nervous system, and 
their effects appear to be mediated by both genomic and non-genomic 
mechanisms.(Kelly et al., 1977; Gordon & Diamond, 1981; Biegon eta l., 1983; 
Nabekura eta l., 1986; Bethea, 1993)
Animal studies support interactions with various neurotransmitter systems, as well 
as a role in neuronal excitability. Further, oestrogens can affect vascular tone, 
most likely through mechanisms involving nitric oxide release.(Caulin-Glaser et 
al., 1997; Florian etal., 2004) Thus, genes involved in hormonal pathways 
represent likely candidates for migraine susceptibility.
Griffiths and co-workers at the Genomics Research Centre, Australia, have been 
investigating the possibility that genes involved in hormonal pathways may play a 
role in migraine susceptibility.(Colson etal., 2006; Colson et al., 2007) In 2004 
they investigated the role of the oestrogen receptor 1 (ESR1) gene in migraine by 
analysing the G594A SNP in 575 migraineurs and 575 controls (analysed as two 
independent study groups). Results of both studies showed a significant 
association of the A allele of the SNP with migraine.(Colson et al., 2004)
More recently, they investigated the progesterone receptor (PGR) PROGINS insert 
in the same two study groups.(Colson et al., 2005) Results also implicated a role 
for this gene in migraine in both independent study groups. They found that 
women who carried a copy of both PR and ESR1 risk alleles were 3.2 times more 
likely to suffer from migraine, an effect that is greater than the independent effects 
of these genetic variants on disease susceptibility. It is anticipated that this 
association w ill be stronger in women with menstrual migraine, who have a 
strong hormonal trigger for attacks.
To this end, we are undertaking a case-control directed to identifying genes that 
play a role in menstrual migraine (pure menstrual migraine and menstrually- 
related migraine), in collaboration with the Genomics Research Centre, Griffith 
University, Australia.
The hypothesis is that ESR and PGR INSERT, which have already been implicated 
with susceptibility variants in typical migraine, are likely to play a more specific 
role in menstrual migraine.
The primary objective is to look at the specific genes, ESR and PGR Insert, which 
are already implicated. The secondary objective is to look at other genes, not 
previously studied, which may also play a role in menstrual migraine.
The results of this research collaboration have the potential to provide valuable 
insights into the genetic susceptibility of menstrual migraine. If the genes that play 
a role in this sub-type of migraine can be identified, it should be possible to 
develop objective ways of testing for these genes as a diagnostic tool. Accurate 
diagnosis of menstrual migraine can aid the selection of currently available 
treatments. Further, identification of the genes involved could ultimately lead to 
the development of more effective treatments, targeted to the specific genes.
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Summary of Questionnaire Responses n=35 ( 3  q u e s t i o n n a i r e s  n o t  r e t u r n e d )
Question Response Number %
Expectations Met?
Yes 15 43%
No 8 23%
Partially 10 28%
Not Sure 2 6%
35 100%
Migraine Management Influence?
Positive 26 74%
Negative 0 0%
Both 2 6%
N/A 1 3%
No Change 6 1 7%
35 300%
Keeping Diaries Useful?
Yes 33 94%
No 1 3%
Both 1 3%
35 100%
Using Fertility M onitor Useful?
Yes 33 94%
No 1 3%
Blank 1 3%
35 100%
More Info Reg Mens Cycles?
Yes 31 89%
No 4 11%
35 100%
M onitor As Treatment Aid?
Yes 27 77%
No 6 17%
Not Sure 2 6%
35 100%
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Were your expectations about taking part in the study met?
Volunteers' expectations centred on finding out about causes of their migraines, 
how to prevent attacks and how to deal w ith them. Many were keen to see if 
there really was a pattern between their hormones and migraine attacks, to see if 
there was an alternative to their usual treatments and whether symptoms could be 
lessened. Some women wanted to help others in the future.
43% of respondents felt that their personal expectations had been met:
"I entered into trial with an open mind. A t worst, I would at least be 
assisting the research. A t best it m ight help me to find a better way to 
manage the migraines...It gave me a much better understanding as to why 
my migraines occur."
28% felt that their expectations were partially met:
"I d id  find out a lot about my m onthly cycles but the gel d idn 't seem to 
make a lot o f difference."
23% felt that their expectations were not met:
"N o conclusive results emerged about m y particular hormonal pattern." 
"M y cycle was not as regular as before because o f my age."
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How did you feel that taking part in this study influenced (positively or 
negatively) the management of your migraines?
Although for some volunteers (1 7%) there was no change in the management of 
their migraines, most volunteers who responded felt that taking part in the study 
influenced the management of their migraines in a positive way (74%), although 
this was for various reasons:
"It was extremely positive for me, because apart from maybe finding my 
'wonder cure', I have been given some very helpful advice on how I might 
help reduce the impact o f migraine on my life ."
"Knowing that I could be doing something positive helped me mentally."
"Positive influence as I d idn 't feel that I was so different from other women 
o f my age."
No one felt that there was only a negative influence on their migraine 
management, but two volunteers did record negative aspects:
"By keeping the diaries and using the gel I was more reluctant to try other 
treatments pain killers because I felt that they might mask any effects from 
the gel."
"In itia lly it was good to feel involved...later on in the study I had difficulty 
doing all I was required to d o ."
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Did you find keeping diaries helpful?
Most volunteers (94%) felt that keeping migraine diaries was helpful, although 
one volunteer wrote "N O " because she,
"Already d id  this" and another felt that she,
.. was more reluctant to try other treatments."
Generally, the volunteers felt that the diaries were useful for looking at patterns 
and overall pictures of migraine attacks:
"Could see definite patterns."
" Helpful to give accurate picture o f my migraines."
"They show frequency and tim ing o f attacks."
Other comments included:
"Helps track causes and triggers (may be able to use this to recognise 
triggers in the fu ture)."
"Learnt when to expect headaches... "
"Memory plays strange tricks; a diary is an easy reference tool and helps in 
discussion with your doctor e tc."
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Did you find using the fertility monitor helpful?
Most volunteers (94%) thought that using the fertility  monitor was helpful and 
give a variety of reasons often relating to knowledge and the predictability of 
periods and therefore migraines:
"It was interesting and revelatory to realise I wasn't ovulating every month 
and that it made no difference to the headaches!"
" Helps me plan around my migraine attacks."
"This was useful in confirm ing exactly when my oestrogen level was going 
to start dropp ing."
"....he lped knowing the end o f cycle was on its w ay."
"Interested to see ovulation and changes in m y body."
"Ability  to p in-po int when period was due."
"You could adjust your life style because you had more o f an idea when 
migraine would occur. ...it helped p lo t more accurately [than the diaries]."
" Gave me a sense o f control by knowing what was happening to my body 
and w hen."
" . ...reassuring to know cycles were generally norm al."
"Helped provide a specific data to contribute to my more personal 
interpretations o f what was going on in m y body !"
"Most definitely! It taught me a lo t about m y menstrual cycle, which has 
never been completely reliable and regular!"
"I found I could judge the "danger pe riod " for migraine very accurately." 
"Very helpful -  as cycle not 100% regular I found it very useful."
"Helped me to know when period approaching and therefore attacks."
" Interesting to see what's going on "inside" and when I am ovulating." 
"Showed me how  body was really working."
"Could plan ahead o f an attack."
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"I found just being totally tuned in to where my body was in its month 
cycle helped me to "manage" attacks. For instance, I felt more confident 
as to whether I could or could not risk a glass o f w ine !"
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Did you feel that you have gained more information about your own menstrual 
cycle?
Most volunteers (89%) felt that they had definitely gained more information about 
their menstrual cycle:
"Yes -  definitely -  very interesting."
O f those that did not gain more information (11%), this was because they were 
already aware of the link between their periods and migraines:
"N o not really, other than confirm ing what I already thought that my 
migraines were linked to menstruation
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Would you be willing to use the monitor as a treatment aid for you in the 
future?
Most volunteers (77%) felt that they would be w illin g  to use the monitor as a 
treatment aid despite some having more d ifficu lty w ith  it than others:
" I f  I could be sure it would not malfunction and i f  the purpose was made 
clear for example, it would reduce the frequency and severity o f my 
migraines. Urine samples are a nuisance though."
"To rem ind me IF I should be taking oestrogen ge l."
"...anyth ing to help predict the fluctuation in hormone levels. Perhaps this 
would help i f  the monitor read daily urine samples all through the m onth."
" If  I felt this would help my situation, I w ou ld  try anyth ing!"
"Yes, i f  it helped p inpo in t time for treatment and migraine prevention."
"This I found very easy to use it became part o f m y daily routine, I even 
used it when camping. No problem ."
"Although I d id  find daily urine testing quite a commitment- especially 
away from hom e."
"Yes, in fact, I have missed the m onitor a lot since the trial ended. Slightly 
irregular cycles mean I have to guess a lo t more than I'd  like when it comes 
to applying the ge l."
"I feel it keeps a more accurate track o f the menstrual cycle."
"Oh yes please. I w ould know  when to take supplements, as my periods 
are becoming a little erratic n ow ."
"In fact it would help me to be more clear when to commence using the 
oestrogen supplement each m onth ."
"W ould obviously only use it i f  it were for a purpose. D idn 't find it time 
consuming and it was interesting to see fluctuations."
"Once used to it, it was not problem to use. It helped me work out when 
an attack was possible."
203
"It was invaluable at working out exactly when my period was due so I 
could try and take preventative measures before migraine started."
1 It made me feel very 'in contro l' . "
Two respondents (6%) were not sure whether they would use the monitor and six 
more (1 7%) felt that it would not be of benefit to them or had another reason:
"No as I d id  not feel it was o f benefit to me regarding my migraines."
"The m onitor is very easy to use, but I prefer Almogran to oestrogel."
" I found the use o f the monitor restricting and I became "regimented" in 
my day to day liv ing ."
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APPENDIX 3:
INDIVIDUAL GRAPHS OF HORMONES LEVELS FOR EACH 
PATIENT (PAPER V AND PAPER VII)
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216
L M C  post-treatm ent: V o l. 15 Set 5
smoothed n ^ m  I smoothed P3(> ug/mL
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LMC pre-treatment: Vol. 17 Set 1
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L M C  post-treatm ent: V o l. 18 Set 3
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L M C  post-treatm ent: V o l. 21 Set 1
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| L M C  post-trea tm en t: V o l. 26  Set 5
smoothed K3(» ny/m l smoothed ug/mL
4090
80
70
60
40
30
290 300 310 320 330 340 350 360 370
T r ia l Day
! cycle start | E3G take oft L lf surge 1.H peak [ luteal E3G mas 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  p ost-trea tm en t: V o l. 27  Set 1
smoothed k 3 ( j  ng/m Lsmoothed K*3t» ug/m L
90
80 C3
60
50
40
30
20
70 80 9060
T ria l Day
| cycle start | E3G take off L lf surge | LH peak luteal E3G mas 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 27 Set 2
smoothed t 3 ( j  ng/m l smoothed P 3 li ug/mL
90
80
70
60
20
40
30
80 90 100 110 120 130 140 150 160 170
T ria l Day
cycle start | E3G take off L I) surge | LH peak | luteal E3G ntas 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  p o st-trea tm en t: V o l. 27 Set 3
smoothed t .H i  ng/niLsmoothed P3U ug/m L
90
80
(BMIO)GD T8
60
40
20
200 210 220 230 240170 180 190
T ria l Day
cycle Oar! E H . lake off L lf  surge L H  peak luteal E3G max
* Falling E3G | migraine event | migraine day
O  -  Active Gel ___________
LMC pre-treatment: Vol. 27 Set 1
smoothed L 3G  ng/m lsm oothed P3G u g /m L
. . . . .  > . . . j , . . . . . . . .  j
10 20 30 40 50 60 70
T ria l Day
| cycle start | E3G take off L lf surge I LH peak | luteal E3G mat 
* Falling E3G i mipraine event l mipraine dav
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I cycle start | E3G take oft LfJ surge I II peak I luteal EJG 
* Falling E3G migraine event | migraine day 
O *  Active Gel
255 256
L M C  p ost-trea tm ent: V o l. 30  Set 2
smoothed K3(» ng/mlsmoothed P3G ug/mL
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T r ia l Day
| cycle start | E3G take off L l f  surge L H peak | luteal EJG mas 
* Falling E3G I migraiqe event I migraine day 
O = Active Gel
L M C  p o s t-trea tm en t: V o l. 30 Set 4
smoothed ng/mlsmoothed P 3 (j ug/mL
rnpri'rmTTTTTTi 
253 254245 246 247 248
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T ria l Day
| cycle start | E3G take off L lf  surge 1 11 peak j luteal E3C
*  Falling E3G 1 migraine event | migraine day
O  — Active Gel
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LMC pre-treatment: Vol. 31 Set 1
sm oothed L 3 C  ng/mLsmoothed P 3G  u g /m L
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T ria l Day
I cycle start | E3G take off L lf  surge LH  peak | luteal E3G max
* Fallinp E3G migraine event I migraine dav
LMC pre-treatment: Vol. 30 Set 1
smoothed L 3 G  ng/mLsmoothed P 3C  u g /m L
30 40 50
T ria l Day
| cycle start | E3G take off L lf surge I II peak | luteal E3G 
* Faliini' E3G i mipraine event I mtoraine dav
T ria l Day
| cycle start | E3G take off LFJ surge LH peak | luteal E3G max 
*  Falling E3G | migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 30 Set 3
smoothed K3C» ng/mlsmoothed P3(. ug/m L
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LMC pre-treatment: Vol. 31 Set 2
smoothed E 3G  n g /m lsmoothed P 3C  ug/mTT
C4
i r '
84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 
T r ia l Day
| cycle start | E3G take off L l f  surge I II peak luteal E3G mai 
* Fallinu E3G migraine event l mioraine dav
L M C  post-treatm ent: Vo l. 31 Set 2
smoothed K3t» n jj/m lsmoothed P3l» uj>/ml.
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| cycle start | E3G take off Llf surge | I.II peak | luteal E3G man 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 31 Set 3
smoothed t 3 ( i  ng/mljsmoothed P3t» ug/m L
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T ria l Day
| cycle start | F.3G take off L l f  surge I II peak I luteal E3G mai 
* Falling E3G | migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 31 Set 4
smoothed K3C ng/mLsmoothed ug/mL
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T ria l Day
| cycle start | E3G take off L l f  surge LH peak luteal E3G max 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 32 Set 2
smoothed K3(» ng m I smoothed P3(j ug/mL
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T ria l Day
| cycle start | E3G take off LFjl surge LH peak luteal E3G max
* Falling E3G | migraine event | migraine day
O  ■ Active Gel
LMC pre-treatm ent: Vol. 32 Set 1
smoothed K 3C  n g /m lsm oothed  F3G  ug /m L
10 20 30 40 50 60 70
T ria l Day
| cycle start | E3G take off L lf  surge | L H peak | liiteal E3G max
* Fallini' E3G micraine event I mioraine dav
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L M C  post-treatm ent: V o l. 32 Set 3
smoothed K3l« ng/iiil«moothed P3Cj ug/ml.
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T r ia l Day
| cycle start | E3G take off Llf surge LH peak | luteal E3G inuv 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 32 Set 4
smoothed K3(« ng/ml smoothed P J(i ug/m l.
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T ria l Day
I cycle slur! | E3G take off L lf surge 141 peak luteal E3G mxl 
* Falling E3G migraine event j migraine day 
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L M C  post-treatm ent: V o l. 32 Set 5
smoothed E3G ng niI smoothed P 3(j ug/mL
•n i rrnrr TmTrrrrf 111111111 1111111111 m 111 n ri n rrrrrr iTTTTTTJTTT
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T ria l Day
| c>cle start | E3G take off Llf surge I H peak luteal E3G mas 
* Failing E3G j migraine event | migraine day 
O = Active Gel
L M C  p o st-trea tm en t: V o l. 33 Set 1
smoothed l\3 t i ng/mlsmoothed l’3<J ug/ml.TT T a;■
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T ria l Day
| cycle start | F.3G take oil L lf  surge I I I  peak I luteal E3G max
* Falling E3G | migraine event | migraine day
O  = Active Gel
L M C  post-treatm ent: V o l. 33 Set 2
smoothed K3C ng/mlsmoothed P3C« ug/ml.
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T ria l Day
| cycle start j E3G take off L lf  surge I I I  peak luteal E3G max
* Falling E3G | migraine event | migraine day
O = Active Gel
LMC pre-treatment: Vol. 33 Set 1
smoothed E 3G  ng/m lsm oothed P3C  u g /m L
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T ria l Day
| cycle start | E3G take off L lf surge LH peak luteal E3G max 
* Falliiu> E3G migraine event I mieraine dav
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L M C  p ost-trea tm ent: V o l. 33 Set 3
smoothed K .lt. n*>m lsmoothed P3(J ug/mL
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T r ia l Day
| cycle start | E3G take off Llf surge L.H peak | luteal E K i max 
* Falling E3G | migraine event | migraine day 
C) = Active Gel
LMC pre-treatment: Vol. 34 Set 1
smoothed E 3G  ng/m lsm oothed  P 3C  u g /m L
10 20 30 40 50 60 70
T ria l Day
| cycle start | E3G take off LF} surge I H peak | luteal E3G max 
* Fallim* E3G I migraine event ! mieraine dav
LMC pre-treatment: Vol. 34 Set 2
smoothed E3G  ng/m lsm oothed  P3C  u g /m L
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T ria l Day
| cycle start | E3G take off L lf surge LH peak luteal E3G max 
* Fallint* E3G mii'raine event I mieraine dav
L M C  post-treatm ent: V o l. 34 Set 2
smoothed 0 ( 1  ny/m l smoothed P3C ug/mL
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T ria l Day
| cycle start | E3G take off L lf surge LH peak luteal E3G max 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-trea tm en t: V o l. 34 Set 3
smoothed K3(; ri” /n il smoothed ug/mL
T ria l Day
| cycle start | E3G take off L lf  surge LH  peak j luteal E3G max
* Falling E3G I migraine event | migraine day
O = Active Gel
L M C  post-treatm ent: V o l. 34 Set 4
smoothed L3 (j  ng/mlsmoothed P 3ti ug/mL
1 1 1 1 I
250 260 270
T ria l Day
| cycle start | E3G take off L lf  surge I I H peak | luteal E3G max
* Falling E3G | migraine event | migraine day
O = Active Gel
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LMC pre-treatment: Vol. 35 Set 1
smoothed E 3G  ng/m lsm oothed P3G u g /m L
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T r ia l  Day
| cycle start | E3C take off LfJ surge I H peak luteal E3G max 
* Fallim' F.H> mioraine event I mioraine dav
L M C  post-treatm ent: V o l. 35 Set 2
smoothed l- 3 (. njr'm I smoothed M ( i  ug/mL
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T ria l Day
| cycle start | E3G take off L f j  surge LH  peak I luteal E3G max 
* Falling E3G | migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 35 Set
smoothed kJO  ng/inlsmoothecl P3<j ug/ml
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T ria l Day
cycle start | E3G take off LFJ surge LH peak luteal E3G max 
* Falling E3G migraine event I migraine day 
O = Active Gel
L M C  p ost-trea tm ent: V o l. 35 Set 4
smoothed K3<, n<rm I smoothed 1*3( i ug/mL
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T r ia l Day
cycle start | E3G take off LFJ surge LH peak j luteal E3G max 
* Falling E3G | migraine event | migraine day 
O = Active Gel
LMC pre-treatment: Vol. 36 Set 1
smoothed L 3 C  n g /m lsm oothed  P 3C  u g /m L
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T ria l Day
| cycle d art | E3G take o il L1J surge < I  H peak | luteal E3G max
* Fallim* E3G 1 mioraine event I mioraine dav
LMC pre-treatment: Vol. 36 Set 2
smoothed L 3 G  ng/m lsm oothed  P 3C  ug/m L
T ria l Day
| cycle start | E3G take off LFJ surge LH peak | luteal E3G max 
* Fallim* E3G 1 inirraine even! i migraine dav
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| L M C  post-treatm ent: V o l. 36  Set 2
smoothed K3G ng/mlsmoothed P3C» ug/mL
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| cycle start j E3G take off I.IJ surge [ I H peak | luteal E.Mi max 
* Falling E3G migraine e>t*nl | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 36 Set 3
smoothed K,3(; ng/in I smoothed l’3C  ug/m l.
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T ria l Day
| cycle start | E3G take off LfJ surge I H peak | luteal E3G max 
* Falling E3G I migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 36 Set 4
smoothed K 3(j ng/mlsmoothed P3(J ug/mL
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T ria l Day
| cycle start | E3G take off Lff surge LH peak | luteal E3G max 
* Falling E3G j migraine event | migraine day 
O = Active Gel
LMC pre-treatment: Vol. 38 Set 1
smoothed K 3C  ng/m lsm oothed  P3G u g /m l.
100 
90 
80 
70 
60 
50 
40 
30 
20  
10
0 10 20 30 40 50 60
T ria l Day
| cycle start | E3G take off LFJ surge LH peak | luteal E3G max 
* Fallim.* E3G migraine event 1 miuraine dav
L M C  p o st-trea tm en t: V o l. 38 Set 1
smoothed E3G  ng/mlsmoothed P 3(j ug/mL
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T ria l Day
| cycle nturt | E3G  take oft L lf  surge I I.H  peak luteal E JC  max
* Falling E3G j migraine event | migraine day
O = Active Gel
L M C  post-treatm ent: V o l. 38 Set 2
smoothed E3G  ng/mlsmoothed P3Ci ug/ml.
90 100 110 120 130 140 150 160
T ria l Day
| cycle start | E3G take off LFj surge I LH  peak luteal E3G max
* Falling E3G I migraine event | migraine day
O = Active Gel
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L M C  post-treatm ent: V o l. 38 Set 3
smoothed hW  i nj>/m I smoothed I’.K i ug/ml.
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T ria l Day
| cycle sturt | E3G take off Llf surge L H  peak luteal E3G inai 
* Falling E3G | migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 39 Set 2
smoothed t i t i  ng/mlsinoothed P 3tj ug/mL
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T ria l Day
I cycle start | E3G take off Llf surge I.H peak I luteal F.3G max 
* Falling E3G | migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 39 Set 4
smoothed E 3 (j ng/mlsmoothed P3(_; ug/mL
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T ria l Day
| cycle start | E3G take off L lf surge I H peak luteal E3G max
* Falling E3G , migraine event | migraine day
O = Activ e Gel
LMC pre-treatment: Vol. 39 Set 1
smoothed L 3G  ng/m lsm oothed P3C  u g /m L
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T ria l Day
I cycle start | E3G take off Llf surge ; I II peak ) luteal E3G max 
* Fallim* E3G mieraine event I mieraine dav
L M C  post-treatm ent: V o l. 39 Set 3
smoothed k3l> ng/mlsmoothed P 3(j ug/m l.
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T ria l Day
I cycle start | E3G take off Llf surge I.H peak | luteal E3G max 
* Falling E3G | migraine event | migraine day 
O = Active Gel
LMC pre-treatment: Vol. 40 Set 1
smoothed L 3 C  ng/mLsmoothed P3C  ug/m L
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T ria l Day
| cycle start | E3G take off L lf  surge | LH  peak | luteal E3G max
* Fallint* E3G 1 mieraine event I mieraine dav
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LMC pre-treatment: Vol. 40 Set 2
smoothed l i3 C  ng/mLsmoothed P3C* u g /m L
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T r ia l Day
| cycle start | E3G take off LIJ surge | LH peak | luteal E3G mat 
* Fallint* E3G ! inii*raine event I micraine dav ___
L M C  post-t real m ent: V o l. 40  Set 3
smoothed K3C..' nu/m I smoothed P3(! ug/mL
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T ria l Day
| cycle start | E3G take off L I) surge I H peek | luteal E3G max 
* Falling E3G | luigraiiye event | migraine day 
O -  Active Gel
L M C  post-treatm ent: V o l. 40  Set 4
smoothed k3(« ng/mlsmoothed P3t> ug/mL
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CIO
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T ria l Day
| cycle start | E3G take off LI# surge I.H peak j luteal E3G mat 
* Falling E3G migraine event | migraine day 
O = Active Gel
L M C  post-treatm ent: V o l. 40 Set 5
smoothed ng/mlsmoothed 1*30 ug/m l,
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T ria l Day
I cycle start I E3G take off L I} surge | LH peak I luteal E3G max 
* Falling E3G | migraine event | migraine day 
O = Active Gel
